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Abstract
The G-protein coupled receptor, GPR120, has ubiquitous expression and multifaceted roles in
modulating metabolic and anti-inflammatory processes. GPR120 - also known as Free Fatty
Acid Receptor 4 (FFAR4) is classified as a free fatty acid receptor of the Class A GPCR
family. GPR120 has recently been implicated as a novel target for cancer management.
GPR120 gene knockdown in breast cancer studies revealed a role of GPR120-induced
chemoresistance in epirubicin and cisplatin-induced DNA damage in tumour cells. Higher
expression and activation levels of GPR120 is also reported to promote tumour angiogenesis
and cell migration in colorectal cancer. A number of agonists targeting GPR120 have been
reported, such as TUG891 and Compound39, but to date development of small-molecule
inhibitors of GPR120 is limited.
This research applied a rational drug discovery approach to discover and design novel
anticancer agents targeting the GPR120 receptor. A homology model of GPR120 (short
isoform) was generated to identify potential anticancer compounds using a combined in
silico docking-based virtual screening (DBVS), molecular dynamics (MD) assisted
pharmacophore screenings, structure–activity relationships (SAR) and in vitro screening
approach. A pharmacophore hypothesis was derived from analysis of 300 ns all-atomic MD
simulations on apo, TUG891-bound and Compound39-bound GPR120 (short isoform)
receptor models and was used to screen for ligands interacting with Trp277 and Asn313 of
GPR120. Comparative analysis of 100 ns all-atomic MD simulations of 9 selected
compounds predicted the effects of ligand binding on the stability of the “ionic lock” – a
characteristic of Class A GPCRs activation and inactivation. The “ionic lock” between
TM3(Arg136) and TM6(Asp) is known to prevent G-protein recruitment while GPCR agonist
binding is coupled to outward movement of TM6 breaking the “ionic lock” which facilitates
G-protein recruitment. The MD-assisted pharmacophore hypothesis predicted Cpd 9, (2hydroxy-N-{4-[(6-hydroxy-2-methylpyrimidin-4-yl) amino] phenyl} benzamide) to act as a
GPR120S antagonist which can be evaluated and characterised in future studies.
Additionally, DBVS of a small molecule database (~350,000 synthetic chemical compounds)
against the developed GPR120 (short isoform) model led to selection of the 13 hit molecules
which were then tested in vitro to evaluate their cytotoxic, colony forming and cell migration
activities against SW480 – human CRC cell line expressing GPR120.
i

Two of the DBVS hit molecules showed significant (> 90%) inhibitory effects on cell growth
with

micromolar

affinities

(at

100

µM)

-

AK-968/12713190

(dihydrospiro(benzo[h]quinazoline-5,1′-cyclopentane)-4(3H)-one) and AG-690/40104520
(fluoren-9-one). SAR analysis of these two test compounds led to the identification of more
active compounds in cell-based cytotoxicity assays – AL-281/36997031 (IC50 = 5.89–
6.715 µM), AL-281/36997034 (IC50 = 6.789 to 7.502 µM) and AP-845/40876799
(IC50 = 14.16-18.02 µM). In addition, AL-281/36997031 and AP-845/40876799 were found
to be significantly target-specific during comparative cytotoxicity profiling in GPR120silenced and GPR120-expressing SW480 cells. In wound healing assays, AL-281/36997031
was found to be the most active at 3 µM (IC25) and prevented cell migration. As well as in the
assessment of the proliferation ability of a single cell to survive and form colonies through
clonogenic assays, AL-281/36997031 was found to be the most potent of all three test
compounds with the survival rate of ~ 30% at 3 µM.
The inter-disciplinary approach applied in this work identified potential chemical scaffolds –
spiral benzo-quinazoline and fluorenone, targeting GPR120 which can be further explored for
designing anti-cancer drug development studies.
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Chapter 1
Background and literature review
According to World Health Organization (WHO), cancer – also called neoplasm and
malignant tumour, is a term used to define a large group of diseases affecting any part of the
body. The defining feature of cancer is an abnormal and uncontrolled growth of cells that can
be altered by various internal and external environmental factors (WHO, 2022). While a
tumour is defined as mass of tissue due to abnormal proliferation of cells (Jiang, Puntis and
Hallett, 1994). Cells produce signals to control how much and how often the cells divide. If
there is a shift in the control mechanisms due to changes within the genes of a cell or a group
of cells that govern cell proliferation and differentiation, cells may start to grow and multiply
at an abnormal rate and form a group called a tumour (Figure 1.1) (Jiang, Puntis and Hallett,
1994; Luther and Chan, 2016).

Figure 1.1: Graphical diagram of tumour growth through the basement membrane of
epithelium / mesothelium / endothelium tissue; with detached cancer cells starting metastasis.
(Image Copyright of Cancer Research UK)
A small subpopulation of cells within the tumour can be described as tumour stem cells,
which retain the ability to undergo repeated cycles of proliferation as well as to migrate to
distant sites in the body to colonize various organs in a process called metastasis (Figure 1.1).
Tumour stem cells often have chromosome abnormalities reflecting their genetic instability,
which leads to progressive selection of subclones that can survive more readily in the
multicellular environment of the host (Luther and Chan, 2016; Palucka and Coussens, 2016).
1|Page

Quantitative abnormalities in various metabolic pathways and cellular components
accompany the tumour progression. The invasive and metastatic processes as well as a series
of metabolic abnormalities resulting from the cancer cause illness and eventual death of the
patient unless the neoplasm can be eradicated with treatment (Jiang, Puntis and Hallett, 1994;
Luther and Chan, 2016).
The International Agency for Research on Cancer (IARC) in GLOBACAN cancer statistics
survey for 2020 estimated 19.3 million new cases of cancer and ~10 million deaths from
cancer worldwide (Ferlay et al., 2021). Lung cancer, liver cancer and stomach cancer were
the top three causes of cancer death. Worldwide, lung, liver and stomach cancers were the top
three causes of cancer death. In Europe, breast cancer, prostate cancer, colorectal cancer, and
lung cancer are the top four diagnosed cancers accounting for 50% of all diagnosed cancers
in both sexes (Bray et al. 2018; Ferlay et al. 2021). Colorectal cancer was the third leading
cause of cancer deaths following prostate and lung cancer in males, and breast and lung
cancer in females in 2020 (Ferlay et al., 2021). With an ageing population worldwide,
colorectal cancer (CRC) is emerging as a formidable health problem (Arnold et al., 2016).
According to the IARC GLOBOCAN reports from 2018 and 2020 (Figure 1.2), CRC remains
the third most common cancer in both sexes (1,931,590 cases, 10% of the total in 2020) and
the second in causing deaths due to cancer following lung cancer (935,173 cases, 9.4% of the
total) worldwide with 55% of the cases occurring in more developed regions (Bray et al.,
2018; Ferlay et al., 2021; Arnold et al., 2016).

2|Page

Figure 1.2: Graphical overview of incidence and mortality rates of different cancers
worldwide in 2018 and 2020. (Bray et al., 2018; Ferlay et al., 2021)
1.1 Colorectal cancer
CRC is a cancer of the lower bowels in which tumour growth occurs in the tissues of the
colon and/or rectum. As colon cancer and rectum cancer have many common features, they
are mostly referred to as colorectal cancer (CRC). Although the prevalence of CRC has
slowly increased since the 1960s worldwide, the mortality rate has decreased over the past
decades due to improved treatments (Arnold et al., 2016). The rates of CRC incidence and
mortality vary widely worldwide. Global patterns suggest that CRC incidence and mortality
are rising rapidly in many middle-income developing countries linked to rapid westernisation
of diet and lifestyle. Countries, such as Japan, have observed a substantial increase in the
number of new cases of CRC whereas the African nations have the lowest recorded rates of
CRC incidence and mortality (Arnold et al., 2016; Bray et al., 2018). Such trends in CRC
incidence and mortality have been observed in Ireland as well (Figure 1.3, Table 1.1). The
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number of new CRC cases recorded increased from 2,426 (in 2010) to 3178 (in 2020) which
is corresponding to an increase in deaths from 942 (in 2010) to 1,282 (in 2020) in the Irish
population (Cancer Incidence, Survival and Mortality Data - HSE.ie, 2019; Cancer today,
2020).

Figure 1.3: Trends in incidence and mortality of CRC cases in Ireland. Annual percentage
changes from 1994 to 2015. (NCRI.ie, 2021)
In Ireland, CRC is the fourth most common, newly diagnosed cancer, among men and
women (Table 1.1). The number of new cases is expected to increase significantly over the
next 10 years, due mainly to an increasing and ageing population (Arnold et al. 2016). Cancer
incidence projections 2020-2045 report of Ireland predicted that the annual number of CRC
cases to increase in males from 1,021 in 2015 to 2,196 in 2045 (+115%) and in females from
776 in 2015 to 1,617 in 2045 (+108%) – an increase to 3,813 overall (+112%)
(NCRI.ie, 2021). CRC is currently the second most common cause of cancer death in Ireland
(up from the third in 2018) and about 40 percent of colorectal cancer patients die from the
disease. With increasing projections of CRC incidence, CRC related deaths will likely also
increase. (Arnold et al. 2016; Cancer incidence projections for Ireland 2020-2045, 2021).
Relatively few CRCs occur in the population below 40 years of age. However, rates increase
rapidly with age, more markedly for colorectal cancer (Keum and Giovannucci, 2019; Arnold
et al. 2016).

4|Page

Table 1.1: Top five cancers sited from estimated number of new cases and deaths in 2020
recorded in Ireland both sexes and individually for male and female population – IARC
GLOBOCAN 2020 (Cancer today, 2020)
Table 1.1A: Top 5 cancer sites by number of cases and deaths in both sexes
Incidence case count
Mortality case count
Prostate
4503
Lung
2232
Breast
3433
Colorectum
1282
Lung
3271
Breast
745
Colorectum
3178
Pancreas
618
Skin
1316
Prostate
569
Table 1.1B: Top 5 cancer sites by number of cases and deaths in male population
Incidence case count
Mortality case count
Prostate
4503
Lung
1194
Colorectum
1856
Colorectum
749
Lung
1643
Prostate
569
Bladder
729
Pancreas
358
Kidney
673
Oesophagus
347
Table 1.1C: Top 5 cancer sites by number of cases and deaths in female population
Incidence case count
Breast
Lung
Colorectum
Corpus uteri
Skin

3433
1628
1322
808
772

Mortality case count
Lung
Breast
Colorectum
Ovary
Pancreas

1038
745
533
297
260

1.1.1 Aetiology of CRC
CRC results from the progressive accumulation of genetic mutations and epigenetic
alterations that lead to the transformation of normal colonic epithelium to colon
adenocarcinoma. Epigenetic alterations are the inheritable changes in gene activity and
expression that occur without an alteration in DNA sequence (Keum and Giovannucci, 2019).
The molecular genesis of CRC is based on a multistep event that may take several years to
develop full scale malignant tumours (Fearon and Vogelstein, 1990; Keum and Giovannucci,
2019; Lengauer, Kinzler and Vogelstein, 1998). These can include:
1) Genetic and epigenetic (non-genetic influences on gene expression) alterations that
underlie and promote the colon tumour formation process because they provide a
clonal growth advantage to the cells that acquire them. (Hong, 2018; Jung et al., 2020)
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2) The loss of genomic stability from point mutations to chromosomal rearrangements
which leads to tumour development.
3) The hereditary cancer syndromes which frequently correspond to germ line forms of
key genetic defects whose somatic occurrences drive the emergence of sporadic colon
cancers.
Tumour development in sporadic CRC is known to arise from different pathways such as:
chromosomal instability (CIN), microsatellite instability pathway (MSI) and CpG (5’-Cphosphate-G-3’) island methylator phenotype (CIMP) (De Rosa et al., 2015).
1.1.1.1 Chromosomal instability (CIN)
CIN is characterised by an accumulation of mutations in tumour suppressor genes (such as
APC, MADR2, and p53 genes) and oncogenes (such as KRAS, ErbB2, PI3KCA, and
CCND1 genes), which lead to transformation of normal colonic epithelium to colon
adenocarcinoma (Dunican et al., 2002). CIN occurs in 60-70% of all CRC cases, and
characteristically are aneuploid (the presence of an abnormal number of chromosomes in a
cell – one less or one more); highly differentiated, with no lymphocytic infiltration; have a
poor prognosis, and no specific tumour site (colon or rectal) predominance (Dunican et al.,
2002; Arriba et al., 2015).
1.1.1.2 Microsatellite instability (MSI)
MSI refers to repetitive DNA expansions and contractions in the cell. Molecular causes of the
MSI phenotype are DNA replication and repair defects with 15% occurrence in CRC,
(Dunican et al., 2002) and is predominantly caused by hyper methylation of the promoter
region of MLH1 (encode for MutL homolog 1), resulting in transcriptional silencing
(Koyuncuer and Ozkan, 2020). MSI results in inactivation of the mismatch repair system, and
thereby failure to correct nucleotide mismatches, which causes a high frequency of mutations
in coding and non-coding regions of repetitive sequences throughout the cancer genome.
Typical of MSI tumours are frameshift mutations in specific genes such as β-catenin,
transforming growth factor β receptor II (TGFβRII), epidermal growth factor receptor
(EGFR) or Bcl-2-associated X protein (BAX) (Koyuncuer and Ozkan, 2020). MSI tumours
are also associated with larger tumour size and are more frequently observed in women
(Koyuncuer and Ozkan, 2020). Rectal tumours exhibiting MSI are rare, in terms of
occurrence; they are often associated with Lynch syndrome – a hereditary disorder caused by
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a mutation in a mismatch repair gene in which affected individuals have a higher-than-normal
chance of developing CRC, endometrial cancer, etc. (Razvi, Giardiello and Law, 2017).
1.1.1.3 CpG island methylator phenotype (CIMP)
CpG sites or CG sites are regions of DNA where a phosphate links a cytosine and a guanine
in the linear sequence of bases (5'—C—phosphate—G—3'), that is, cytosine and guanine
separated by only one phosphate. CpG islands are part of the promoter of ~50% of all genes
(Tapial et al., 2019). Promoter CpG island hyper methylation results in inactivation of tumour
suppressor and DNA repair genes causing transcriptional silencing, which reflects an
epigenetic change (Bae et al., 2016). The MLH1 gene is frequently inactivated, which is
reported in most CRCs and has also been identified in adenomas (Bae et al., 2016; Tapial et
al., 2019). CIMP tumours are associated with proximal colon localisation, older age, MSI,
high frequency of BRAF (proto-oncogene B-Raf) and KRAS (Ki-ras2 sarcoma viral
oncogene) mutations and poor differentiation (Bae et al., 2016).
1.1.2 Pathology and staging of CRC
Colon and rectum walls are made up of several layers which are (from inner to outside layer):
mucosa, submucosa, muscularis propria and serosa (serosa is not found on most of the
rectum). CRC starts in the innermost layer (the mucosa) in the form of non-cancerous polyps
(Figure 1.4) and its roots can grow through some or all the other layers. When cancer cells
are in the wall; they can then grow into blood vessels or lymph vessels (tiny channels that
carry away waste and fluid). From there, they can travel to nearby lymph nodes or to distant
parts of the body. The extent of spread of CRC depends on its depth into the intestinal wall
and if it has spread outside the colon or rectum (Kay Washington, 2008).

Figure 1.4: Graphical view of colonic polyps.
(Image Copyright of Cancer Research UK)
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Polyp is a non-specific term for the growth on the inner surface of the colon or rectum which
may eventually develop into cancer. The two-common type of polyps found in colorectal
regions are: 1) Hyperplastic and inflammatory polyps (these are generally non-cancerous); 2)
Adenomas / adenomatous polyps. Adenomas are pre-malignant lesions most likely to become
cancers, about 96% of CRCs are adenocarcinomas (cancer developed from adenomas), which
evolve from glandular tissue (Uyar, 2020; Stewart et al., 2006). These start in the glandular
cells that make mucus to lubricate the inside of the colon and rectum (Kay Washington, 2008;
Dubé et al., 2017). Adenomas are sub classified as tubular, tubulovillous and villous based
on their architectural features (Dubé et al., 2017).
1.1.2.1 Cancer staging systems
Staging defines the severity and extent of cancer. The American Joint Committee on Cancer
(AJCC) established the tumour/node/metastasis (TNM) system, which is most commonly
used for cancer staging (AJCC Cancer Staging Manual, 7th Edition).

The TNM system

assigns a number based on:
•

Degree of invasion of intestinal wall – “T”
o TX : Primary tumour which cannot be evaluated.
o T0 : Primary tumour is not evident.
o Tis : Early cancer stage limited to specific tissue / area.
o T1-T4 : Size and/or extent of tumour.

•

Degree of lymphatic node involvement – “N”
o NX: Regional lymph nodes cannot be evaluated.
o N0: Cancer is not present in lymph nodes.
o N1-N3: Number/extent of lymph nodes involved.

•

Degree of metastasis – “M”
o M0: Cancer cells have not metastasised.
o M1: Cancer cells metastasised to other tissues/organs.
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Different cancers have different classification systems in which the letters and numbers may
not have the same meaning. The broader stage of a cancer is defined by I, II, III, IV derived
from the TNM values grouped together. The TNM staging of CRC in humans is described in
table 1.2 (Tong et al., 2018).
Table 1.2: TNM staging of CRC in prognostic groups (Tong et al., 2018)
AJCC stages

TNM stages

Prognosis

Stage 0

Tis N0 M0

Tis: Tumour confined to mucosa; cancer-in-situ

Stage I

T1 N0 M0

T1: Tumour invades submucosa

Stage I

T2 N0 M0

T2: Tumour invades muscularis propria

Stage II-A

T3 N0 M0

T3: Tumour invades sub serosa or beyond (without other
organs involved)

Stage II-B

T4 N0 M0

T4: Tumour invades adjacent organs or perforates the
visceral peritoneum (the inner lining of abdominal cavity)

Stage III-A

T1-2 N1 M0

N1: Metastasis to 1 to 3 regional lymph nodes. T1 or T2.

Stage III-B

T3-4 N1 M0

N1: Metastasis to 1 to 3 regional lymph nodes. T3 or T4.

Stage III-C

any T, N2

N2: Metastasis to 4 or more regional lymph nodes. Any T.

M0
Stage IV

any T, any N, M1: Distant metastases present. Any T, any N.
M1

CRC stage progression, tumour development and metastasis are the result of essential cell
physiology alterations such as: insensitivity to growth inhibitory signals; self-sufficiency in
growth factors; evasion of apoptosis; unchecked replicative potential; reprogrammed energy
metabolism; evasion of immune destruction and tumour angiogenesis (Tong et al., 2018;
Mathonnet, 2014; Salem, Puccini and Tie, 2020). The formation of new vasculature
(angiogenesis) is reported to be actively involved in the metastasis of CRC, which can turn
even benign tumours to malignant tumours (Salem, Puccini and Tie, 2020).
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1.2 Tumour angiogenesis in CRC
Angiogenesis is the growth of new blood vessels from existing vessels and involves the
migration, growth, and differentiation of endothelial cells to line the inside wall of blood
vessels. The term comes from the Greek words: angio, meaning blood vessel, and genesis,
meaning beginning (Folkman, 2007).
The process of angiogenesis is controlled by chemical mediators (illustrated in Figure 1.5) in
the body. These mediators can stimulate both the repair of damaged blood vessels and the
formation of new blood vessels (angiogenesis). Other chemical factors, called angiogenesis
inhibitors, interfere with blood vessel formation. Normally, the stimulating and inhibiting
effects of these chemical factors are in equilibrium so that blood vessels form only when and
where they are required (Adams and Alitalo, 2007; Folkman, 2007; Yin et al., 2020). In
healthy adults, a balance of growth factor signalling maintains endothelial cells in a quiescent
or resting state.
Blood vessels are comprised of an inner lining of closely assembled endothelial cells
sheathed by pericytes, (the basement membrane) embedded in the stromal compartment
(various stromal cells and extracellular matrix) (Yin et al., 2020). But conditions such as
hypoxia or other endogenous signals activate these cells and induce the release of signalling
factors, such as vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF)
and chemokines. VEGF is secreted by cells (e.g., tumour cells) and binds to its receptor
(VEGF receptor 2) and neuropilin-I receptor on endothelial cells (Figure 1.5). VEGF is the
most common of at least six other pro-angiogenic proteins released from tumours (Adams
and Alitalo, 2007; Folkman, 2007).
For capillary formation (Figure 1.5), a tumour cell stimulated / influenced by Neuropilin,
VEGF/VEGFR, notch/delta-like 4 (Notch/DLL4) and Jagged1 (JAG1) signalling and releases
matrix metalloproteases (MMP) to degrade the basement membrane and remodel the
extracellular matrix. MMPs, released from tumour cells, mobilize pro-angiogenic proteins
from stroma (Adams and Alitalo, 2007).
Tumour cells secrete angiopoietin 2 (ANGPT2), which is pro-angiogenic and competes with
ANGPT1 (housekeeping protein / anti-angiogenic) for binding to the endothelial TyrosineProtein Kinase Receptor Tie-2 receptor (TEK). ANGPT2 increases the degradation of the
vascular basement membrane and migration of endothelial cells, therefore facilitating
capillary / sprout formation (Adams and Alitalo, 2007; Folkman, 2007) (Figure 1.5). Tumour
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cells are polarized and extend numerous ﬁlopodia to guide sprout migration (via
semaphorins, ephrins, and integrins guidance signals) towards angiogenic stimuli (VEGF
gradient) (Adams and Alitalo 2007).
Platelet-derived growth factor (PDGF) and basic fibroblast growth factor (bFGF; also known
as FGF2) are angiogenic proteins secreted by some tumour cells (Folkman, 2007).
Endothelial cells also contain integrins, which carry signals both upstream and downstream to
facilitate endothelial cell binding to extracellular membranes, helping the cells to maintain
viability and responsiveness to growth regulatory proteins (Folkman, 2007).
Fusion of neighbouring branches occurs when tumour cells encounter each other, establish
endothelial cell junctions, and form a continuous lumen of blood vessel. An extracellular
matrix is deposited to establish a new basement membrane; endothelial cell proliferation
ceases, and pericytes are recruited to stabilize the new vessel. Once blood flow is established,
the perfusion of oxygen and nutrient reduces angiogenic stimuli (VEGF expression) and
inactivates endothelial cell oxygen sensors, re-establishing the quiescent state of the blood
vessel (Adams and Alitalo, 2007).
The growth and proliferation of cancer cells, particularly in metastatic colorectal cancer
(mCRC), depends essentially on tumour angiogenesis through various signalling pathways.
Tumour angiogenesis generates neovascularization (formation of new blood vessels) in
response to cellular need for nutrients and oxygen. During this process, the angiogenic switch
(such as VEGF and EGFR) is activated leading to new vessel sprouting that sustain the
expanding tumour growth (Adams and Alitalo, 2007; Folkman 2007). The process of cell
growth, cell death, cell migration and alterations in vascular matrix is a complex system of
vascular remodelling that is controlled by manifold physical, biochemical, and genetic
components. Molecular triggers commonly derived from tumour cells imbalance the process
of vascular remodelling leading to tumour progression (Adams and Alitalo, 2007; Yin et al.,
2020).

11 | P a g e

Figure 1.5: Key factors involved in the angiogenic switch in tumour angiogenesis. The
angiogenic

switch

is

the

interactional

initiation

between

the

tumour

and

its

microenvironment. Tumour-derived chemoattractants (ANGPT1, ANGPT2, MMP) promote
the secretion of multiple angiogenic growth factors and proteinases (VEGF, bFGF, PDGF).
Reproduced with copyright permission from Nature Publishing Group (Folkman 2007).
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1.3 Treatment of CRC
In developed countries widespread screening programmes – especially for risk populations
are the primary mode of early detection leading to earlier diagnosis and treatment have been
successful in preventing late-stage CRC development. The treatment of CRC is
individualised and based on the CRC staging to provide the patient with the best quality of
life after survival. For patients with localised and potentially curable CRC, surgery is the
primary treatment. The localised stage-dependent relative five-year survival rate (~64%) has
improved in CRC patients (SEER, 2021; Xie, Chen and Fang, 2020) due to a combination of
curative resection and evolved therapy implementation. Radiation and chemotherapy with
recent targeted therapies have played an important role in the advancement of CRC treatment.
Preoperative and postoperative radiotherapy studies have shown decreased risk of CRC
recurrence (Sauer et al., 2012). A new approach termed total neoadjuvant therapy (TNT) is
being practised for advanced stage CRC patients where chemotherapy and chemoradiation
therapy are given six months before the surgery resulting in increased complete pathologic
response and prolonged disease-free survival rate of ~39% (Cercek et al., 2018; Petrelli et al.,
2020). In brief, these therapeutics-based CRC treatments can be divided into chemotherapy,
targeted therapy, and immunotherapy (Xie, Chen and Fang, 2020; Petrelli et al., 2020).
1.3.1 Chemotherapy
A regimen of chemotherapy consists of a specific number of cycles over a set period during
which the patient may receive a combination of different anticancer drugs based on the
therapist’s discretion. The commonly used chemotherapy regimens are summarised in Table
1.3 (Biller and Schrag, 2021) along with the associated toxicities and adverse effects.
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Table 1.3: Commonly used chemotherapy regimens for CRC treatment. (Biller and Schrag, 2021)
Regimen

Component drugs

FOLFOX: the most commonly used
adjuvant regimen.

fluorouracil,
leucovorin, and
oxaliplatin

Irinotecan: patients with uridine
diphosphate glucuronosyltransferase
1A1 (UGT1A) polymorphism

Irinotecan

FOLFIRI: Not used in adjuvant
regimens.
Fluorouracil and leucovorin: for frail
patients with major co-morbidities
Capecitabine: preferred if no plans to

fluorouracil,
leucovorin, and
irinotecan
fluorouracil and
leucovorin
capecitabine

Mechanism of action / drug
Toxicities and adverse effects
target
Inhibition of DNA synthesis in
cancer cells: fluorouracil inhibits
the formation of thymidylate - the
precursor
of
thymidine
triphosphate, which is essential for
DNA synthesis.
Leucovorin enhances the activity
of fluorouracil by stabilizing the
interactions of its active metabolite
to the enzyme thymidylate
synthetase.
Oxaliplatin binds to the guanine
and cytosine moieties of DNA,
leading to cross-linking of DNA
Inhibition of DNA synthesis by
blocking topoisomerase I-DNA
complex
Inhibition of DNA synthesis

Firstline
use

Neuropathy, hypersensitivity,
and pancytopenia (lower than
normal number of red and white Yes
blood cells and platelets in the
blood)

Severe diarrhea and neutropenia No

Pancytopenia, diarrhea

Yes

Pancytopenia, mucositis

Yes

A prodrug that is selectively Pancytopenia, hand/foot

Yes

Inhibition of DNA synthesis
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intensify treatment
CAPOX / XELOX: most common;
substitutes oral capecitabine for
intravenous fluorouracil.

capecitabine and
oxaliplatin

CAPIRI /XELIRI: Substitutes oral
capecitabine for intravenous
fluorouracil

capecitabine and
irinotecan

FOLFOXIRI: Intensive regimen used
for patients who are fit for surgical
resection.

fluorouracil,
leucovorin,
oxaliplatin, and
irinotecan

FOLFOX + BRAF/KRAS inhibitors:
For tumors that are
KRAS/NRAS/BRAF wild type;
ineffective for tumors with sequence
variations in these genes.

fluorouracil,
leucovorin,
oxaliplatin and
cetuximab or
panitumumab

IROX: Nonstandard regimen for
patient’s intolerant of fluorouracil due
to severe dihydropyrimidine
dehydrogenase deficiency or coronary
vasospasm

irinotecan and
oxaliplatin

tumour-activated to its cytotoxic – syndrome
fluorouracil
Inhibition of DNA synthesis
Pancytopenia, diarrhea,
hand/foot-syndrome,
neuropathy, and
hypersensitivity
Inhibition of DNA synthesis
Pancytopenia, diarrhea,
hand/foot-syndrome
Inhibition of DNA synthesis

Cetuximab and panitumumab
binds to EGFR and competitively
inhibits the binding of epidermal
growth
factor
resulting
in
inhibition of cell growth, induction
of apoptosis.
Inhibition of DNA synthesis

Yes

Yes

Pancytopenia, diarrhea,
neuropathy, and
hypersensitivity

Yes

Pancytopenia, diarrhea,
hand/foot-syndrome,
hypomagnesemia,
hypersensitivity reactions,
neuropathy, skin toxicity

Yes

Diarrhea and neuropathy

Rare
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1.3.2 Targeted therapy
As the name suggests, targeted therapy targets the CRC specific genes, proteins, or the tissue
environment contributing to the tumour growth. Targeted therapies include monoclonal
antibodies (mAb) and small molecules with a molecular weight of <900 Dalton, which can
directly inhibit cell proliferation, differentiation, or migration. The targeted inhibitors are also
included in some chemotherapy regimens (Table 1.3). For CRC, the following are the
targeted therapy options:
EGFR inhibitors such as Cetuximab (Garrett and Eng, 2011; Price et al., 2014) and
Panitumumab (Price et al., 2014) are used in the treatment of mCRC. These inhibitors bind to
EGFR and competitively inhibit the binding of epidermal growth factor resulting in inhibition
of cell growth, induction of apoptosis. EGFR mAb in combination with chemotherapy has
shown improvement in progression-free survival in CRC patients (Chan et al., 2017).
Anti-angiogenesis therapy inhibits tumour angiogenesis and prevents the tumour growth.
Preclinical and clinical evidence suggest the benefit of anti-angiogenic agents such as
bevacizumab (Avastin - Genentech, Inc., 2021; Cao et al., 2019), aflibercept (Sun and Patel,
2013) and regorafenib (Papadimitriou and Papadimitriou, 2021) in the treatment of mCRC.
Combined targeted therapies: In ~8 % of CRC patients, a specific mutation called BRAF
V600E was detected (AACR Project GENIE: Powering Precision Medicine through an
International Consortium, 2017). The negative charge of glutamic acid (E) due to the V600E
mutation initiates phosphorylation of nearby serine and threonine residues and therefore
functions to activate BRAF. This loss of inhibition of BRAF leads to an increase of basal
oncogenic activity (Liang, Khorana and Kalady, 2015). Patients with BRAF V600E mutation
markers are treated with BRAF inhibitors such as encorafenib and cetuximab (Liang,
Khorana and Kalady, 2015).
Tumour-agnostic therapy: This approach targets specific genomic alterations or molecular
features irrespective of tumour sites. In mCRC patients, neurotrophic tyrosine receptor kinase
(NTRK) gene fusion is another biomarker where surgery is not possible due to extensive
spread of cancer and other treatments have been reported to fail (Cocco, Scaltriti and Drilon,
2018). In this genetic alteration, two genes of the NTRK family fuse together and produce an
altered tropomyosin receptor kinase (TRK) protein, which leads to uncontrolled cell growth
(Lange and Lo, 2018). Larotrectinib (Burki, 2018) and entrectinib (Drilon et al., 2017) are the
TRK inhibitors used for mCRC treatment where NTRK alterations are present.
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1.3.3 Immunotherapy
Immunotherapy

in

CRC

treatments

explores

the

concept

of

T-cell

mediated

immunosuppression. Tumour cells can upregulate immune checkpoint molecules –
programmed death (PD-1), programmed death-ligand 1 (PD-L1), and CD152, that exhaust T
cells and inhibit apoptosis of malignant cells. PD-1 binds to PD-L1 to prevent binding of T
cells and escape cellular apoptosis. Inhibitors of either PD-1 (Pembrolizumab, Nivolumab,
Cemplimab) or PD-L1 (Atezolizumab, Avelumab, Durvalumab) (Tumeh et al., 2014;
Golshani and Zhang, 2020) are used for mCRC treatment.
The improved aggressive surgical resections and development of novel chemotherapy
regimens has increased the survival rate in cancer patients but with less focus on the quality
of life of cancer patients and survivors (Buiting and Olthuis, 2020). Various surveys and
statistical studies have reported CRC patients and survivors, especially elderly (aged > 80),
consider quality of life as important as survival both during the treatment and post-treatment
(Yucel, 2015; McCombie, Frampton and Frizelle, 2021). As the number of toxicities and
adverse effects of the present mCRC and CRC chemotherapy regimens (enlisted in Table 1.3)
are very high, the quality of life of patients is reduced to a great extent. About one-third of the
CRC patients have been reported to terminate their chemotherapy regimens prematurely
(known as early discontinuation - EDChemo) due to strong adverse effects (Boakye et al.,
2021).
Over the last two decades, with despite ~70 new cancer therapies approved (from 2002 to
2014) for various cancer types, the overall cancer survival rate has barely improved - by ~2
months, (Fojo, Mailankody and Lo, 2014) compared to the cost of drug development and
treatment. More recently, anti-cancer research has shifted focus from cytotoxic drugs to
target-based drugs to reduce the toxicities and adverse effects. The known drug-targets are
being repurposed for anticancer therapies against chemoresistance, tumour angiogenesis, etc.
(Spugnini and Fais, 2019; Huang, Zhao, Liu and Liu, 2018; Houthuijzen et al., 2017; Wu et
al., 2013). The combination of these target-based drugs as adjuvants and/or neo-adjuvants
with lower-dose chemotherapy regimens (Spugnini and Fais, 2019; Boakye et al., 2021),
which help reducing the adverse treatment effects and improve patient compliance to the
regimen. One of the analytical studies (Munker et al., 2018) has inferred that dosage
reduction with longer chemotherapy regimen in mCRC therapy reduces the treatment adverse
effects without compromising the survival rate. With extensive data linking G protein
coupled receptors (GPCRs) and CRC, GPCRs have emerged as attractive targets to develop
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novel strategies targeting tumour progression and metastasis in CRC (Kumari, Reabroi and
North, 2021; Usman et al., 2020; Liu et al., 2017).
1.4 G protein coupled receptors – novel drug targets for CRC therapy.
New drug discovery is impeded by the limited number of novel and validated disease targets
(Chandra, 2011; Gilbert, 2013). Target-based drug discovery focuses on specific known
protein targets and can explore the possible importance of functionally lesser understood
proteins that may be involved in disease mechanism. Hence, the approach provides an
effective means of moving beyond well understood targets to discover novel drug targets
(Kue et al., 2016).
The Molecular Libraries Program (MLP) by the National Institute of Health (NIH) performed
large-scale screenings to identify new chemical entities to explore novel drug targets (Austin,
2004). These screens identified G protein coupled receptors (GPCRs) as one of the most
targeted protein family involved in high-throughput screening (HTS) in the MLP (Przydzial
et al., 2013; Insel et al., 2019). From a 2011-2019 sales report, drugs targeting GPCRs were
estimated to hold ~ 30-34 % of marketed therapeutics sales (Hauser et al., 2017; Hauser et al.,
2018; Zhou and Wild, 2019; Kooistra et al., 2020).
GPCRs are found only in eukaryotes - including animals, plants, fungi, and protozoa (Salon,
Lodowski and Palczewski, 2011). In humans, GPCRs have about 800 members known
according to phylogenetic analysis studies (Kooistra et al., 2020). However, a limited number
of known GPCRs (~110) out of the ~800 human GPCRs were considered as drug targets
(Salon, Lodowski and Palczewski, 2011; Qu, Wang and Wu, 2020) while the remaining were
regarded as orphan receptors as neither their endogenous ligand nor their physical function
has been elucidated. The identification and quantification of previously unrecognised GPCRs
further increased the number of viable GPCR drug targets to 134 (Sriram and Insel, 2018;
Insel et al., 2019). Thus, GPCRs represent a rich source of drug targets (34% of marketed
drugs), comprising the largest (4% of human genome) and most diverse group of membrane
receptors in the human genome (Salon, Lodowski and Palczewski, 2011; Kooistra et al.,
2020).
The signalling pathways of GPCRs have been reported to play crucial roles in blood vessel
development, such as lysophosphatidic acid/LPA4, sphingosine 1-phosphate/Edg-1, and
lysophospholipid / GPR4 (Liu et al., 2000; Yang et al., 2007; Parker, Parker, Sah and Sallee,
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2005). Crosstalk between GPCR downstream signalling and VEGFR2 pathways has been
reported but not profoundly understood during development of angiogenesis. It has been
shown that Gαq/Gα11 and Gα13 proteins regulated VEGFR2 tyrosine phosphorylation through
interaction with VEGFR2 (Zeng et al., 2003). The disruption of the gene for the heteromeric
G protein subunit Gα13 disable endothelial cells from developing into an organised vascular
system. Thrombin protein (binds to protease activated receptors) has also been shown to
directly stimulate VEGFR1 and VEGFR2 expression (Richard, Vouret-Craviari and
Pouysségur, 2001), suggesting that the transcription of VEGF/VEGFR2 and tumour
angiogenesis could be regulated by GPCRs.
Mutations and alterations in some GPCRs have been linked to tumorigenicity where tumour
cells overexpress and aberrantly activate GPCRs by releasing an excess of GPCR agonists
such as bioactive lipids, peptides, chemokines, hormones, etc (Liang et al., 2020; Usman et
al., 2020). A number of GPCR targeted drugs against various cancers have been approved by
the Food and Drug Administration (FDA) but none for CRC yet (enlisted in Table 1.4).
Table 1.4: FDA approved GPCR target-based drugs for anticancer therapy since 1996
(Usman et al., 2020).
Drugs

GPCR Receptor

Cabergoline

Dopamine receptor
D1

Lanreotide
Degarelix

Somatostatin
receptor
Gonadotropin
releasing factor
hormone receptor

Cancer
Neuroendocrine
tumours, pituitary
tumours

Approval year
1996 (Lin, Zhang, Zhang
and Wu, 2019)

Pancreatic cancer

2007 (Godara, Siddiqui,
Byrne and Saif, 2018)

Prostate cancer

2008 (Olsson et al., 2017)

Plerixafor

C-X-C chemokine
receptor 4

Multiple myeloma

Vismodegib

Smoothened receptor

Metastatic basal cell
carcinoma

Raloxifene

Estrogen receptor

Breast cancer

Sonidegib

Smoothened receptor

Mogamulizumab

C–C Chemokine
receptor 4

Metastatic basal cell
carcinoma
T cell lymphoma

2008 (Wang, Tannous,
Poznansky and Chen,
2020)
2012 (Bánvölgyi et al.,
2019)
2014 (Ağardan et al.,
2020; Mirzapur, Khazaei,
Moradi and Khazaei,
2018)
2015 (Chen et al., 2018)
2018 (Moore et al., 2019)
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Overexpression of a variety of GPCRs is associated with CRC development. Overexpression
of Formylpeptide receptor 2 (GPCR) is linked to abnormal migration and proliferation in
mammalian colon cells (Chen et al., 2013; Liang et al., 2020; Tian et al., 2020). Similarly, for
phospholipid GPCRs – activation of Lysophosphatidic acid receptor 1 and 2 has been
reported to stimulate cell proliferation and cell invasion activity in CRC cells (Yun, 2019;
Kitamura et al., 2019; Ishimoto et al., 2020). Another GPCR - GPR120 also called free fatty
acid receptor 4 (FFAR4), has been identified as a promotor of tumour angiogenesis in human
colorectal carcinoma (Wu et al., 2013).
1.4.1 Introduction to GPCRs
GPCRs, also known as seven transmembrane (TM) domain receptors, hepta-helical
receptors, serpentine receptors, and G protein-linked receptors (GPLR), sense external stimuli
molecules outside the cell and transmit cellular signals to the cytoplasm and eventually to the
nucleus (Salon, Lodowski and Palczewski, 2011).
GPCRs have a common structural feature of seven helical domain which transverse the
plasma membrane forming the serpentine structure as shown in Figure 1.6. The GPCR
structure can be split into three segments: the seven TM helical bundle (which forms the core
of the GPCR) and often with a perpendicular helix (H8) in the intracellular domain; three
extracellular loops (ECL), which connect the helices at the extracellular end and modulate
ligand access; and three intracellular loops (ICL), which connect the helices at the
intracellular end and interacts with effector signalling proteins. The bundle-like core
conformation of the seven TM domains is stabilized by an essential disulfide linkage formed
by two cysteine residues, one on the TM3/ECL1 interface and one in ECL2 (Figure 1.6) in all
the GPCRs. The N-terminus of a GPCR is at the extracellular side, and the C-terminus is
located intracellularly. The various domains of GPCRs vary in length in different types of
GPCRs providing specific structural and functional properties (Grisshammer, 2017; Insel et
al., 2019).
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Figure 1.6: Schematic view of the general structure of a G protein-coupled receptor (GPCR)
embedded in the cell membrane illustrating the conserved S-S (disulfide linkage) essential for
structural stability. Figure adapted from “Virtual Background – Cell Membrane”, by
BioRender.com (2021).
1.4.2 Classification of GPCRs
Based on sequence homology, the Nomenclature Committee of the International Union of
Basic and Clinical Pharmacology (NC-IUPHAR) classified six GPCR classes (A to F)
(Kolakowski, 1994; Attwood and Findlay, 1994), which includes GPCRs from all species
even classes that do not appear in humans (such as Class D and Class E).
Class A-F classification system is represented as:
Class A: Rhodopsin-like GPCR
Class B: Secretin-like GPCR
Class C: Metabotropic glutamate-like GPCR
Class D: Fungal mating pheromone GPCR
Class E: Cyclic AMP GPCR
Class F: Frizzled/smoothened GPCR
More recently another popular system was presented by Fredriksson known as the GRAFS
classification system (Fredriksson, Lagerström, Lundin and Schiöth, 2003) based on
phylogenetic sequence relations: Glutamate (Class C), Rhodopsin (Class A), Adhesion,
Frizzled and Secretin (Class B) which is summarised in Table 1.5. Both the classification
schemes have shortcomings and inconsistencies that cannot assign new GPCR sequences
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from invertebrate species to any existing family or subfamily (Scholz, Langenhan and
Schöneberg, 2019).
Table 1.5: GPCR Glutamate, Rhodopsin, Adhesion, Frizzled, Secretin (GRAFS)
Classification with characteristics, biological roles, and representative examples for each
group. (Fredriksson, Lagerström, Lundin and Schiöth, 2003; Kooistra et al., 2020; Byrne et
al., 2021)
GRAFS /
Characteristics
Biological roles
Number of
known human
Sequences
Glutamate (Class Presence of 9
Neurobiological roles,
C) 22
conserved cysteine gustatory roles (sweet and
residues known as sour tastes)
cysteine rich domain
(CRD) or NCD3G
in the N-terminal
region
Rhodopsin (Class Presence of D/ERY Olfactory and vision stimuli,
A) 719
in TM3, NPxxY in neurotransmitter signalling,
TM7 and disulfide cardiovascular and
bond
immunological functions,
by cysteines (C) in etc.
ELC1 and ELC2
Adhesion (Class Long N-termini
Developmental biology of
B2) 33
containing multiple Central Nervous System,
functional domains immunological functions,
and having
etc.
numerous sites for
glycosylation
Frizzled (Class F) Characterized by
Developmental biology,
11
presence of 10
cancer development,
conserved cysteine perception of bitter taste,
residues known as also known
FZ_CRD domain or as receptors for Wnt proteins
FZ domain between
N-terminal and TM
regions
Secretin (Class Evolved from
Endocrine and metabolic
B1) 15
Adhesion receptor disorders
family

Representative
examples
Metabotropic glutamate
receptors, GABA
receptors, taste-1
receptors

Adrenergic receptors,
opioid receptors,
chemokine receptors

Latrophilin receptors,
Brain-specific
angiogenesis inhibitor
proteins
Smoothened receptor,
taste-2 receptors

Glucagon receptor,
GLP-1 receptor, growth
hormone releasing
hormone receptor
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1.4.3 Class A - Rhodopsin-like GPCRs signalling
The present research has focused on the Rhodopsin-like receptors, which play a crucial role
in many physiological processes, for instance, the transmission of the light and odorant
signal, the mediation of neurotransmission and hormonal action, cell growth and immune
defence (Ballesteros, Shi and Javitch, 2001; Kinoshita and Okada, 2015). These GPCRs
initiate downstream signalling networks by coupling with heterotrimeric guanine-nucleotidebinding regulatory proteins (G-proteins) and β–arrestin resulting in a broad range of
physiological and pathological processes (Kinoshita and Okada, 2015).
GPCRs can possess some degree of constitutive activity (a basal level of activity in the
absence of any agonist) (Salon, Lodowski and Palczewski, 2011; Kinoshita and Okada,
2015). The basal activity of a receptor can increase or decrease depending upon the type of
ligand binding in an orthosteric cavity located in the TM-bundle core towards the
extracellular end of the receptor. The binding ligands can be characterised according to their
pharmacological effects on the target receptor (Figure 1.7) as:
1) Full agonist: induce the maximal level of activation possible.
2) Partial agonist: activate the receptor above basal levels but not maximally.
3) Neutral antagonist: bind to the receptor but maintains basal levels by neither
stimulating nor inhibiting the receptor.
4) Inverse agonist: decrease the level of receptor activation below basal levels

Figure 1.7: Pharmacological effect of agonists, partial agonists, neutral antagonists, and
inverse agonists (Neubig, Spedding, Kenakin and Christopoulos, 2003)
The receptor activation typically starts with agonist binding and triggers a conformational rearrangement of TM and loop regions, which allows the coupling of a G protein present in the
cytosol leading to downstream signalling (Figure 1.8 a, b). During activation the GPCRs
transforms from basal (ground) state to an active state mediated by small conformational
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changes of the ligand binding (agonist) at the orthosteric site. These small structural changes
are amplified into larger structural changes at the intracellular domain (known as the “active
state” - Figure 1.8a) of the GPCR to facilitate G-protein coupling or arrestin interaction
(Latorraca, Venkatakrishnan and Dror, 2016). Where the ligand binding at the orthosteric site
is an antagonist or inverse agonist, the receptor retains the basal state or attains “inactive /
closed” state (Figure 1.8a), which cannot facilitate the G-protein coupling or arrestin
interaction at the intracellular domain (Latorraca, Venkatakrishnan and Dror, 2016; Nygaard
et al., 2013).
The heterotrimeric G protein consists of one α-subunit (there are 16 encoding genes
expressing 20 different Gα) bound to guanosine diphosphate (GDP); a β subunit (5 genes);
and a γ subunit (12 genes) (Kolakowski, 1994; Nygaard et al., 2013). The G protein remains
in an “inactive” state when its α subunit is bound to GDP and associated with its respective
βγ subunit. When the agonist binds to the inactive GPCR, the α subunit of the G protein
catalyses the GDP-GTP exchange and this promotes the dissociation of the βγ subunit (Figure
1.8). Subsequently, the free GTP-α (s, i, q, 12) and βγ subunits can transfer the signal to their
intracellular effectors, such as enzymes and ions channels through second messenger
molecules (such as cAMP, DAG and IP3) which lead to effector functions (Table 1.6)
(Ballesteros, Shi and Javitch, 2001; Kinoshita and Okada, 2015; Nygaard et al., 2013).
As Figure 1.8b illustrates two of the signalling pathways – Gαs and Gαq. Activated Gαs
stimulates membrane associated enzyme adenylyl cyclase (AC), which increases ATP to
cyclic AMP (cAMP) conversion. cAMP acts as a second messenger to activate protein kinase
A (PKA) which can phosphorylate multiple downstream targets; whereas the Gαi pathway
inhibits AC. Activated Gαq stimulates the membrane-bound phospholipase C (PLC) to cleave
phosphatidylinositol biphosphate (PIP2) into second messenger’s inositol triphosphate (IP3)
and diacylglycerol (DAG). IP3 increases intracellular calcium concentrations (Ca2+) while
membrane-bound DAG activates protein kinase C (PKC) by translocating it from cytosol to
plasma membrane.
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a)

b)

Figure 1.8: a) General flow of transformation of GPCR from basal state to active state when
an agonist (green) binds or inactive state when an antagonist / inverse agonist (red) binds at
the orthosteric binding site. H – helical transmembrane domains (Adapted from Nygaard et
al., 2013); b) Schematic diagram of G-Protein Coupled receptors diverse signaling pathways
upon activation of G-protein subunits [α, β and γ] or β-arrestin binding; Figure adapted from
“Virtual

Background

–

Cell

Membrane”,

by

BioRender.com

(2021).

Retrieved

from https://app.biorender.com/biorender-templates. (Byrne et al., 2021)
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Activated GPCRs also produce G protein independent biochemical responses through βarrestin molecules (versatile adapter proteins) that form complexes with GPCRs following
agonist

binding

and

phosphorylation

of receptors by GPCR

kinase

(GRK).

GRK

phosphorylates G-Protein independent ligand-bound GPCRs to initiate the recruitment of βarrestin and blocks G-Protein coupling. GPCR-β–arrestin complex promotes endocytosis,
trafficking ligand-GPCRs to sorting endosomes for either recycling to plasma membrane or
signaling and regulation of various cellular processes (Figure 1.8b). They play a central role
in the interrelated processes of homologous desensitization and GPCR internalization, which
lead to the termination of G protein-GPCR signal transduction (Kinoshita and Okada, 2015;
Nygaard et al., 2013). Similarly, several GPCRs have been shown to complex with small
GTP-binding proteins such as Ras, Rab, and Rho, leading to activation of phospholipase D
(Kinoshita and Okada, 2015).
Table 1.6: Classification of G proteins (Kolakowski, 1994)
Class

α subtype

Effector functions

Gs

αs, αolf

Adenyl

cyclase

(AC)

stimulation,

Ca2+

channel

activation
Gi

αo, αi1-3, αt, αgust, αz

AC inhibition, regulation of K+ and Ca2+ channels,
activates cyclic guanosine monophosphate (cGMP)
phosphodiesterase

Gq/11

αq, α11, α14-16

Phospholipase C-β activation

G12

α12, α13

Na+/ K+ exchange; stimulates Bruton’s tyrosine kinase
and ras-GTPase activating protein.
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1.5 GPR120 – discovery and therapeutics
GPR120 was originally described as an orphan GPCR in 2003 (Fredriksson, Lagerström,
Lundin and Schiöth, 2003). An orphan receptor is a protein that has a similar structure to
other identified receptors but are activated by binding to unknown signalling molecules. The
orphan receptors are said to be deorphanized when their endogenous / signalling molecules
are identified by various experimental assays describing their pharmacological activity (Yasi
et al., 2019; Laschet, Dupuis and Hanson, 2018). GPR120 was later deorphanized and found
to be a Rhodopsin-like GPCR based on the presence of canonical NPxxY and D/ERY (ERM
in GPR120) conserved motifs indicative of rhodopsin-like GPCRs (Hirasawa et al., 2004).
Subsequently, based on the nomenclature of the Free fatty acid receptor (FFAR) family,
GPR120 was named systematically as the Free fatty acid receptor 4 (FFAR4) - as its
endogenous ligands, poly-unsaturated long-chain free fatty acids (FFA), were known
(Davenport et al., 2013; Fredriksson, Lagerström, Lundin and Schiöth, 2003; Hirasawa et al.,
2008). However, the GPR120 receptor, unexpectedly, is only distantly related in terms of
sequence identity and location to the other FFA-responsive GPCRs such as FFAR1-3 (Table
1.7). The distant relatedness of GPR120 to the other members of FFAR family has been
reported in various other species as well (Mus musculus, Rattus norvegicus, Bos taurus,
Gorilla

gorilla,

Rhesus

monkey,

etc.)

at

NCBI

Gene

database

(https://www.ncbi.nlm.nih.gov/gene/).
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Table 1.7: Summary of characteristic profiles and biological activity of the members of Free
fatty acid receptor sub-family (Milligan, Shimpukade, Ulven and Hudson, 2016; Grundmann,
Bender, Schamberger and Eitner, 2021; Carullo et al., 2021).
Nomenclature
Coupling protein
Location (Homo
sapiens)
Location (Mus
musculus)
Location (Rhesus
monkey)
GPR120
Sequence identity
Endogenous
Agonist (FFA)

Expression sites

Major functions

GPR40/FFAR1
Gαq/11
Gαi/o
Gαs
Gα12/13
β-arrestin

GPR43/FFAR2 GPR41/FFAR3

GPR120/FFAR4

Gαq/11
Gαi/o
Gα12/13
β-arrestin

Gαi/o
β-arrestin

Gαq/11
Gαi/o
β-arrestin

19q13.12

19q13.12

19q13.12

10q23.33

7; 7 B1

7; 7B1

7; 7B1

19; 19 C2

19

19

19

9

20.66%

18.64%

23.43%

100%

Short chain,
C3>C4>>C2

Medium-long
chain, C14-18

Peripheral nervous
system
Pancreas (β-cell)
Intestine (L, K
cells)
Immune tissue
(DCs, thymus)

Adipose tissue
Macrophages
Lung
Intestine (L, K, I
cells)
Bone

Increase in heart
rate, energy
expenditure,
reduction of gut
motility,
Inhibition of
insulin secretion,
Gut hormone
release,
Decrease Th2
response

Differentiation,
browning,
Anti-inflammatory,
Epithelial repair,
Gut hormone
release,
Bone formation

Medium-long
chain, C6-C12

Short chain,
C3~C4~C2
PMNs
Pancreas (β(Neutrophils,
cells)
Eosinophils)
Intestine (L, K, Lymphocytes
I cells)
Monocytes
Bone
Pancreas (βCentral nervous cells)
system
Intestine (L
Immune cells
cells, IECs)
White adipose
(Monocytes)
tissue
Immune cell
activation,
Insulin
Cytokine
secretion,
secretion,
Gut hormone
Insulin release,
Gut hormone
secretion,
Bone
secretion,
remodelling,
ImmunePain perception, modulatory,
Macrophage
Reduction in
M2
lipolysis, lipid
differentiation
accumulation,
and insulin
resistance
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1.5.1 GPR120 expression and functions
During deorphanization, expression of GPR120 mRNA (human) in intestine, lung, spleen,
adrenal glands, and thymus was found to be abundant (Hirasawa et al., 2004). Later it was
found to be highly expressed in adipose tissues especially, during adipocyte differentiation
(Gotoh et al., 2007; Wang, Xie, Zhang and Leung, 2019). The detailed expression profiling of
GPR120 in intestine indicated that GPR120 is expressed in each of L, K, and I cells of
intestine (Iwasaki et al., 2015). These cells of the intestine secrete gastrointestinal hormones
or peptides which help digestion of ingested foods and absorption of released nutrients. The
global gene expression analysis of GPR120 by various groups showed that GPR120 is also
expressed in the taste buds and pancreatic islets (Matsumura et al., 2007; Wang, Xie, Zhang
and Leung, 2019), with gene co-expression and protein-protein interactions associated with
insulin secreting islets and haemoglobin glycosylation (Kaur et al., 2021). Many studies have
now clearly demonstrated that GPR120 plays a significant role in pathophysiology of various
metabolic disorders such as diabetes, obesity, and inflammatory disorders (Kaur et al., 2021).
The Human Protein Atlas (HPA) analysed RNA-seq data from 37 human tissues samples to
estimate protein expression of GPR120 (Figure 1.9) (Uhlen et al., 2017) indicating possible
expression of GPR120 on the somatic cells or possibly expressed by a subpopulation of cells
in the corresponding tissue.

The HPA RNA-seq analysis reported the highest TPM

(transcripts per million) of GPR120 in rectum and colon tissues. The expansive expression
pattern and diverse physiological roles of GPR120 (Table 1.5) has made GPR120 receptor a
potential target of therapeutic interventions as well as lead to a major challenge of off-target
effects.
The high expression of GPR120 mRNA in subcutaneous, epididymal and mesenteric adipose
tissue in HFD-fed (high fat diet) mice suggests that GPR120 has important roles in adipocyte
differentiation and maturation (Ichimura et al., 2012) as GPR120 deficient HFD-fed mice are
reported to develop obesity, glucose intolerance and fatty liver with decreased adipocyte
differentiation, lipogenesis, and enhanced hepatic lipogenesis (Ichimura et al., 2012).
Adipocyte differentiation from bone marrow mesenchymal stem cells has also been
suggested to be promoted by GPR120 (Gao et al., 2015).
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Figure 1.9: GPR120 mRNA expression levels across 37 tissue samples from Human Protein
Atlas RNA-seq dataset. RNA-seq tissue data reported as mean TPM (transcripts per million),
color-coding is based on tissue groups, each consisting of tissues with functional features in
common (Uhlen et al., 2017). (Figure obtained from HPA - https://www.proteinatlas.org/)

GPR120 is responsive to long-chain fatty acids (LCFAs), and in particular, LCFAs stimulate
secretion of the incretin GLP-1 from the STC-1 mouse enteroendocrine cell line (Hirasawa et
al., 2004) and α-LA increases plasma GLP-1 levels in a rat model (Tanaka et al., 2008). The
long-term administration of LCFAs can upregulate the proliferation of pancreatic β-cells. The
resulting increased secretion and plasma levels of GLP-1 has been shown to enhance the
glucose stimulated insulin secretion (Tanaka et al., 2008) playing a significant role in type II
diabetes (Milligan, Shimpukade, Ulven and Hudson, 2016)
Eicosapentaenoic acid (EPA), an endogenous agonist of GPR120 (Figure 1.10), activated
GPR120 induced autophagy in mesenchymal stem cells derived from murine bone marrow
(Gao et al., 2015; Gao et al., 2016). GPR120 has also been reported to work as a dual acting
factor in bone metabolism as it increases the osteoblastic bone formation as well as
decreasing osteoclastic bone resorption (Ahn et al., 2016). Thus, GPR120 works as an
important target for modulating bone production and degradation.
GPR120 expressed in macrophages has been shown to have an anti-inflammatory role.
Docosahexaenoic acid (DHA), an endogenous agonist of GPR120 (Figure 1.10), activated
GPR120 and significantly reduced the lipopolysaccharide (LPS) stimulated secretion of
cytokines TNF-α (tumour necrosis factor) and IL-6 (interleukins) plasma inflammatory
markers (Alvarez-Curto and Milligan, 2016).
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α-linolenic acid (αLA)

Eicosapentaenoic acid (EPA)

Docosahexaenoic acid (DHA)
Figure 1.10: Endogenous long chain fatty acid activators of GPR120.
1.5.2 GPR120 – isoforms and signalling
In humans, GPR120 is present in two splice variants: the short isoform (361 amino acid long
– GPR120S) and long isoform (377 amino acid long – GPR120L) (Figure 1.11) (Hirasawa et
al., 2004; Watson, Brown and Holliday, 2012; Hudson, Shimpukade, Milligan and Ulven,
2014). Notably, due to alternative splicing GPR120L contains an additional 16 amino acid
sequence within the third intracellular loop (ICL3) (Figure 1.11) (Watson, Brown and
Holliday, 2012), a GPCR domain that is typically involved in protein interactions,
downstream signalling, and desensitization (Davenport et al. 2013). In humans the
ubiquitously expressed short isoform couples effectively to both Gαi/o, Gα

q/11

and β-

arrestin2 pathways, while the long isoform is known to only bind β-arrestin and relays
signalling to ERK1/2 (Senatorov et al., 2020; Carullo et al., 2021; Watterson et al., 2017).
The short isoform is present in all parts of the human gastrointestinal tract while the long
isoform has been detected only in human colon or colon epithelial cell lines being suggested
as a distinct human gene (Senatorov et al., 2020). The GPR120 long isoform has not been
detected in rodents, canines, bovines or nonhuman primates such as cynomolgus monkeys
(Kim et al., 2015; Senatorov et al., 2020).
GPR120 has been reported to couple with both Gαq/11 and Gαi/o when activated by LCFAs
in different tissues (Engelstoft et al., 2013; Stone et al., 2014). The Gαq/11 coupling induces
mobilisation of intracellular calcium (Hirasawa et al., 2004; Hudson et al., 2013; Carullo et
al., 2021). Gαq/11-coupled GPR120 has been reported to function in release of GLP-1 from
enteroendocrine cells in the colon region (Tanaka et al., 2008). While Gαi/o coupled GPR120
inhibits adenylate cyclase activity which in turn inhibits ghrelin secretion from gastric
mucosal cells (Engelstoft et al., 2013). Alvarez-Curto reported that Gαq/11 knockout / null
cells could not produce mobilisation of intracellular calcium upon agonist exposure,
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confirming Gαq/11 mediated signalling at GPR120 (Alvarez-Curto and Milligan, 2016).
GPR120 activation by LCFAs and PUFAs also resulted in β-arrestin2 recruitment (Hudson et
al., 2013). The anti-inflammatory actions of GPR120 are induced through β-arrestin2 /
TAB1, independent of G protein - Gαq/11-coupled pathway (Engelstoft et al., 2013).

Figure 1.11: Human GPR120S structure: Snake plot. The insert shows the additional 16
amino acids gap introduced to GPR120L. The amino acid residues shaded in red are
implicated as residues involved in the orthosteric binding pocket (Arg99(R), Trp104(W),
Phe115(F), Trp207(W), Phe211(F), Trp277(W), Phe304(F)). The amino acids shaded in
yellow are known phosphorylation sites (Thr347(T), Thr349(T), Ser350(S), Ser357(S),
Ser361(S)) of GPR120S and GPR120L, which along with the noted acidic residues
(Glu341(E), Asp348(D), Asp355(D)) shaded in green, create the β-arrestin phosphosensors
(Hudson, Shimpukade, Milligan and Ulven, 2014). Figure was modified from Senatorov et
al., 2020.
The physiological consequences of the two GPR120 receptor isoforms in humans is unknown
although GPR120L contains four additional phosphor-labile residues in ICL3 (threonine and
serine) compared to GPR120S (Kim et al., 2015). Agonism with FFAs lead to the
phosphorylation of both isoforms at the same time with no significant difference but the basal
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phosphorylation of GPR120S is two-fold higher than that of GPR120L in the absence of any
FFA (Senatorov et al., 2020). The difference in the basal phosphorylation might be due to the
blocking of phosphorylation sites by the 16 additional amino acids of GPR120L. Despite
such studies, the functional and physiological importance of the long isoform remains
uncertain (Watson, Brown and Holliday, 2012; Milligan, Shimpukade, Ulven and Hudson,
2016; Senatorov et al., 2020).
1.5.3 GPR120 ligands
Both the GPR120 isoforms are activated by specific long-chain fatty acids (LCFAs), both
saturated and unsaturated, and by the poly unsaturated fatty acids (PUFAs) such as αlinolenic acid (αLA), EPA, DHA (shown in Figure 1.10) (Hirasawa et al., 2008) as the
orthosteric binding residues are identical in both isoforms. A single arginine in TM2 (Arg99)
has been reported to form a critical interaction between receptor and -COOH group
(carboxylate) of its ligands (Hudson, Shimpukade, Milligan and Ulven, 2014). The sitespecific mutation study identified six other specific residues essential for agonist binding and
activation of GPR120 which are: Trp104 (ECL1), Phe115 (TM3), Trp207, Phe211 (TM5),
Trp277 (TM6) and Phe304 (TM7) (Hudson, Shimpukade, Milligan and Ulven, 2014) (Figure
1.11, residues in red).
There is a marked overlap in activation of GPR120 and FFAR1 receptors by fatty acid
receptor ligands even though they share less than 10% homology in amino acid sequence
(Senatorov et al., 2020). The residues involved in recognition of endogenous ligands of the
FFA1 receptor such as pair of Arg residues in TM5(Arg183) and TM7(Arg258) as well as
Asp residue in TM6 (Asn244) are not conserved in GPR120 (Milligan et al., 2015). This
elevates the need to develop receptor selective and specific ligands for GPR120 to achieve
targeted effect of receptor activation / inhibition. GPR120 can be activated by both saturated
and unsaturated medium to long chain fatty acids (Figure 1.10). Being a potential therapeutic
target with diverse physiological functions, several labs (such as Graeme Milligan Lab,
University of Glasgow; Trond Ulven-Lab, University of Southern Denmark) are still
developing GPR120 ligands (Son, Kim and Im, 2021; Carullo et al., 2021).
GW9508 (see Table 1.8) was the first synthetic ligand identified to bind to GPR120, which
was originally developed as a FFAR1 agonist (Briscoe et al., 2006). Later, another nonselective ligand, NCG21, was developed as a GPR120 agonist using structure-activity
relationship (SAR) analysis in combination with computer aided drug design (CADD) (Sun et
33 | P a g e

al., 2010). Finally, this drive led to the development of the first GPR120 specific ligand
TUG891, which acts as a receptor agonist (Hudson et al., 2013). Over the years, a few
GPR120 ligands have been developed (Table 1.8)– all of which act as receptor agonists and
to date no antagonists have been developed for the GPR120 receptor. Lombardo and group
discovered a series of benzofuran propanoic acid derivatives as potent and selective GPR120
agonists. Compound39 of this series demonstrated acute mechanism-based pharmacodynamic
effects with high selectivity for GPR120 over FFAR1 in human and mouse models
(Lombardo et al., 2016).
Compound AH7614 was developed by GlaxoSmith Kline (Sparks et al., 2014) and was
postulated to be an orthosteric antagonist of GPR120 but later it was found to be a probedependent (screened with endogenous agonists) negative allosteric modulating drug (NAMD)
of GPR120 (Watterson et al., 2017). As a NAMD, AH7614 does not bind to the orthosteric
binding pocket of receptor, instead it binds to another pocket on the receptor, which results in
conformational changes in the orthosteric binding pocket and reduces the binding affinity of
other ligands (Watterson et al., 2017; Wild, Cunningham and Zhou, 2014).
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Table 1.8: Human GPR120 ligands – representations of different chemical scaffolds are presented according to IC50 / EC50 values (Carullo et al.,
2021; Son, Kim and Im, 2021).

Ligand

Ligand / Type

Agonist;
Chromane
propionic acid
analogues

GPR120 mediated functions

Improvement of glucose tolerance.

Agonist
activity
at
human
GPR120S in CHOK1 cells;
Improvement of glucose tolerance.

CHEMBL3973101

Agonist;
Non-acidic
analogues
CHEMBL3910333

β-arrestin binding assay => EC50 =
5 nM;
IP1 accumulation – HTRF assay
=> EC50 = 14 nM; (Adams et al.,
2016)

CHEMBL3952043

Agonist;
Aryloxybutanoic
acid analogues

Bioassays with drug potency
data
Agonist
activity
at
human
GPR120S in CHOK1 cells;

IP1 accumulation – HTRF assay
=> EC50 = 21 nM; (Lombardo et
al., 2016)
Agonist activity at human GPR120
receptor in Flp-In T-Rex293 cells;

Improvement of glucose tolerance.

Calcium ions mobilization assay
by Fura2-AM dye => EC50 = 38.9
nM (Azevedo et al., 2016)
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TUG-891 / CHEMBL2058533

Improve inflammation and insulin
resistance; Increase of fat oxidation
and reduction of fat mass; Increase
of GLP-1 secretion; Decrease of
Agonist;
circulating LDL; Repair of acute
Biphenyl analogues kidney injury; Inhibition of motility
and phagocytosis in alveolar
macrophages;
Induction
of
adipogenic differentiation. (Murtaza
et al., 2020)

Agonist;
Spirocyclic
CpdA / CHEMBL3919973

Compound39 / CHEMBL3927879

GSK137647 / CHEMBL3311198

Agonist;
Benzofuran
propanoic acid
analogues

Anti-inflammation in macrophages;
Improvement of glucose tolerance;
Decrease
of
hyperinsulinemia;
Increase of insulin sensitivity;
Decrease of hepatic steatosis;
Improve atopic dermatitis. (Oh et al.,
2014, Son et al., 2020)

Agonist activity at human GPR120
receptor in HEK293 cells;
β-arrestin recruitment assay by
BRET assay => EC50 = 43.65 nM.
(Shimpukade et al., 2012)

Agonist
activity
at
human
GPR120S in CHOK1 cells;
β-arrestin recruitment assay by
luminescence assay => EC50 = 66
nM. (Cox et al., 2016)
Agonist activity at human GPR120
in CHOK1 cells;

Improvement of glucose tolerance.

IP1 accumulation – HTRF assay
=> EC50 = 97 nM; (Lombardo et
al., 2016)
Increase in mineralization of Agonist activity at human GPR120
differentiated
osteoblasts; in human bone osteosarcoma
Suppression
of
adipogenic epithelial cells (U2OS);
Agonist;
differentiation of mesenchymal stem
Diarylsulfonamides
cells; Protection of pancreatic β cell Calcium ions mobilization assay
dysfunction; Inhibition of islet by FLIPR => EC50 = 398.11 nM.
inflammation. (Hasan et al., 2017)
(Sparks et al., 2014)
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Agonist;
Acidic analogues
NCG21 / CHEMBL463785

Partial Agonist;
Acidic analogues
GW9508 / CHEMBL207881

Agonist activity at human GPR120
in HEK 293 cells;

Increase of GLP-1 secretion. (Sun et
al., 2010)
β-arrestin recruitment assay by
BRET assay => EC50 = 2398.23
nM (Shimpukade et al., 2012)
Increase glucose-stimulated insulin
release; Inhibition of inflammatory
responses; Decrease of ghrelin
secretion;
Anti-osteogenesis;
Induction of InterLeukin-4 secretion
from eosinophils; Promotion of
angiogenesis and motility in
colorectal carcinoma.

Agonist;
Improvement of glucose tolerance.
Biphenyl analogues
SR13

Agonist activity at human GPR120
in HEK 293 cells;
β-arrestin recruitment assay by
BRET assay => EC50 = 1412.54
nM.
GPR120 non-selective; higher
selectivity
towards
FFAR1
(Shimpukade et al., 2012)
Agonist activity in Chinese
hamster ovary (CHO) cells
expressing human GPR120;
Calcium influx activity assay =>
EC50 = 93 nM
High selectivity over FFAR1
(Sheng et al., 2018; Zhang, Sun,
Wen and Yuan, 2019)
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AH7614 / CHEMBL3311302

Block α-linolenic acid induced
Negative allosteric
intracellular Ca2+ response in
Inhibit endogenous signalling of
modulator
U2OS cells; IC50 = 79.43 nM.
GPR120; Reduce DHA induced
(Watterson et al.
inhibition of lipid accumulation.
Recently characterised as a
2017);
(Kang et al., 2018)
Diarylsulfonamides
NAMD (Watterson et al. 2017;
Sparks et al., 2014).
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1.6 GPR120 signalling in CRC and angiogenesis.
In addition to prior research, colorectal gene expression profiling by various groups
(Kheirelseid, Miller and Kerin, 2013) enlisted GPCR expressing genes that are consistently
represented as anticancer drug targets (Table 1.4; Usman et al., 2020). Dysregulation of
GPR120 (a rhodopsin-like GPCR) expression and signalling has been recognized as one of
the markers in cancers, such as breast cancer, renal cancer, prostate cancer, hepatic cancer,
pancreatic cancer, and CRC (Fukushima et al., 2015; Houthuijzen et al., 2017; Senatorov and
Moniri, 2018). GPR120’s role in tumorigenesis, migration and metastasis is becoming
evident with increasing reports.
GPR120 has been reported to play a pro-oncogenic role in human colon cancer by enhancing
angiogenesis and cell migration (Wu et al., 2013), implying GPR120 antagonists could have a
therapeutic effect. Regarding signal transduction of GPR120, direct effects of GW9508 (a
partial agonist - Table 1.8) were examined in CRC cell lines which demonstrated activation
of PI3K/Akt and nuclear factor kB. Regarding the effects of GPR120 agonists on the
proliferation and migration, the GPR120 agonist EPA was shown to activate ribosomal
protein S6 kinase β-1 (p70S6K1) in the CRC Caco2 cell line (Hopkins, Liu and Meier, 2014).
S6K1 is a serine/threonine kinase that acts downstream of PIP3 and phosphoinositidedependent kinase-1 in the PI3 kinase pathway. The kinase activity of p70S6K1 leads to an
increase in protein synthesis and cell proliferation.
The GPR120 partial agonist, GW9508 is reported to be mitogenic for CRC cells (Wu et al.,
2013), but not for prostate cancer cells (Hopkins, Liu and Meier, 2014). GW9508 (at 10 μM
dose) stimulates migration of colon cancer cells whereas TUG-891 (GPR120 agonist) inhibits
migration of prostate cancer cells (Wu et al., 2013; Hopkins, Liu and Meier, 2014). TUG-891
and omega-3 fatty acids stimulating GPR120 were shown to inhibit proliferation of DU145
prostate cancer cells (Hopkins and Meier, 2015). However, the knockdown of GPR120
prevented TUG-891-induced inhibition of growth and migration in these cells, confirming the
key role of GPR120 (Hopkins and Meier, 2015). The contrasting reports from such studies
further confuse the role GPR120 in cell proliferation and migration requiring further study.
Omega-3 PUFAs (such as DHA and EPA, see Figure 1.10) bind to a variety of known
GPCRs such as lysophospholipid receptors, prostanoid receptors, free fatty acid receptros
(FFAR1, GPR120), etc., (Im, 2012; Hopkins, Liu and Meier, 2014; Gao et al., 2016) as well
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as various nuclear receptors (peroxisome proliferator-activated receptor α, γ; retinoic acid
receptor RXR- α, β, γ), ion channels, transcriptase, reductase, kinase receptors, matrix
metalloproteinases, etc. DHA has been reported to inhibit VEGF-induced phosphorylation of
cell migration (translation of cells from one location to another), ERK1/2 and endothelial
nitric oxide synthase 3 (eNOS) (Chao et al., 2014). eNOS is primarily responsible for the
generation of NO in the vascular endothelium which plays crucial roles in regulating vascular
tone, cellular proliferation, leukocyte adhesion, and platelet aggregation (Fish and Marsden
2006). There is a crosstalk relationship between these pathways. DHA shows the inhibitory
actions via binding to GPR120 and induction of protein phosphatase 2 (PP2A, a tumour
suppressor) enzyme activity (Chao et al., 2014).
Whereas GPR120 activation by EPA is reported to upregulate VEGF-A by stimulating
protein kinase C (PKC), which subsequently activates PI3K in HEK293 cells (Hasan et al.,
2015). Silencing of the GPR120 gene diminished the EPA-induced upregulation of VEGF-A
release (Hasan et al., 2015). In the downstream cascade, a specific peroxisome proliferatoractivated receptor γ (PPARγ) antagonist GW9662 annulled EPA-induced (eicosapentaenoic
acid) release of VEGF-A. The transfection experiments in HEK293 cells confirmed that
GPR120 activation with EPA specifically enhanced the binding of peroxisome proliferatoractivated receptor γ (PPARγ) to the PPAR-response element (PPRE) in the VEGF-A
promoter region. Intracellular EPA can also directly activate PPARγ, which also enhances
VEGF-A release from adipocytes (Hasan et al., 2015).
In summary, GPR120 receptor activation has been reported to promote angiogenesis in CRC
cells by stimulating release of VEGF, IL-8 and COX-2-derived PGE2 (Wu et al., 2013).
GPR120 has also been shown to regulate tumour growth and migration of various cancer
types, including melanoma and prostate cancers (Hopkins and Meier, 2016; Houthuijzen,
2016). GPR120 activation results in a signalling cascade that ultimately induces
chemoresistance suggesting that antagonism of GPR120 can limit the development of
chemotherapy resistance (Houthuijzen et al., 2017; Wang et al., 2019). Taken together, these
results support contrasting roles of DHA and EPA through activation of GPR120 in cell
migration and VEGF induced angiogenesis, which are implicated in GPR120’s anticancer
therapeutic functions. Several conflicting studies showing pro and antitumour effects pointed
out a contribution for GPR120 in CRC progression and prognosis. Being a novel target in
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CRC therapy, exploration studies for GPR120 ligands may yield better therapies and help the
next generation of CRC patients (Ungaro, D’Alessio and Danese, 2021).
1.7 GPCRs and drug development
As mentioned previously, GPCRs are amongst the most frequently investigated drug targets
accounting for ~34% of the prescription drugs (Kooistra et al., 2020). However, successful
drug development strategies are assisted by the target structure determination. Structure
determination of GPCRs have had a high failure rate as it is challenging to crystalise a highly
unstable protein structure. GPCRs are transmembrane signalling proteins with flexible, multiconformational states as a functional requirement (O'Brien et al., 2020). Being membrane
proteins, GPCRs have large hydrophobic surface with low polar surface areas which reduce
the crystal formation (Broecker, Eger and Ernst, 2017). Furthermore, GPCRs become
thermolabile and unstable outside of the cell membrane for which short-chain detergents or
fused mAb are required to stabilise the GPCR proteins in crystallising solution (Zimmermann
et al., 2018).
1.7.1 Protein structure prediction
Over the last two decades, with evolving crystallisation techniques there has been an
exponential increase in GPCR 3D structure determination. Since the publication of the first
GPCR crystal structure of bovine rhodopsin in 2000, a total of ~110 unique (~600 in total)
GPCR structures has been solved by X-ray crystal or cryo-EM methods in different
conformations – Inactive state: ~30; Active state: 64; Intermediate states: 16
(https://gpcrdb.org/structure/statistics; Qu, Wang and Wu, 2020). More recently, the
availability of such an expansive range of GPCR structures has boosted GPCR targeted
structure-based drug discovery (SBDD). However, comparing the total number of GPCRs
determined structures (~110) against the total number of GPCRs known in human genome
(~400 druggable GPCRs) (Qu, Wang and Wu, 2020), highlights the fact that solving GPCR
structures is still a tedious, time consuming and expensive strategy. However, the
knowledgebase built from the solved GPCR structures has been successfully employed to
predict the 3D structures of homologous GPCR members (homology/comparative modelling)
and study protein dynamics using in silico / computational methodologies (Gusach et al.,
2020) and possibly lead to CADD.
The principle behind protein structure prediction is that protein structures are more conserved
than protein sequences during evolution in response to mutations (Illergård, Ardell and
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Elofsson, 2009; Pearce and Zhang, 2021; Tiss et al., 2021). If the two proteins are
evolutionarily related and share similarity in the primary sequence, the term “homology
modelling” is used or synonymously “comparative modelling” – where a 3D structure of a
protein can be predicted computationally if its sequence is comparable to an experimentally
determined structure of a protein. The experimentally determined protein is used as a
template and the sequence of the template is aligned to the sequence of the query protein with
unknown structure. Using a computational algorithm, such as MODELLER (Webb and Sali,
2016), the 3D coordinates of the query structure are optimised according to the template
structure and sequence alignment (Sailapathi et al., 2021).
Recently, a neural network-based 3D structure predictor of proteins – AlphaFold,
demonstrated prediction accuracy comparable to experimental structures at the Critical
Assessment of protein Structure Prediction – CASP14 challenge (Jumper et al., 2021). The
latest application of artificial intelligence (such as AlphaFold2 from DeepMind) for in silico
protein structure predictions has reported accuracy of free-modelling predictions improved to
~ 90% (Jumper et al., 2021). With the advancement of the computational 3D structure
predictors, the bottlenecked structural elucidation of hard to crystallise proteins like GPCRs
is becoming more precise and accurate (Pearce and Zhang, 2021).
1.7.2 Molecular docking
The experimentally determined GPCR structure or a homology model can be used to analyse
GPCR-ligand binding patterns by molecular docking. Molecular docking predicts the binding
pose of a small molecule or peptide in the binding pocket of the target protein. The docking
algorithm predicts the binding pose by exploring the conformational landscape of the small
molecule defined by the degree of freedom (number of rotatable bonds) and then ranks the
candidate poses by summing the electrostatic and van der Waal forces (Pagadala, Syed and
Tuszynski, 2017). The ranking of the candidate poses is performed by scoring functions
which approximate the summed-up forces for greater computational efficiency. Large
databases or computational chemical libraries can be screened by molecular docking – termed
as virtual screening (VS). The molecular docking and scoring algorithms can be streamlined
using the unique interaction fingerprints determined by GPCR-ligand co-crystal structures or
site-specific mutagenic studies (Mitro et al., 2012; Hudson, Shimpukade, Milligan and Ulven,
2014).
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1.7.3 Molecular dynamics simulations
Crystal structures can reveal important atomic level details of GPCR ligand binding and the
activation mechanism but as a single snapshot of the protein-ligand complex. Molecular
dynamics (MD) simulations employ Newtonian mechanics to study the interactions in the
protein-ligand complex over a time period. Using molecular mechanics, the acting forces are
divided into bonded (connected atoms) and non-bonded (disconnected atoms, separated by
more than 3 bonds) terms. The bonded term can be separated into 3 components: bonds,
angles, and dihedrals, while the non-bonded terms can be divided into Coulomb’s law for
electrostatic forces and Lennard-Jones potential for van der Waals forces (Swegat, Schlitter,
Krüger and Wollmer, 2003).
While performing the MD simulation on the protein-ligand system, a random initial velocity
is provided to the initial 3D protein-ligand structure. Forces acting on every particle is then
calculated as a function of time (Swegat, Schlitter, Krüger and Wollmer, 2003). At every set
timestep, a 3D snapshot of the system is saved along with all the forces. At the end of the
simulation, the time-averaged energies from an ensemble of all the snapshots,
thermodynamic and kinetic properties of the protein-ligand can be measured.
Employing SBDD in combination with homology modelling and MD simulations have
previously resulted in several successful drug discovery cases such as Dorzolamide – antiglaucoma agent; Imatinib – anticancer tyrosine kinase inhibitor; and Vemurafenib –
anticancer BRAF inhibitor (Sancineto, Massari, Iraci and Tabarrini, 2013; Jacquemard and
Kellenberger, 2019; Wang et al., 2020; Bagchi, 2020).
1.7.4 Pharmacophore screening
A pharmacophore can be defined as a three-dimensional spatial arrangement of chemical
features in a drug molecule required for biological activity. These chemical features include
H-bond donors, H-bond acceptors, aromatic and lipophilic regions as well as positive and
negative ionizable ions (Wermuth, Ganellin, Lindberg and Mitscher, 1998; Voet et al., 2014,
Voet et al., 2014a). Structure-based pharmacophore models (SBPMs) are generated by
probing the known or predicted protein-ligand interactions. The co-crystalised protein-ligand
structures solved by X-ray or cryo-electron microscopy assist the development of verified
SBPMs along with knowledge obtained from biological assays such as site-specific mutation
or alanine scanning studies (Dhasmana et al., 2019). The predictive SBPMs are ones where
the essential protein-ligand interactions are not known and predictive computational tools
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such as molecular docking and MD simulations of protein-ligand complexes are performed to
predict the essential protein-ligand interactions (Voet et al., 2014). SBPMs overcome the
limitations of ligand-based pharmacophore and molecular docking as they are based on the
protein-ligand interaction residues and spatial conformation of the target active site (JosephMcCarthy et al., 2003; Steindl, Schuster, Laggner and Langer, 2006; Voet et al., 2014a).
Several studies employing SBPMs have identified various chemical scaffolds proposed as
potential leads for development of novel anticancer agents (Crisan, Avram and Pacureanu,
2017; (khtar, Jabeen, Jalal and Antilla, 2018).
1.7.5 Pharmacokinetics compliance
Pharmacokinetics represents the study of the dynamic movements of drug molecules during
their passage through the patient’s body and encompassing the kinetics of ADME-tox.
Estimation of absorption, distribution, metabolism, excretion, and toxicity (ADME-tox) is of
vital importance during early drug discovery as it helps reducing the pharmacokineticsrelated failures in the clinical phases (Hay et al., 2014). When a drug is absorbed orally it gets
distributed via the portal circulation to liver where hepatic metabolism occurs. Typically, the
drug metabolism pathway consists of oxidation followed by conjugation of oxidised moiety
with polar molecules like cysteine, methionine, glucose, glutathione, or glucose. Both
oxidation and conjugation phases are catalysed by various enzymes. The important drug
properties such as metabolic stability, drug-drug interactions and drug toxicity are determined
during drug metabolism (Bhhatarai et al., 2019). Drug toxicity remains the most significant
and unpredictable property to date as it is most difficult property to predict or screen. Drug
toxicity could involve multiple host factors and could be organ specific or species specific
which are difficult to model adequately at early-stage drug discovery experiments. Drug
toxicity is the leading cause of restricted use or withdrawal of drug from market even after
lead candidates were reported to be safe in preclinical or early clinical trials (Bhhatarai et al.,
2019; Tetko et al., 2006; Sohel et al., 2022).
Pharmacokinetics parameters are used as filters in virtual screenings to evaluate lead-like or
drug-like molecules. Some of the filters being used can be listed as (Daina, Michielin and
Zoete, 2017):
•

Lipinski’s filter includes molecular weight ≤ 500, logP (lipophilicity) ≤ 4.15,
hydrogen bond acceptors ≤ 10, and hydrogen bond donors ≤ 5.
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•

Ghose’s filter includes 160 ≤ molecular weight ≤ 480, −0.4 ≤ logP ≤ 5.6, 40 ≤ the
molar refractivity ≤ 130, and 20 ≤ number of atoms ≤ 70.

•

Veber’s filter includes the number of rotatable bonds ≤ 10 and the total polar surface
area (TPSA) ≤ 140.

•

Egan’s filter includes logP ≤ 5.88 and TPSA ≤ 131.

•

Muegge’s filter includes 200 ≤ molecular weight ≤ 600, −2 ≤ logP ≤ 5, TPSA ≤ 150,
the number of rings ≤ 7, the number of carbons > 4, the number of heteroatoms > 1,
the number of rotatable bonds ≤ 15, the hydrogen bond acceptors ≤ 10, and the
hydrogen bond donors ≤ 5.

1.8 Cytotoxicity screening of small molecules
For decades, monolayer cell cultures – growing cells on flat surfaces of laboratory vessels,
have been used extensively as the cellular in vitro cancer model for early-stage drug
discovery and development (Stock et al., 2016). Cell-based in vitro cancer models for drug
discovery provide a commercially viable and robust methodology to screen potentials lead
compounds

for their cytotoxicity, anti-proliferative and anti-migratory properties

(Voskoglou-Nomikos, Pater and Seymour, 2003; Stock et al., 2016). For drug discovery
screening, a cell line with higher expression of target receptor and lower expression of
receptors sharing same ligands of the target receptor are recommended (Stock et al., 2016).
SW480 – human CRC cell line, was selected for in vitro screening of compounds derived by
SBDD targeting GPR120 receptor. SW480 are the epithelial cells of large intestine
established from a primary adenocarcinoma of the colon of Dukes’ type B CRC patient
(ATCC-SW480, 2021). A gene expression study reported that GPR120 is overexpressed
(3.17 folds) in SW480 cell lines as well as did not detect GPR40 (also known as FFAR1)
expression in SW480 (Wu et al., 2013). GPR40 is another member of FFAR family which
shares orthosteric ligands with GPR120 (Wu et al., 2013; Grundmann, Bender, Schamberger
and Eitner, 2021). The absence of GPR40 expression in SW480 enabled GPR120 selective in
vitro screenings and reducing the probability of false positives.
Fluorometric assays of cytotoxicity and cell viability are recommended over traditional dye
exclusion and colorimetric assays for being more sensitive and non-toxic to cells under
treatment (Lindhagen, Nygren and Larsson, 2008; Aslantürk, 2018). These assays can be
performed with ease using a fluorometer, fluorescence microplate reader or flow cytometer.
Alamar Blue (resazurin salt) assay is a reduction assay based on the conversion of the blue
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non-fluorescent resazurin dye to the pink fluorescent resorufin by mitochondrial and other
cellular enzymes (Aslantürk, 2018). It is a nontoxic and cell permeable indicator of cell
viability. As the dye enters the viable cells, it is reduced to fluorescent compound and
increases the overall fluorescence of the cell culture medium. CFDA-AM assay (5carboxyfluorescein diacetate, acetoxymethyl ester) and protease viability marker assay
(glycylphenylalanyl-aminofluorocoumarin - GF-AFC) are other fluorometric dye assays that
are used for cytotoxicity quantification (Aslantürk, 2018).
For target identification of test compounds, the process of regulating the target gene
expression in vitro and quantifying the drug response in regulated and unregulated
environment can be useful. Small interfering RNA (siRNA) also known as silencing RNA
provides a simple and inexpensive in vitro toolkit to confirm target specificity of a potential
test compound (Neumeier and Meister, 2021). siRNA transfection modulates the mRNA and
temporarily supresses the gene-product of interest. In mammalian cells, the siRNA duplexes
can be introduced directly by transfection to generate transient cell lines with silenced gene
expression. SW480 has been reported a suitable transfection host (ATCC-SW480, 2021).
1.9 Overview of thesis
This introduction has demonstrated that target-based drugs when used as adjuvants and/or
neo-adjuvants in combination with lower-dose chemotherapy regimens (Spugnini and Fais,
2019; Boakye et al., 2021) might fulfil the need for CRC chemotherapy regimens that could
reduce the adverse treatment effects. GPR120 has tremendous potential of being such a novel
therapeutic target for inhibiting tumour progression and tumour angiogenesis especially in
colorectal cancer due to high expression level of GPR120 in colorectal tissue (Figure 1.9). In
addition, the development of GPR120-targeted anticancer drugs might help to improve CRC
and mCRC prognosis with reduced adverse effects. Although the pharmacology of GPR120
has been well documented, the understanding of its signal transduction is still at an early
stage and despite its therapeutic potential no drugs have yet been approved by the FDA for
GPR120.
The present study aims to answer the research question ‘Can a combination of in silico and in
vitro approaches lead to identification of chemical scaffolds targeting GPR120, which can be
optimised by structural activity relationship profiling to design potential anti-cancer lead
compounds?’.
To address these questions following research objectives were identified:
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1. A structural model of the human GPR120 receptor will be developed and validated to
facilitate in silico ligand design.
2. Molecular docking of reference (known) ligands to validate the binding mode and
stability of ligand binding and protein-ligand interactions using MD simulations.
3. In silico (docking and pharmacophore) and in vitro (cytotoxicity) screening for new small
molecule ligands based on the better understanding of the ligand binding site from the
developed 3D model of the GPR120 receptor.
4. Optimisation of the hit compound(s) through structure-activity relationship (SAR)
analysis, and computational physicochemical profiling.
5. Advanced in vitro assays on optimised hits, e.g., wound healing and clonogenicity to
further evaluate the anticancer and potential anti-angiogenic properties of the preferred
compounds
6. siRNA-based functional target validation: Comparative profiling of hit compounds in
siRNA-mediated GPR120 silenced CRC cell line (SW480) and wild-type CRC cell line
(SW480) by in vitro cell proliferation assays.
Chapter 2 details and describes the methods and protocols used for the computational and
biological experimental work.
Chapter 3 first details the results of GPR120 homology model generation and validation of
the 3D model of GPR120 (short isoform). The validated 3D model of GPR120 was used to
determine the docking poses of reference ligands (TUG891 and Compound39) followed by
preparation of GPR120-ligand complexes for MD simulations.
Chapter 4 details the analysis of MD simulations of TUG891 and Compound39 bound
GPR120 systems and development of an Asn313 interaction hypothesis to design GPR120
antagonists. The potential hits derived from the Asn313 hypothesis were further analysed by
GPR120-ligand MD simulations.
Chapter 5 enlists the results from virtual screening of chemical libraries followed by in vitro
screenings in SW480 CRC cell lines and SAR analysis of the initial hit compounds. The best
hits from the SAR analysis were further tested by wound healing and colony formation
assays. The target specificity of the best hits was tested by siRNA-GPR120 transfected
SW480 cell lines.
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Chapter 6 summarises the work presented with critical discussion and projects on the future
work that could be performed.
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Chapter 2
Methods and Protocols
2.1 Computational methodology
In this section, the computational methodologies used are outlined along with the structural
and sequence retrieval information. The visual analysis and homology model building were
carried out on an in-house 8 node (Intel® Core™ i7-4790 CPU @ 3.60GHz × 8) Linux
cluster. The molecular dynamics simulations were performed on the Irish Centre for HighEnd Computing (ICHEC – www.ichec.ie) cluster. Class B (Project name: nmlif042b) and
Class C (Project name: dtlif001) projects were approved by the Irish Centre for High End
Computing (ICHEC), which provided 60,000 CPU core units for computational processing
and 1000 gigabits (GB) of data storage space.
2.1.1 Protein data retrieval and analysis
The primary protein sequences used for various bioinformatics analysis were retrieved from
the Universal Protein Resource (UniProt) database (Uniprot, 2016) that contains ~ 550,000
manually annotated and reviewed protein entries. The short (S) and long (L) isoform
(Q5NUL3-2 and Q5NUL3) sequences of human GPR120 were used. Class A GPCRs for
which crystal structures were known (in January 2017), were retrieved from the RCSB
protein databank (Deshpande et al., 2005) to be used as a template database for homology
modelling. The X-ray crystal structures were manually cleaned using PyMol (DeLano,
2018) and screened to include only templates in the inactive state i.e., co-complexed with an
antagonist or inverse agonist (Table 3.1).
The sequence alignments of screened templates were performed against human GPR120 (S
and L) sequences on the Clustal Omega server (Sievers and Higgins, 2017) and the sequence
alignments were visually inspected for the alignment of conserved motifs in the TM helices
of the sequences. Three different secondary structure prediction algorithms - UCDPorter, JPred, TMHMM server (Mirabello and Pollastri, 2013; Drozdetskiy et al., 2015;
Krogh et al., 2001) were used to predict the range of α-helical TM regions and the topologies
of the loop regions in the extra- and intracellular regions of the plasma membrane. The
phylogenetic analysis of the screened templates with human GPR120 (S and L isoforms) was
performed in SeaView (Gouy, Guindon and Gascuel, 2009) using the PhyML algorithm at
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100 bootstrap values (assigns measures of accuracy to sample estimates) to trace evolutionary
sequence conservation.
The 3D crystal structures of selected homologous proteins were visually analysed and
screened for the presence of non-protein molecules (such as water molecules, lipids,
heteroatoms, etc.) using PyMol Open-source version 2.1.0 (DeLano, 2018). The PDB files of
3D structures were cleaned manually to keep a single chain of protein in PyMol (DeLano,
2018).
2.1.2 Homology modelling and validation
The homology modelling of the human GPR120 (S and L isoforms) receptor was performed
using the MODELLER v9.14 homology modelling tool (Webb and Sali, 2016). The
procedure for modelling involved python scripts run through command line for advanced
homology modelling based on multiple templates. The multiple templates-based HM in
MODELLER started from multiple sequence alignment (MSA) (Appendix Table IIa),
template structures alignment, and 3D model generation to model evaluation by discrete
optimized protein energy (DOPE) based scoring function. Each step was processed by a
separate python script supplied with the MODELLER installation suite. The automated
sequence alignment file generated by MODELLER was replaced by a manually annotated
sequence alignment file generated by Clustal Omega (Sievers and Higgins, 2017). The 3D
model generation script was set to generate 100 models for each template group as multiple
template combinations were used for HM development (detailed in section 3.4.2).
As mentioned, different combinations of selected templates (Appendix Table IIa) were used
for 3D model generation of human GPR120 S and L isoforms – making the process repetitive
and time consuming. A python-based pipeline was developed in KNIME (Konstanz
Information Miner;

Berthold

et

al.,

2008),

GITHUB

(https://github.com/jay4pal/KNIME_GPCRs) which read the user-defined configuration file
to automatically make template combinations to build and evaluate the homology models
(Figure 2.1). KNIME is a data analytics platform which allows the integration of configurable
nodes and community-built nodes in different scripting languages. The nodes developed for
the HM pipeline using MODELLER were configured in the Python 3.0 scripting language.
The output from the pipeline consists of sub-subdirectories named after each template
combination containing respective models generated and a table of scores of the models.
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Figure 2.1: KNIME workflow to automate the homology modelling using MODELLER
(moving from left to right). “Set_up_Dir” node collects the configuration file from working
directory which is read by the “Read_config” node into machine language and then parsed by
the “Collect_Var” node. The next four nodes align the templates, generate 3D models, and
evaluate them by the scoring function respectively. The last node removes the temporary files
created during the processing.
The top ten scoring models from the selected template combination were assessed for
stereochemical properties using the MolProbity webserver (Chen et al. 2009). The side chains
of the top ten selected models were optimized by SCWRL4 (Krivov, Shapovalov and
Dunbrack, 2009)

followed

by

a

second

stereochemical

assessment

using

the MolProbity webserver (Chen et al., 2009). The difference in stereochemical properties
between before and after structures were compared to determine if side-chain optimization by
SCWRL4 improved the structural stability. Finally, the structural conformations and
stereochemistry

of

the

transmembrane

(TM),

intra-cellular

loop

(ICL) and extra-

cellular loop (ECL) regions of the predicted model were assessed through Ramachandran (ɸΨ) plots using the MolProbity webserver (Chen et al., 2009) and structural quality
by ProSA (Wiederstein

and Sippl,

2007) and

ERRAT (Colovos

and Yeates,

1993) webservers were used.
2.1.3 Molecular docking protocol
SMINA – scoring and minimization in AutoDock VINA – was the docking program used for
molecular docking (Koes, Baumgartner and Camacho, 2013; Trott and Olson, 2009) (selected
after benchmark studies of four different docking algorithms - Appendix III). SMINA is
available as an open-source program, and it can treat both the ligand and the protein as
flexible structures.

Prior to molecular docking, the protein structure was prepared

in AutoDock Tools (ADT) (Morris et al., 2009). The protein was read in from the PDB file to
remove non-polar hydrogens, add polar hydrogens and charges are applied. Specific residues
in the binding pocket were selected as residues (Hudson et al., 2014) with flexible sidechains
and the output file were saved in as PDBQT format with default charges and torsions. For the
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next step, the search space – the binding site grid box (Table 2.1) was visually defined by
employing AutoDock tools’ Grid setting feature, based on the site-specific mutation study by
Hudson et al., 2014 to include residues – Arg99(TM2), Trp104 (ECL1), Phe115 (TM3),
Trp207 (TM5), Phe211 (TM5), Trp277 (TM6) and Phe304 (TM7), deemed essential for
ligand binding.
Table 2.1: Binding pocket co-ordinates and box size used in docking experiments with the
GPR120 homology model.
center_x

61.622

center_y

59.75

center_z

46.597

size_x

60

size_y

60

size_z

60

Spacing

0.375 Å

The docking experiment was run through the command line which defines the ligand or an
ensemble file of multiple ligands, target receptor to dock into, the binding pocket space
(Table 2.1) and the exhaustiveness set at 8 (it can be set between 1 and 8 – where 8 is the
highest level of exhaustive search with a net increase on the computational time). Each
docking experiment was run at random seed to keep the experiment random and unbiased.
For VS of large chemical libraries, the chemical libraries were retrieved and processed
in Biovia Discovery Studio’s Pipeline Pilot v9.1 from Dassault Systèmes (Dassault Systèmes
2017) to remove compounds with molecular weight (greater than) > 650 and (less than) <
250 Dalton. The stereoisomers of all the ligands used for docking experiments were built in
the Pilot Pipeline tool available with BIOVIA suite (by Dr Gemma Kinsella). The filtered
chemical database was energy minimised using MMFF94 forcefield (steepest descent) in the
open-source OpenBabel software package (http://openbabel.org/) and saved in sdf
format. The docking experiments with single ligands were performed on the in-house 8
core linux cluster while docking experiments with large ligand ensemble databases (such as
the decoy database, virtual screening databases, etc.) were performed on the ICHEC
cluster. For chemical database libraries ICHEC cluster’s taskfarm module was used, which
read in the shell script containing command line arguments. The taskfarm module allocates
one command per thread for execution on ICHEC cluster.
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Later, in collaboration with Dr Anthony J. Chubb (Royal College of Surgeons, Ireland), the
KNIME pipeline for HM was extended to include the molecular docking pipeline and
increase the flexibility to give more options to the user (detailed in Appendix IV).
2.1.3.1 Enrichment study
In the enrichment studies, a set of inactive compounds was used to perform the enrichment
test. A group of 28 active ligands of GPR120S was selected based on their known activity
and potency from the literature (Appendix table IIb). The active ligands were used as the
active set (i.e., known binders), and for the decoys, a set of 1,150 (unique) druglike decoys
obtained from DUD.E (Database of Useful Decoys: Enhanced) (Mysinger, Carchia, Irwin and
Shoichet, 2012). Tautomer and stereoisomers were not generated for the decoy databases.
The decoys were energy minimized using Avogadro software and docked with the GPR120S
model using the docking and binding protocols (section 2.1.3) in SMINA. The docked
molecules were then ranked according to the docking score obtained from SMINA. Receiver
Operating Characteristic (ROC) curves were then plotted and their corresponding AUCs
calculated using R-Studio’s ROCR package with gplots (RStudio Team 2015). The ROC
graphically relates the sensibility and the specificity of the selected model.
2.1.3.2 Scoring function for VS of chemical libraries
Default scoring function of AutoDock SMINA was used for all docking experiments unless
mentioned otherwise. The docked poses generated by AutoDock SMINA by VS chemical
libraries (Chapter 5) were rescored with three different scoring functions, AutoDock Vina
(Trott and Olson, 2009), NNScore 2.0 (neural network-based scoring function) (Durrant and
McCammon,

2011)

and

DLSCORE

(Deep learning

based scoring

function) https://github.com/sirimullalab/DLSCORE), to calculate the consensus binding
affinity score (Cscore) using Equation I. AutoDock VINA and SMINA predicts the binding
affinities as approximations of interaction energies (kcal/mol) such as Gaussian, repulsion,
hydrogen bonding, hydrophobic, non-hydrophobic contact and Lennard-Jones 4–8 van der
Waals interactions (Koes and Camacho, 2012), while NNScore 2.0 and DLSCORE predicts
the binding affinities as pKd values (Brunner, 2004).
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Equation I:
𝐶𝐶𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 =

𝑉𝑉𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 + 𝑆𝑆𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 + (−𝑁𝑁𝑁𝑁𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 ) + (−𝐷𝐷𝐷𝐷𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 )
�𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁 𝑜𝑜𝑜𝑜 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓

where: Cscore is consensus docking score.

Vscore is docking using AutoDock Vina’s default scoring function.
Sscore is docking score using SMINA’s default scoring function.
NNscore is docking score using NNScore 2.0 function.
DLscore is docking score using DLScore function.

2.1.4 Energy minimization (EM) and molecular dynamics (MD)
As mentioned in section 1.5, GPR120 is transmembrane receptor, which spans through the
thickness of the plasma membrane (~35 Å) (Calmet et al., 2016). As such the predicted
models of GPR120S and GPR120L were inserted in a lipid bilayer to mimic the insitu environment and relax the predicted receptor models. The lipid bilayer of 512 molecules
of 1-palmitoyl-2oleoyl-sn-glycerophosphocholine (POPC) was generated from the Berger
lipid parameters for POPC molecules (gro and itp files), obtained from the ATB
repository (Koziara et al., 2014), using GROMACS v5.1.4 (Abraham et al., 2015). The
protein structure file of the predicted structure was converted to a GROMACS readable file
using the gmx_pdb2gmx function with the GROMOS 54a7 forcefield. Then the protein was
inserted into the generated lipid bilayer using Lambda and InflateGro2 program (Schmidt and
Kandt., 2012) and solvated with water molecules using the single point charge water (SPC)
model (spc216.gro) parameter file using gmx_solvate function of GROMACS. The charge on
the solvated protein-lipid system was neutralized through addition of the required number of
Na+ and Cl- counter-ions with gmx_genion. As the system prepared did not contain any
bound ligand in the protein – it was termed the Apo protein system. Similarly, ligand-bound
protein models of GPR120S were prepared (using the molecular docking protocol) and
inserted into the lipid bilayer. The general workflow of GROMACS based MD system
preparation, equilibration, production run and analysis are shown in Figure 2.2.
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As GROMACS cannot prepare the topologies of heteroatoms (ligands), the topology and
GROMOS force field parameter for the ligands were obtained from the ATB repository
server (Koziara et al., 2014). The prepared protein system was subjected to 50,000 steps of
the steepest descent EM algorithm with maximum force set at 1,000 kJ/mol/nm, which was
further consecutively reduced to 10 kJ/mol/nm using a conjugate gradient EM. The ligandbound systems were energy minimized using position restraints on the ligand topologies to
keep the ligands bound to the protein. The ligand position restraints were used during EM and
equilibration steps in all the MD simulations and removed in MD production runs unless
mentioned otherwise.

Figure 2.2: GROMACS Molecular Dynamics Simulation Workflow. (Image adapted from
http://www2.mpibpc.mpg.de/groups/grubmueller/Lugano_Tutorial/)
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For the MD equilibration runs, the energy minimized systems were subjected to a
500 ps position restraining simulation with 1,000 kJ mol-1 harmonic constraint to relieve the
close contacts with POPC and water under NVT (constant Number of particles, Volume, and
Temperature) ensemble conditions, with a Vrescale (modified Berendsen) temperature
coupler (Bussi, Donadio and Parrinello., 2007). This was followed by another 5 ns
equilibration run under NPT (constant Number of particles, Pressure, and Temperature)
ensemble conditions, before a final production run of 300 ns on each system. The systems
were run at 300 K, i.e., above the phase transition temperature of pure POPC, to ensure that
the lipids maintained their proper density, and 1 bar pressure under isothermal-isobaric
ensemble with ligand constraints. Nosé-Hoover (which is used widely for membrane NPT
and MD simulations) temperature and Parrinello-Rahman pressure couplers were used to
maintain the temperature and pressure values with the protein, ligands, lipids and water (plus
ions) molecules coupled separately with a coupling constant of τt=0.1 ps. Semi-isotropic
pressure coupling was set with τp=2 ps, allowing the bilayer to deform in the x–y plane
independently of the z-axis. A time-step of 2 fs was used throughout with periodic boundary
conditions. LINCS constraint algorithm was used to maintain the geometry of the molecules
(Hess, 2008). Long-range electrostatic interactions were calculated using the particle-mesh
Ewald (PME) method. Van der Waal’s interactions and Coulomb interactions were cut off at
12 Å with updates every five steps. The checkpoint on the MD production run were saved
every 50 ps which recorded the conformational 3D coordinates, system velocities and energy
parameters.
The trajectory and energetics of the protein systems were analysed by in-built GROMACS
tools

and

visualized

in PyMol (DeLano

2018) and XMGRACE

(http://plasma-

gate.weizmann.ac.il/Grace/). The overall stability of the simulated systems was also checked
with respect to temperature, pressure, and potential energy of the systems to check
thermodynamic equilibrium during the production simulation runs, confirming the
convergence of individual trajectories. The webserver WADDAICA was used to compute the
protein-ligand binding free energies of protein-ligand snapshots extracted from the MD
trajectory every 5 ns using the Binding Affinity by AI module of WADDAICA (Bai et al.,
2021). The protein-ligand interaction plots from the MD trajectory were generated using
Molecular-dynamics-Interaction-plot.

(https://github.com/tavolivos/Molecular-dynamics-

Interaction-plot).
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2.1.5 Structure-based pharmacophore screening
A six-feature pharmacophore model was generated by manual curation of docked reference
structures (TUG-891 and compound 39) using the ZINCPharmer web interface (Sterling and
Irwin, 2015; Koes and Camacho, 2012) (Table 2.3), which was then screened against the
ZINC15 database containing ~230 million purchasable lead-like 3D molecules (Sterling and
Irwin, 2015). The pharmacophore screening results from ZINCPharmer were downloaded as
structures data files (sdf format). The 3D molecules were then prepared and docked against
the GPR120S receptor model following the set protocol in section 2.1.3.
2.1.6 Pharmacokinetic profiling
The physicochemical and drug-likeness profiling of the screened hits was performed using
the online webserver SwissADME (Daina, Michielin and Zoete, 2017). The selected
compounds were prepared for 100 ns MD simulations following the protocol described in
section 2.1.3 and 2.1.4. Multiple linear regression (MLR) was used to correlate the
physicochemical descriptors (obtained from SwissADME) with the binding affinity
predictions from WADDAICA (Bai et al., 2021). The ChemMine tools webserver was used
to develop a structural similarity clustering scatterplot (Backman, Cao and Girke, 2011).
ChemMine clustering tool converts the Tanimoto similarity matrix into distance matrix to
cluster the molecules.
2.2 Biochemical assay protocols
2.2.1 Cell culture and materials
SW480, a human CRC cell line was obtained from Dr Alan Casey’s Nanolab (TU Dublin)
and was cultured in RPMI1640 growth media (R8758) supplemented with 10% (v/v) Fetal
Bovine Serum (cat no. F7524) and incubated at 37 °C ± 1 °C in a humidified atmosphere
with 5% CO2. Trypsin-EDTA 0.25% sterile-filtered (cat no. T4049) solution was used for
detaching adherent cells from the culture flask surface. The autoclaved sterile phosphate
buffered saline (PBS) was used for washing purposes. The PBS tablets (cat no. P4417) were
dissolved in deionised water as per the manufacturer’s instructions to yield 140mM NaCl,
10mM phosphate buffer and, 3mM KCl solution at pH 7.4. The cell culture media and
reagents were procured from Merck-Sigma, unless otherwise mentioned. TUG891
(SML1914), AH7614 (SML2025), Adapalene (A7486), Azilsartan (SML0432), Gliquidone
(CDS021537) and Lapatinib (SML2259) were procured from Sigma-Aldrich (Merck), and
Sonidegib (M4841) was procured from AbMole (abmole.com). The test compounds for in
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vitro screening assays mentioned in section 5.3 were procured from SPECS (www.specs.net).
A stock solution of test compounds (20 mM) was prepared in 100% (w/v) DMSO and stored
at −20 °C.
2.2.2 SW480 in vitro screenings by cell-based cytotoxicity assay
Alamar blue based cytotoxicity assays were performed to determine inhibitory effects of the
test compounds. SW480 cells were seeded at 10,000, 5,000 and 2,500 cells per well in 96well plates for 24, 48 and/or 72 h drug treatment, respectively. Required dilutions of test
compounds were freshly prepared in 0.5% (v/v) DMSO growth media for cytotoxicity assays.
After the treatment period, drug concentrations were replaced with 6% (v/v) alamar blue dye
solution and the cells were incubated for 3 h under cell incubation conditions. Finally, the
fluorescence signal was read using 560 nm excitation and 590 nm emission filters with
Varioskan LUX Multimode Microplate Reader from ThermoFisher Scientific.
2.2.3 SW480 siRNA transfection
SW480 cells were transfected with 50 nM GPR120 (human) − 27mer siRNA duplex (cat no.
SR317391) using siTran 2.0 siRNA transfection reagent (OriGene – www.origene.com)
according to manufacturer’s instructions after overnight seeding. Universal scrambled siRNA
duplex (cat no. SR30004) was used as negative control in transfection experiments. The
27mer GPR120-siRNA duplex was provided as two different samples labelled –
siRNA-1 (rArGrArArArUrGrArCrUrUrGrUrCrGrArUrUrArUrUrUrCTG) and
siRNA-2 (rGrGrArUrGrCrArArGrArGrCrUrGrUrCrGrUrGrArCrUrCAC).
siRNA-1 was selected for GPR120 silencing in in vitro assays based on the results obtained
from relative quantification studies (section 2.2.4 and 5.2.2; Figure 5.3a).
2.2.4 RT-qPCR protocol
Real-time quantitative polymerase chain reaction (RT-qPCR) was used for detection and
measurement of GPR120 expression in control and siRNA-treated SW480 cell lines. Fast 96well PCR reaction (cat no. 7321161) plates covered with optical adhesive films (cat no.
4360954 from Thermo Fisher Scientific) were used in Applied Biosystems 7500 Fast Realtime PCR system for the RT-qPCR run. RT-qPCR run was performed according to
manufacturer’s instructions.
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2.2.4.1 RNA extraction
RNA was extracted from GPR120-siRNA treated SW480 cells using TRI reagent (cat no.
93289) obtained from Merck-Sigma and following the protocol provided by the
manufacturer. After 24 hours of siRNA transfection treatment cells were collected from 6
well plates by directly lysing the cellular monolayer using 1 ml per well TRI solution in a
sterile fume hood. After addition of TRI solution, the cell lysate was repeatedly pipetted up
and down to form a homogenous lysate mix. The homogenous lysate mix was transferred to
1.5 ml sterile microcentrifuge tubes and allowed to stand for 5 minutes at room temperature.
Then for each 1ml of TRI solution 0.2 ml chloroform (HPLC grade) was added and mixed
thoroughly by gently inverting the tubes repeatedly for 15 seconds and then allowed to stand
for another 5 minutes. The resting tubes were transferred to the centrifuge pre-calibrated at
4°C, 12,000 x g for 15 minutes. At this stage, the centrifugated mixture was separated into 3
phases- colourless top aqueous phase containing RNA, a turbid interphase containing DNA
and the pink-coloured organic phase at bottom containing protein materials.
The colourless aqueous phase was transferred to a fresh tube followed by addition of 0.5 ml
2-propanol (HPLC grade) per ml of TRI reagent used. The sample tubes were allowed to
stand for 5 min at room temperature and then centrifuged at 12,000 x g for 10 minutes at 4°C.
After centrifugation, the RNA precipitate formed a colourless pellet at the bottom of the tube.
The supernatant was removed, and the pellet was washed with 1ml of 75% ethanol per 1ml of
TRI solution used. The sample was vortexed and then centrifuged at 7,500 x g for 5 minutes
at 4°C. The excess of ethanol supernatant was removed, and the pellet was left for air drying
in the PCR laminar hood to remove the residual ethanol. The dried RNA pellet was resuspended in 20 µL of RNase/DNase-free-water.
The RNA yield of the collected sample was calculated using the µDrop plate in Multimode
Microplate Reader from ThermoFisher Scientific at 230, 260, 280 nm wavelengths with
RNase/DNase-free-water as blank (Appendix Table IId).
2.2.4.2 cDNA synthesis and RT-qPCR run
Total RNA extracted from siRNA treated and wild SW480 cells (control) extracted was
transcribed into complementary DNA (cDNA) following the instructions provided with the
qScript cDNA SuperMix (cat no. 95048-025) obtained from Quantabio. SuperMix, extracted
RNA samples (from siRNA-1 treated, siRNA-2 treated and untreated control cells) and
RNase/DNase-free water were thawed on ice and centrifuged for 5-10 seconds to collect
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residual liquid from sides of the tube. For each sample, 1 µg of RNA template was mixed
with 4 µL of qScript cDNA SuperMix and make up the volume to 20 µL with RNase/DNasefree water in 0.2mL micro-tubes sitting on ice. A control sample without RNA template was
prepared as well. After sealing each reaction tube, the mix was gently vortexed and then
centrifuged to collect component at the bottom of tube.
Appropriately labelled reaction tubes were placed in the Thermocycler with following
cycling steps:
Cycle 1:

25°C for 5 min

Cycle 2:

42°C for 30 min

Cycle 3:

85°C for 5 min

Cycle End:

4°C hold

If RT-qPCR was not performed on the same day, the cDNA mix tubes were stored at -20°C,
else the cDNA mix tubes were place on ice and steps for RT-qPCR run were followed.
The second step of RT-qPCR follows the protocol provided with PerfeCTa SYBR Green
FastMix – Low ROX (cat no 95074-025 from Qunatbio). The primers for GPR120 were
designed using Primer3 online webserver (Ye et al., 2012) with NM_181745.4 (Homo
sapiens free fatty acid receptor 4, transcript variant 1, mRNA) as input and optimum primer
melting temperature (Tm) set at 60 °C. The primer sequence for GAPDH (housekeeping gene
as control) was obtained from literature (Wang et al., 2019). The primers (Table 2.2) were
obtained from Merck Sigma in lyophilised form and reconstituted with RNase/DNase-free
water to prepare 100µM solutions.
Table 2.2: Sequence of primers used for RT-qPCR of GPR120 and GAPDH.
GPR120
5′GGATGCAAGAGCTGTCGTGA3′ Tm = 60.39°C
Forward primer
GPR120
5′TTACCGACGCTGTGGATGTC3′ Tm = 60.11°C
Reverse Primer
GAPDH
5′GGATTTGGTCGTATTGGG3′
Tm = 53.5°C
Forward primer
GAPDH
5′GGAAGATGGTGATGGGATT3′ Tm = 54.3°C
Reverse Primer
The final reaction cocktail for each sample was prepared by mixing 10 µL of PerfeCTa
SYBR Green FastMix – Low ROX with 5 µL of cDNA and 1 µL of each forward and reverse
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primer (10µM) and make up the volume to 20 µL with RNase/DNase-free water in each well
of 96-well Fast reaction plate. The plate layout is illustrated in Table 2.3. To prevent pipetting
error of small volumes, 80 µL of reaction mix for each sample was mixed well in 1 well and
then dispensed 20 µL to each well of the corresponding column. The optical adhesive film
was used to seal the plate and the plate was centrifuged briefly to collect the residual volumes
from sides of wells at the bottom. Finally, the plate was placed in the Applied Biosystems
7500 Fast Real-time PCR system with following cycling steps:
1) Initial denaturing (holding stage):

95°C

30 sec

2) PCR cycling (45 cycles):

95°C

05 sec

3) Collect data at end of extension step:

60°C

30 sec

Table 2.3: RT-qPCR 96-well plate layout followed for the experiments.

GPR120

GAPDH

Untreated
Control
Repeat 1
Repeat 2
Repeat 3

siRNA-1
treated
Repeat 1
Repeat 2
Repeat 3

siRNA-2
treated
Repeat 1
Repeat 2
Repeat 3

Blank
(No cDNA)
Repeat 1
Repeat 2
Repeat 3

Repeat 1
Repeat 2
Repeat 3

Repeat 1
Repeat 2
Repeat 3

Repeat 1
Repeat 2
Repeat 3

Repeat 1
Repeat 2
Repeat 3

At the end of RT-qPCR run, the result sheet was exported as an excel file for final
calculations.
2.2.5 Wound healing / Scratch assay
SW480 cells were seeded at 3x 106 cells per well in 6 well-plates 24 hours prior to scratch to
obtain a confluent monolayer. The monolayer was scratched using a sterile 200 µL pipette tip
held at 45° angle in the laminar hood. Each well was scratched both horizontally and
vertically to obtain at cross point at centre of the well. The cross point was used as a
reference point while taking snapshots of wells. The old media was discarded, and cells was
gently washed with PBS solution without disturbing or dislodging the cells in the well. After
washing, the vehicle control and subtoxic (IC25) concentrations of test compounds were
added. Snapshots of scratched surfaces were taken at 10X zoom using the Tucsen camera
(ISH500) mounted Optika XDS-2 trinocular inverse microscope and plates were incubated at
37°C with 5% CO2 for 24 hours. After incubation, plates were removed turn by turn and
snapshots were taken at 10X zoom following the same protocol. Image processing and
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relative scratch area quantification was performed using Fiji (Schindelin et al., 2012) with the
Wound Healing tool plugin. Three independent experiments were performed for each test
compound in triplicates.
2.2.6 Clonogenic assay
SW480 cells (5 cell/well) were seeded on 96-well plates and maintained in a humidified
chamber atmosphere comprising 95% air and 5% CO2 at 37°C overnight. After which, media
was replaced with serial dilutions of test compounds 5, 7 and 2X prepared in 0.5% DMSO /
RPMI1640 media and incubated for 2 weeks at 5% CO2 at 37°C. Following treatment, cells
were fixed with 0.25 % glutaraldehyde at room temperature for 20 min and stained using
crystal violet solution (0.1% crystal violet and 1X PBS) at room temperature for 30 mins.
Stained cells were washed with water by dropping gently, and air dried at room temperature.
The number of colonies were quantified using the Tucsen camera (ISH500) mounted Optika
XDS-2 trinocular inverse microscope and Fiji program (version 1.6.0; Schindelin et al.,
2012). Survival rate of the colony formation was calculated using the equation II:
Equation II:
𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟 =

𝑁𝑁𝑁𝑁. 𝑜𝑜𝑜𝑜 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓 𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠
𝑁𝑁𝑁𝑁. 𝑜𝑜𝑜𝑜 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 𝑋𝑋 100

2.3 Statistical analysis
All data was presented as mean ± standard error of the mean (SEM). For the analysis and
graphical representation of biological experimental IC50 values were calculated (GraphPad
Prism 6 Software, La Jolla CA) using dose–response curves for the compounds. For plotting
the dose–response curve, a non-linear regression curve fitting method was used where the
mean positive control (50% DMSO in growth media) was defined as 0% and the mean
vehicle control (0.5% DMSO in growth media) was defined 100%. For significance analysis,
two-way analysis of variance (ANOVA) followed by Tukey’s multiple comparison test was
performed. P < 0.05 was considered statistically significant.
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Chapter 3
Homology Modelling of G-Protein Coupled Receptor:
GPR120
GPCRs are the largest family of transmembrane proteins in the human body comprising ~800
distinct receptors. In 2000, the first high resolution crystal structure of a mammalian GPCR bovine rhodopsin – PDB-ID: 1F88 (Palczewski, 2000) was resolved. Later in 2007, a
structure of an inverse-agonist bound human β2 adrenoceptor was crystallized in a lipid
environment at 3.4/3.7 Å resolution (Rasmussen et al., 2007). These structures provided
significant insights into the GPCR function and stability of the inactive state upon binding of
antagonist or inverse agonist. Since then, crystal structures of 110 unique GPCRs – 88 Class
A

GPCRs,

and

~320

ligand-receptor

complexes

have

been

elucidated

(https://gpcrdb.org/structure/statistics - January 2022; Kooistra et al., 2020). However, about
80% of GPCRs have not yet been crystallised including FFA2, FFA3 and GPR120. The
process of crystalising GPCRs remains slow and challenging (Grisshammer, 2017) due to
low expression levels and difficulties regarding the crystallization process itself (Ghosh,
Kumari, Jaiman and Shukla, 2015). The available experimentally (NMR or X-ray)
determined GPCR structures have been used in comparative homology modelling and in
silico / virtual screening (VS) campaigns of early-stage drug discovery (Chahal, Nirwan and
Kakkar, 2019; Lin, Li and Lin, 2020; Muhammed and Aki-Yalcin, 2018). Subsequently,
millions of compounds can be computationally screened through VS to discover novel druglike compounds (Dailey et al., 2009).
Based upon the observation of the experimentally determined 3D protein structures, the
central dogma of structural biology of proteins is stated as the tertiary (3D) structures of
homologous proteins are evolutionarily more conserved than their primary structure (amino
acid sequence) (Kaczanowski and Zielenkiewicz, 2009). Therefore, if two proteins have
sufficient similarity in sequence (more than 30 %) (Waterhouse et al., 2018), the structural
information of one protein (the template or known 3D structure) can be used as a scaffold for
generating a 3D model of the other protein (target – unknown 3D structure). The amino acid
sequence of the protein of interest and additional information from the protein database
websites are used to identify different goals such as phylogeny of the protein, the prediction
of secondary and tertiary structure of the protein (homology modelling - HM) and the
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identification of functional properties (Basith et al., 2018; Kaczanowski and Zielenkiewicz,
2009).
HM has been used to predict the structures of various GPCRs (Sailapathi et al., 2021) and
predicts the 3D-structure of an unknown protein based on the known structures of a similar /
homologous protein from its amino acid sequence with an accuracy that is comparable to the
best experimental results such as NMR or X-ray crystal structures. The HM methods
primarily consists of four different steps: template selection, target-template alignment,
model building and model assessment. The steps of HM are briefly described below as in
(Webb and Sali, 2016). (Figure 3.1).

Figure 3.1: General schematic of homology modelling methodology followed.
When the experimental 3D structure of a target protein is known, protein-ligand interactions
and binding site information can be used to generate an ensemble of binding modes of
protein-ligand configurations. Different ligands can then be ranked with respect to their
binding modes in the binding pocket of the receptor (Beuming et al., 2015). In cases where,
the crystal structure of the target protein is unknown, and the 3D structure has been generated
by HM, it may contain inaccuracies and errors that may interfere with ligand binding in the
binding site of the receptor. Enrichment studies can be performed to measure the selectivity
of the receptor towards the active known binders through molecular docking studies.
The enrichment factor demonstrates the ability of the generated model to enrich the known /
active ligands of the receptor in the top ranks of the screening from among a wide database of
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molecules. The screening databases for enrichments are prepared to contain actives / known
ligands and drug-like decoys which resemble the active ligands in geometry but are
chemically distinct from actives. The enrichment factor is evaluated by plotting the
corresponding Area Under the Receiver Operating Characteristic (ROC) curves
(AUC) (Lenselink et al., 2014; Mysinger, Carchia, Irwin and Shoichet, 2012).
The overall objective of this chapter is the generation and validation of a structural model of
human GPR120 receptor as well as confirm the basis of recognition of known GPR120
agonist - TUG891 by molecular docking analysis.
3.1 Template selection and sequence alignment
The target protein sequence is used as the query to identify the experimental 3D structures of
homologous proteins in the databases of protein structures such as RCSB-PDB (Deshpande et
al., 2005), GPCRdb (Munk et al., 2016), SCOP (Andreeva et al., 2004), DALI (Dietmann et
al., 2001) and CATH (Pearl et al., 2005). The sequence comparison methods - BLAST and
FASTA, are utilised to detect sequence identity / similarity and quantify the results in terms
of sequence identity or statistical measures such as an E-value or z-score (Altschul et al.,
1990). For more distantly related homologs, sensitive searching methods including profile
matching and Hidden Markov Models (HMM) (Gribskov, McLachlan, and Eisenberg, 1987;
Krogh et al., 1994), position specific scoring matrix (PSSM) (Altschul et al., 1997) are
utilized. In general, the heuristic method, BLAST search – Basic Local Alignment Search
Tool, is a reliable approach that identifies hits with sufficiently low E-value signifying close
evolutionary relatedness. A template with a very poor E-value is not recommended as it can
lead to the generation of a misguided model (Altschul et al., 1990).
There are factors other than sequence similarity that need to be considered to select a
template from identified templates by the search method. The environmental condition of the
target must be considered with respect to the template’s native environment such as solvent,
pH, and ligands complexed in the crystal structure, quaternary interactions, and the location
of the target in the cell (Loo et al., 2018). Another important factor is the experimental
quality of the template. The accuracy of a crystallographic structure depends on the resolution
and R-factor while for a NMR structure, the number of restraints per residue is the indicative
factor for the structure’s accuracy (Webb and Sali, 2014; Loo et al., 2018).
The human GPR120S and GPR120L sequences were used unless mentioned otherwise. The
sequences of short and long isoforms of GPR120 - human GPR120S (Q5NUL3-2), and
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human GPR120L (Q5NUL3) were retrieved from UniProt (Uniprot, 2016) (section 2.1.1).
The sequences of other members of the FFAR family - human FFAR1 (O14842), human
FFAR2 (O15552) and human FFAR3 (O14843) – were also retrieved from UniProt. As
GPR120 belongs to the Class A (Rhodopsin family) of the GPCR gene superfamily, all Class
A GPCRs (Kargman et al., 1999; Fredriksson et al., 2003) for which crystal structures have
been submitted were retrieved from the RCSB PDB (Table 3.1). The retrieved PDB structure
files were screened based on several criteria. Firstly, each template had to include an
antagonist or inverse agonist and with an overall sequence identity above 20% with hGPR120
(an exception was for FFAR family members). Secondly, the templates should not be missing
more than two loop regions. All the selected templates (shown in Table 3.1) were preprocessed manually to remove any additional structures (such as water molecules, lipids,
heteroatoms, ligands, ions, etc.) from the PDB file using Pymol (DeLano, 2018).
To determine the most suitable template(s) for building GPR120 models, the amino acid
sequence of each selected GPCR (Table 3.1) was individually aligned against the GPR120S
(short isoform) as well as performing MSA using Clustal Omega (Sievers and Higgins, 2017)
followed by phylogenetic analysis using SeaView (Gouy, Guindon, and Gascuel, 2009)
which read in FASTA sequences.
The crystal structure of human FFAR1 (PDB ID: 4PHU) was elucidated in 2014 (Srivastava
et al., 2014). As FFAR1 and GPR120 belong to the same subfamily of FFA receptors of
Class A GPCRs, FFAR1 was selected as one of the templates even though the X-ray crystal
structure was co-crystallised with an allosteric ligand. The phylogenetic analysis of the FFA
receptor subfamily shows that FFAR1, FFAR2 and FFAR3 have more than 30% sequence
identity and are phylogenetically closer to nucleotide receptors in the phylogenetic tree of the
Class A family of GPCRs (Figure 3.2). Whereas GPR120 has TM sequence identity of 15%
with FFAR1 and less than 20% with other members of the subfamily and is clustered with
orphan receptors. The PhyML method based phylogenetic analysis in SeaView of the
selected template GPCR sequences showed that endothelin, orexins, and opioids were most
closely related to human GPR120S in the evolutionary tree (Figure 3.2). Consequently,
Orexin receptors (OX1R and OX2R), Opioid Kappa-type receptor (Kappa-type), Opioid
delta-like receptor (Delta-type) and Endothelin type-B receptor (Endothelin) were selected
for generating human GPR120S homology models.
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Table 3.1: Crystal structures of Class A GPCRs in inactive state available in the PDB (Data
retrieved: January 2017).
G Protein Coupled Receptor

PDB-ID Resolution

Crystal Structure of the CCR5 Chemokine Receptor

4MBS

2.71 Å

3ODU

2.5 Å

4EA3

3.0 Å

4DJH

2.9 Å

4N6H

1.8 Å

2KS9

NMR

4PHU

2.3 Å

Crystal Structure of a Lipid G Protein-Coupled Receptor

3V2Y

2.8 Å

Crystal Structure of Bovine Rhodopsin

1U19

2.2 Å

4IB4

2.7 Å

3PBL

2.8 Å

3RZE

3.1 Å

3EML

2.6 Å

3UON

3.0 Å

4IAR

2.7 Å

XFEL structure of human Type 1 Angiotensin-II Receptor

4YAY

2.9 Å

Human Orexin 2 receptor bound to Suvorexant (insomnia drug)

4S0V

2.5 Å

Human endothelin receptor type-B in ligand-free form

5GLI

2.5 Å

The structure of the CXCR4 chemokine receptor in complex with
small molecule antagonist IT1t
Structure of N/OFQ Opioid Receptor in Complex with Peptide
Mimetic
Structure of the human kappa opioid receptor in complex
with JDTic
Structure of the human delta opioid 7TM receptor
Solution conformation of substance P in water complexed with
NK1R (NMR structure)
Crystal structure of Human GPR40 bound to allosteric agonist TAK875

Crystal structure of the chimeric protein of 5-HT2B-BRIL in
complex with ergotamine
Structure of

human dopamine

D3

receptor

in

complex

with eticlopride
Structure of the human histamine H1 receptor in complex with
doxepin
The 2.6 A Crystal Structure of a Human A2A Adenosine Receptor
bound to ZM241385
Structure of the human M2 muscarinic acetylcholine receptor bound
to an antagonist
Crystal structure of the chimeric protein of 5-HT1B-BRIL in
complex with ergotamine
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A multiple sequence alignment employing the Clustal Omega software provided insights
about highly and less conserved areas of the target protein (Figure 3.3). Even though all the
Class A specific (D/ERY in TM3; WxP in TM6; NPxxY in TM7 – highlighted in Figure 3.3,
3.4) motifs are conserved throughout the FFA receptor family with few exceptions, large
gaps and non-identical residues can be observed between the aligned GPR120 isoforms and
other members of the FFA receptor family. Interestingly, the highly conserved GPCR D/ERY
motif of GPR120 shows a difference where Y (tyrosine) is mutated to M (methionine). There
are a few examples of variations at this position in other Class A GPCRs such as for the
Oxytocin receptor which has a DRC motif; Cysteinyl-leukotriene type 1 receptor has FRC.
As the sequence alignments for HM are guided by the highly conserved amino acid residues
(motifs that are shared by the members of this family) between the template and the target,
FFAR1 (the only FFA receptor with an elucidated crystal structure) was not used as it has the
alterations in the conserved motifs compared to GPR120 such as ERM to GRY in TM3 –
negatively charged residues replaced by small uncharged Glycine which favours turns,
WxP to VxP in TM6 and NPxxY to NPxxT of TM7/8 – large aromatic residues replaced by
non-aromatic residues.
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Figure 3.2: Phylogenetic tree of GPR120L and GPR120S with selected Class A GPCRs built
in SeaView (Gouy, Guindon, and Gascuel 2009) using the PhyML algorithm at 100 bootstrap
values – branch length is directly proportional to the number of substitutions per site.
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Figure 3.3: Multiple sequence alignment of the FFA receptor family generated
using Clustal Omega. Conserved residues are shown in square boxes; * indicates a fully
conserved residue; :

indicates conservation between groups of strongly similar

properties; . indicates conservation between groups of weakly similar properties. The
conserved motifs of Rhodopsin-like family are highlighted in black boxes and disulfide bond
forming cysteines are highlighted in yellow boxes.
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The sequence identity of the seven transmembrane regions between the GPR120 receptor and
the selected GPCRs with elucidated crystal structures (listed in Table 3.1) with a cut off ≥ 20
percent sequence identity is detailed in Table 3.2. Only antagonist or inverse agonist-bound
crystal structures were used for templates as they are likely to be in open / inactive
conformation (Figure 1.8). The open / inactive conformation of receptor implies that
the orthosteric binding pocket of the receptor has not closed on (i.e., trapped) the ligand and
ECL2 has not covered the entrance (acting as a lid) of the binding pocket to trap the agonist
inside the pocket. These conformational changes are usually observed in the agonist-bound
Class A GPCRs (activation detailed in section 1.4.3; Figure 1.8). As the GPR120 models
were generated to be used for VS and molecular docking studies, the model was required to
be in an open / inactive conformation.
Table 3.2: Sequence identity / similarity scores from pairwise alignment between the selected
Class A GPCR templates with %identity ≥ 20 % and GPR120S target sequence for the TM
regions from GPCRdb (GPCRdb.org).
GPR120S pairwise aligned against

%Similarity

%Identity

Resolution

Orexin OX2 receptor [4S0V]

45

24

2.5 Å

Opioid Kappa-type receptor [4DJH]

43

22

2.9 Å

Orexin OX1 receptor [4ZJ8]

41

24

2.75 Å

Adenosine A1 receptor [5UEN]

40

22

3.2 Å

Chemokine C-X-C type 4 [3ODU]

39

22

2.5 Å

Endothelin type B receptor [5GLI]

39

21

2.5 Å

Dopamine D3 receptor [3PBL]

39

21

2.89 Å

Chemokine C-C type 5 [4MBS]

38

21

2.71 Å

Opioid delta-like receptor [4N6H]

38

21

1.8 Å

5-hydroxytryptamine receptor 2B [4IB4]

38

21

2.7 Å

Chemokine C-C type 2 [5T1A]

38

21

2.81 Å

Sphingosine 1-phosphate receptor 1 [5A86]

38

21

2.25 Å

Nociceptin/orphanin FQ receptor [4EA3]

37

20

3.01 Å
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Furthermore, the templates were examined for their crystal structure resolutions (Table 3.2).
The higher resolution (lower values) crystal structures were selected as this indicates a more
refined crystal structure useful to investigate receptor-ligand interactions. The crystal
structures of the selected templates were also manually screened for the presence of a
disulfide bond between TM3 and ECL2 forming a lid to trap ligands as well as alignment of
conserved motifs, such as the D/ERY motif in TM3, WxP motif in TM6 and NPxxY motif in
TM7 (Figure 3.4).

Figure 3.4: Conserved motifs of Class A GPCRs selected as templates for GPR120 homology
model. Sequence alignments were generated in GPCRdb (Munk et al., 2016). The position of
the characteristic motifs in the sequence is specified in the Ballesteros-Weinstein numbering
scheme (Ballesteros and Weinstein, 1995).
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3.2 GPR120 topology prediction and homology model generation.
The secondary structure prediction for each amino acid is “three-state” as each residue can be
in one of three “states”: α, β, or other (O) and secondary structure prediction algorithms and
databases can be used to predict whether an amino acid is in a α−helix, a β−sheet, or a loop
region.

The

secondary

structure

information

of

GPR120

isoforms

available

on Uniprot (Uniprot, 2016) when compared with other databases such as GPCRdb (Munk et
al., 2016) and the results from various secondary structure prediction algorithms (UCDPorter, JPred, TMHMM) (Mirabello and Pollastri, 2013; Drozdetskiy et al., 2015; Krogh et
al., 2001) showed different ranges of TM region (Appendix V a-c To have a singular range of
TM regions, a consensus method from three different secondary structure prediction
algorithms (UCD – Porter, JPred, TMHMM) was applied and an overlapping topology range
of residues was selected (Table 3.3).
Table 3.3: Predicted topology of the TM regions of GPR120 short and long isoform based on
the consensus from the topology prediction algorithms.
Helix

Amino acid sequence

Range

Range

GPR120S

GPR120L

TM1

LVLAAVETTVLVLIFAVSLLGNVCALVLVA

37-65

37-65

TM2

ATACLVLNLFCADLLFISAIPLVLAVRWT

73-101

73-101

TM3

PVACHLLFYVMTLSGSVTILTLAAVSLERMVCIV

107-141

107-141

TM4

RRARAVLLALIWGYSAVAALPLCVF

152-175

152-175

TM5

EISWDVSFVTLNFLVPGLVIVISYSKILQIT

204-233

204-233

TM6

IRVSQQDFRLFRTLFLLMVSFFIMWSPIIITILLILI

252-289

268-305

TM7

VIWPSLFFWVVAFTFANSALNPILYMTLCRNEWK

296-324

312-347

TM8

CRNEWKKIFCCFW

326-339

349-362

MODELLER v9.14 (Webb and Sali, 2016) was incorporated into an in-house KNIME
pipeline for HM (Figure 2.1) and used for generating GPR120 homology models using the
protocol explained in section 2.1.2. For each template combination (shown in Appendix
Table IIa), 100 homology models were generated. Initially, models were generated using the
73 | P a g e

complete sequence of both GPR120S (361 residues) and GPR120L (377 residues). As the
protein sequence contains a long N-terminal chain (35 residues) and ICL3 of 17 residues in
GPR120S and 33 residues in GPR120L, the initial models were generated with disordered
structures as shown in Figure 3.5. The N-terminal chain of GPR120L was bending towards
the intracellular region, implying that it was entering the membrane bilayer while in
GPR120S, the N-terminal chain was wrapped around the ECL2; and ICL3 (Cyan – in
GPR120L - long isoform only) was packed into the intracellular pocket, which would result
in steric clashes with trimeric subunits of G-protein (detailed in section 1.4.3; Figure 1.8). A
manual screening was applied on such GPR120 models in which ECL and ICL as well as N
and C-termini enter the membrane as MODELLER protocols (section 2.1.2) do not include
any information about the location of a protein with respect to the membrane.

Figure 3.5: Top DOPE scored 3D model of GPR120L (left) and GPR120S (right) generated
using the 4S0V-4N6H-4DJH-5GLI-4JZ8 template combination; the figure illustrates the
disordered conformation of the N-terminal region (shown in red) and ICL3 (shown in cyan).
Visualised in PyMol (DeLano 2018).
Previous literature suggested that the N-terminal of GPCRs plays an important role in peptide
recognition and binding of bulkier ligands (ligands above 600 Dalton) (Rutz, Klein
and Schülein, 2015). Class C GPCRs are distinguished by their large N-terminals, which
contain a ligand-binding domain, such ligand binding domain are not common in class A
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GPCRs (Rutz, Klein and Schülein, 2015) (explained in section 1.3.1). As the scope of the
research was to screen only small drug like compounds using the 3D models of GPR120, the
N-terminal (1-35 residues) of GPR120S and GPR120L, and C-terminal (339 -361 residues)
of GPR120S were cleaved off to refine the modelled structure (Figure 3.6). If required, the Nterminal and C-terminal can be threaded in the future to the refined seven TM domains of
GPR120.
For the next iteration of HM generation, the protein sequence of GPR120S (36-339 residues)
was utilized (Figure 3.6) and GPR120L (36-355 residues), which has an extra 16 residues
compared to the short isoform with a total of 33 residues in ICL3.
The DOPE scores of the predicted models from all the 25 template combinations (Table 2.1)
were compared and models generated from the 4S0V-4N6H template combination were
found to have the best DOPE scores. The model with the lowest DOPE score signifies the
most stable protein model. MODELLER generated the MSA (shown in Figure 3.6) of target
sequences (4S0V and 4N6H) extracted from the PDB (3D coordinate) files of experimental
structures and the GPR120S sequence to build the 3D models of GPR120S sequence. The
cleavage of N and C terminals from GPR120S sequence improved the percent identity of
4S0V from 24 to 28 % and 4N6H from 21 to 24 % against the query sequence (Table 3.4).
The models generated by 4S0V-4N6H templates were evaluated to confirm the
conformations and stereochemistry of TM and loop regions.
Table 3.4: Clustal Omega Percent Identity Matrix of templates and target sequence used for
the generating the homology model of GPR120S.
1:

GPR120S_trimmed (35-339)

100.00 24.21

28.16

2:

4N6H (Delta-like opioid receptor)

24.21

100.00

30.00

3:

4S0V (Orexin type 2 receptor)

28.16

30.00

100.00
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Figure 3.6: Sequence alignment of GPR120S and templates (4N6H and 4S0V) used for
homology model generation; Conserved residues shown in square boxes. Multiple sequence
alignment generated using Clustal Omega. ‘*’ indicates fully conserved residue; ‘:’ indicates
conservation between groups of strongly similar properties; ‘.’ indicates conservation
between groups of weakly similar properties. The disulfide bond forming Cysteines are
indicated by . The conserved motifs of the Rhodopsin-like family are bolded. Red indicates
helical / transmembrane regions; Green - β-strands; yellow – loop regions.
3.3 Side-chain optimization
From the 4S0V-4N6H model series, the top 10 models were selected (Table 3.5) and were
further screened by their stereochemical properties by assessing their Ramachandran ɸ-Ψ
(phi-psi) plots using MolProbity webserver (Chen et al., 2009) and quality of the predicted
structure by ProSA webserver (Wiederstein and Sippl, 2007).
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Table 3.5: DOPE score of top 10 models of GPR120S derived from templates 4S0V-4N6H
3D Model

DOPE score

3D Model

Dope Score

1 GPR120S_Model_30 -41156.738

6

GPR120S_Model_31 -40959.097

2 GPR120S_Model_63 -41070.296

7

GPR120S_Model_24 -40953.445

3 GPR120S_Model_97 -41042.429

8

GPR120S_Model_77 -40917.972

4 GPR120S_Model_18 -41029.484

9

GPR120S_Model_33 -40915.375

5 GPR120S_Model_45 -40976.371

10 GPR120S_Model_32 -40899.261

The comparative analysis of the stereochemical parameters of the top ten DOPE scoring
models (Table 3.5) of GPR120S by the Molprobity webserver showed high plausibility of the
generated models with respect to the protein stereochemistry. The Ramachandran ɸ-Ψ
evaluation showed that there were no residues (0%) in outlier region and 98-99% residues
were in favoured region. But the models had some poor rotamers / sidechain rotations above
the permitted range of 0.3%, which were removed by sidechain optimization using SCWRL4
(Krivov, Shapovalov and Dunbrack, 2009). GPR120S_model30 with the best DOPE score
was selected for further optimisation. From this point forward, GPR120S_model30 is referred
to as GPR120S.
SCWRL4 contains a backbone-dependent rotamer library based on kernel density estimates,
and it search for the average sidechain rotamer over samples of conformations about the
position of residue in the rotamer library. It consists of a fast-anisotropic hydrogen bonding
functions and using the short-range, soft van der Waals atom-atom interaction potential, it
detects sidechain-sidechain and sidechain-backbone collisions. Finally, it generates an
optimized model from all parameters by determining the interaction graph within the crystal
environment using symmetry operators of the crystallographic space group (Krivov,
Shapovalov and Dunbrack, 2009; Ryu and Kim, 2012).
SCWRL4 read in the 3D coordinate file of the predicted model backbone from which
sidechains were removed. The algorithm searched for the sidechain rotamers over the rotamer
conformational library to generate the complete model with sidechains. Sidechains of all the
selected models (Table 3.5) were optimised using SCWRL4 and the validation parameters of
initial and sidechain optimised models were compared to evaluate and select the best
predicted model (Table 3.6).
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The sidechain optimization by SCWRL4 increased the stereochemical quality of the
generated 3D model (Table 3.6). The number of poor sidechain rotamers decreased from five
to one, bringing the model closer to the permitted range (~ 0.3%) of allowed poor rotamers
from ~2% in 3D models.
Table 3.6: Stereochemical parameters of top side chain optimised GPR120S model generated
by HM (Molprobity webserver).
Model (303 residues)
Poor rotamers (Goal: <0.3%)
Favoured rotamers (Goal: >98%)
Ramachandran outliers (Goal:
<0.05%)
Ramachandran favoured
(Goal: >98%)
Bad bonds (Goal: 0%)
Bad angles (Goal: <0.1%)

GPR120S

Sidechain optimised
GPR120S

5
244

1.88%
91.73%

1
264

0.38%
99.25%

0

0.00%

0

0.00%

297

98.67%

297

98.67%

0 / 2473
33 /
3379

0.00%

7/ 2473

0.28%

0.98%

6/ 3379

0.18%

3.4 Validation of GPR120S homology model
Ramachandran plot analysis (MolProbity - Chen et al., 2009) of the sidechain optimised
model (Table3.6) reveals that ~98% (297/301 residues) of residues are in favourable regions
while only one glycine residue is in the disallowed region (Figure 3.7 a). As glycine do not
have side chains and is the least sterically hindered amino acid and therefore often adopts
conformations that are forbidden to other residues. Glycine can adopt ɸ-Ψ (phi-psi) angles in
all four quadrants of the Ramachandran plot covering a large area on the plot and appear in
the unfavourable or disallowed regions (Ho and Brasseur, 2005).
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c

d
4N6H
Z-score = -4.59

4S0V
Z-score = -1.32

Figure 3.7: Ramachandran plot (a) and Z-score (b-d) of the top GPR120S homology model
and homology templates 4N6H and 4S0V. The most favoured regions in Ramachandran plot
are enclosed by blue boundaries, additional allowed, generously allowed regions are enclosed
in purple boundaries and all areas outside of purple lines are disallowed regions / outliers. No
residues have a bad conformation / are outlier, with only two residues in allowed regions.
Protein structure analysis (ProSA) gives the quality of the overall model in terms of the
deviation of the experimental result from the most probable result in the form of a
graph (Wiederstein and Sippl 2007). The number of residues is plotted versus Z-score for
known structures determined by X-Ray crystallography and NMR. Z-score is a statistical
measure that quantifies the distance in standard deviations of a data point from the mean of a
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data set. The Z-score of the selected SCWRL optimised model (-3.5) indicated that overall
quality of the protein is comparative to the Z-score of the templates used (4N6H: -4.59;
4S0V: -1.32) and lies in the favourable range (Figure 3.7 b-d). In general, positive values
correspond to poor quality of the input structure. The black dot represents the predicted
protein, and the analysis shows that the modelled protein is similar to proteins which have
been characterized using NMR/X-ray. These values indicate that the structural average for
the generated quality control values is within a normal range. Therefore, the final refined
model passes the formal evaluation and need to be considered as suitable for further studies.
The ERRAT analysis of 3D model of GPR120S (Figure 3.8) resulted in an overall quality
factor of 92.6 % where high-resolution structures produce values around 95% or higher while
lower resolutions (2.5 to 3 Å) produce average overall quality factor of ~91%. The highest
error values were recorded in the intracellular loop (ICL) regions – ICL2 (142-151) and ICL3
(234-251) which are not involved in the protein-ligand interactions. ERRAT quality factor
represented clear agreement that the generated 3D model of GPR120S is of comparative
quality with X-ray crystal structures and can be used for further screening studies.

Figure 3.8: ERRAT statistical representation of overall quality of sidechain optimised
GPR120S model in comparison to refined X-ray crystal structures (Colovos and Yeates,
1993). The highest error values were recorded in the intracellular loop (ICL) regions – ICL2
(142-151) and ICL3 (234-251).
Finally, the quantitative analysis of structural features of the generated model was
performed. The X-ray crystallised 3D structures of templates (4N6H and 4S0V) when
superimposed to the GPR120S model, the backbone (Cα, C and N atoms) root mean square
deviation (RMSD) of selected model against 4N6H and 4S0V was found to be 1.386 Å and
0.652 Å, respectively. RMSD measures the difference between C-alpha atom positions
between two proteins. The sidechain optimised homology model GPR120S was selected for
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further EM and investigational studies as it has the lowest mean RMSD (1.019 Å) and highest
structural similarity when compared to other models as well as it was most optimised model
on various parameters such as DOPE scores, Z-score, number of bad angles and ɸ-Ψ
evaluation.
Initially, the GPR120S model was generated and validated and later GPR120L was modelled
from the validated GPR120S 3D model to keep the 3D structure of GPR120L ordered as the
ICL3 (the long isoform – with 16 extra amino acids) of GPR120L has very low similarity
with other GPCRs (Appendix Vd). The range of transmembrane domain for GPR120L was
maintained as that for GPR120S with topology as shown in Table 3.3. Although a model for
GPR120L was also generated the focus was on GPR120S for compound screening as both the
short and long isoforms have identical orthosteric binding pocket sequentially as well as
structurally (Figure 1.11). As the predicted 3D models of GPR120S and GPR120L were
generated to screen hit compounds by VS of chemical databases, only GPR120S was used for
VS of chemical databases and further studies.
3.5 Energy minimization of GPR120S model in a phospholipid bilayer
The aim of the initial energy minimization was to achieve the net force on each atom in the
GPR120S model closest to zero. EM explores different protein motions and conformations to
find optimised free energy states of the protein obtained during evolution of protein structure
towards the global minimum of free energy. Although attaining global minimum of free
energy during the short energy minimisation steps is almost impossible, the optimised protein
structures usually attain local minimum of free energy. The optimised state proteins have low
free energy due to the least number of steric clashes and abnormal geometry (Abraham et al.,
2015). GROMACS v5.1.4 uses semi empirical force fields to run the molecular energetics of
the protein model. Interatomic interactions such as the bond lengths, angles, and torsions as
well as the van der Waals and electrostatic interactions, of the protein model are
approximated to compute the energy of different conformations to find the most accurate
ground state conformation possible.
Being a transmembrane protein, for EM the GPR120S model must be embedded in the
phospholipid bilayer solvated by water under periodic boundary conditions to provide the
optimum environment. This environment mimics the natural lipid bilayer and conserves the
functional properties of the receptor. For example, in silico MD studies have shown that
gradual inactivation of the β2 adrenergic receptor occurred in the neutral lipid membrane of 181 | P a g e

palmitoyl-2-oleoyl-sn-glycero-3-phosphatidylcholine (POPC) molecules (Dror et al., 2011) as
well as activation of rhodopsin receptor induced changes in membrane (Salas-Estrada,
Leioatts, Romo and Grossfield, 2018). Prior to EM the GPR120S was embedded in an
explicit bilayer membrane consisting of POPC molecules (Figure 3.9 a, b), solvated with
water molecules and charge neutralized by addition of sodium and chloride ions following
the set protocol (as explained in section 2.1.4). EM was carried out for an apo receptor model
to ensure that the protein system has no steric clashes or abnormal geometry.
The coordinate file of a hydrated, equilibrated 128 lipid POPC (Figure 3.10) bilayer along
with lipid parameters for the GROMOS 54a7 force field were obtained from the ATB
repository (Koziara

et

al.,

2014). The

coordinate

file

was

then

resized

using

Inflategro2 (Schmidt and Kandt, 2012) - modified to comply with GROMACS v5.1.4, to
produce a fully hydrated, 512 POPC lipid bilayer (Figure 3.10c). First, InflateGro2
incorporates LAMBADA (Schmidt

and

Kandt,

2012) which

determine

the

protein’s LSmin (hydrophilicity profile) configuration using a recursive optimization to test
different protein orientations thus aligning membrane and protein. Then it automatically
embeds the membrane protein into lipid bilayer patches and removes the clashing lipids.
Inflategro2 then stretches the model in the plane of the lipid bilayer and energy minimizes
the system again on contraction allowing optimization of lipid/protein interface over 1000
EM steps for 20 iterative cycles, using a scaling factor of 0.5 (Kandt, Ash and Tieleman,
2007).
Embedding of the GPR120S receptor resulted in the removal of 33 lipid molecules. The final
system contained a 303 amino acid long protein, 477 POPC molecules, 25,529 water
molecules and 14 chloride ions (shown in Figure 3.9d). Each system was charge neutralised
by adding the required number of sodium or chloride ions. The setup of such large systems
(104,505 atoms) invariably leads to close contacts in the initial positions of the atoms. The
close contacts can result in extremely high repulsive forces and cause large displacements by
accelerating the atoms and distort the overall spatial conformation of atoms. EM can relieve
the close contacts and stabilize the system (Kandt, Ash and Tieleman, 2007).
The analysis of 50,000 EM steps showed that after ~14,000 EM steps, the apo protein system
reached a local minimum (U = -2,025,501 kJ/mol/nm) nearest to the starting system and
attained a probable relaxed state (Figure 3.10a). As the EM converged the system to
acceptable potential energy levels before all iterations were completed. The model with the
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lowest energy state from the energy minimized ensemble was selected and subjected to
model validation through enrichment studies.

Figure 3.9: a) Chemical structure of POPC molecule; b) single POPC cartoon view; c) full
minimized bilayer of 512 POPC molecules; d) GPR120S receptor embedded in POPC
bilayer; water molecules removed for clear visualization. Images were rendered and
visualized in PyMol (DeLano, 2018)
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The residue root mean square fluctuation (RMSF) is a measure of the flexibility of a residue.
It is typically calculated for the Cα atom of each residue. RMSF of the apo protein system
obtained from the EM run is shown below in Figure 3.10b, representing the measure of
conformational variance analysis. It highlights that the loop portions especially ECL2 (177203) and ICL3 (236-252) of the protein structure, fluctuated from their mean structure the
most and the TM helices showed the least fluctuation (below 0.2 nm). The larger loop regions
have more disordered structures and are known to fluctuate the most (Baştuğ,
and Kuyucak, 2012). The minimised model of GPR120S was used for further studies.

a

b

Figure 3.10: a) Potential energy (U) curve of the Apo protein energy minimization. The EM
plot demonstrates that the system steadily converged until ~ 4,500 EM steps and afterwards
attained steady state potential; b) Root mean square fluctuation (RMSF) of Cα atoms of each
residue during the EM. The ECL2 and ICL3 regions showed the maximum fluctuation.
3.6 Molecular docking and enrichment studies for affinity prediction
Previous molecular docking and site-specific mutation studies of GPR120 have revealed that
a single arginine residue in TM2 (Arg99) has a critical interaction between the receptor and
the –COOH (carboxylate) of its ligands (Watson, Brown and Holliday, 2012; Hudson et al.,
2013; Hudson et al., 2014). Six other residues were defined essential for TUG891 binding
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and interaction with GPR120 were: Trp104 (ECL1), Phe115 (TM3), Trp207 (TM5), Phe211
(TM5), Trp277 (TM6) and Phe304 (TM7) (Hudson et al. 2014) (shown in Figure 3.11).
These seven residues were selected as the main criterion for defining the orthosteric binding
pocket as well as protein-ligand interactions for binding pose prediction of GPR120 ligands.
To date, while some GPR120 agonists have been developed no orthosteric antagonist of
GPR120 is available. AH7614 (Table 1.8) was postulated as a GPR120S antagonist in 2014
(Sparks et al. 2014) but has recently been reported to act as a negative allosteric
modulator (NAMD) of GPR120 (Watterson et al. 2017).

Figure 3.11: Selected docked pose of TUG891 (binding score -9.875) illustrating hydrogen
bond interactions with Arg99 of GPR120S and a 2D interaction map of TUG891 in the
orthosteric pocket binding pocket. The 3D images were visualized and rendered in PyMol
v2.1.0. The 2D interaction maps were generated in BIOVIA DS Client visualizer v19.1
2019.
The in-silico investigation of receptor activation commenced with semi-flexible docking
(rigid protein vs flexible ligand) of a known agonist to the receptor model in the inactive state
(GPR120S homology model). The best docked pose for TUG891 yielded a binding score 85 | P a g e

9.875 kcal/mol (free energy of binding calculated by AutoDock SMINA). The carboxylate of
TUG891 forms a salt bridge with Arg99 and a strong T-type (perpendicular) pi-stacking
interaction between Phe115 and the cyclic aromatic core structure of TUG891 stabilize the
ligand into the pocket formed between TM3, TM6 and TM7 (Fig 3.11). A molecular docking
study conducted by Hudson and team (Hudson et al., 2014) used the HM of human GPR120S
(based on a nanobody-stabilized active state β2 adrenoreceptor template; PDB id: 3P0G) to
dock TUG891. An extensive overlap is observed between the binding pocket residues
interacting with the agonist in both studies. Other equitable hydrophobic interactions were
also observed to be stabilizing the docked TUG891 in the orthosteric binding pocket (Table
3.7).
Table 3.7: List of residues forming contacts with TUG891 docked to the orthosteric binding
pocket of GPR120S; obtained from PLIP (Salentin et al. 2015; https://plip-tool.biotec.tudresden.de/plip-web/plip/index)

Salt-bridge / Hydrogen bond interactions
Residue
Distance Å
Ligand Group
Arg99
4.32
Carboxylate
π-Stacking interactions
Residue
Distance Å Angle (Degree)
Type
Phe115
5.04
72.46
T
Hydrophobic interactions
Residue
Distance (Å)
Phe88
3.84
Val95
3.99
Trp104
3.84
Leu114
3.84
Phe115
3.59
Phe115
3.53
Thr199
3.67
Leu173
3.99
Trp207
3.19
Phe211
3.77
Ile280
3.47
Ile284
3.61
Phe303
3.65
Phe303
3.56
Val307
3.93
Val307
3.46
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Ideally, for the purpose of binding mode prediction, a homology model is validated via the
reproduction of the experimentally determined binding mode of another ligand (Beuming et
al., 2015; Dhasmana et al., 2019). In the absence of a receptor crystal structure, the energy
minimised GPR120S model was validated using enrichment studies that demonstrated the
ability of the modelled GPR120S to predict the binding affinities of known ligands and
distinguish between known ligands and decoys (Kim and Skolnick, 2008; Park et al., 2009).
The selected model was assessed for the ability to distinguish between known binders of
GPR120 and a set of drug-like decoys (obtained from DUD.E; see Appendix Table IIb) in a
virtual screening exercise, which was evaluated by plotting their corresponding ROC curves
and calculating the AUC (Beuming et al., 2015; Lenselink et al., 2014; Mysinger, Carchia,
Irwin and Shoichet, 2012). The docked pose of TUG891 (Figure 3.11) was used as a
reference pose for docking the active and decoy sets to perform enrichment studies.
The best AUC obtained for the ROC curve for the GPR120S receptor model was 0.89 (Figure
3.12), which indicates a significant ability to distinguish between the active compounds and
the decoys. The AUC obtained for the GPR120S receptor (< 0.9), was expected considering
the binding affinity prediction and ranking power of the docking algorithms in the absence of
high-resolution protein-ligand crystal structure. An analysis of the top-ranking decoys which
contributed significantly to the false positive rate at the initial part of the test revealed them to
be mostly compounds of high logP (above 5) and molecular weight (more than 450
Daltons). The Enrichment factor (EF) of the top 1% of the data set is 9.375 (top 20% is 4.23)
indicating that the modelled structure bound with the active ligands in the top 1% of the
ranked database. The EF of 9.3 indicates that ~9 times more active compounds in the top 1%
of the screening would appear. Based on the ROC curves obtained, the enrichment studies
provided additional support to the validation of selected model as a reasonable representation
of the GPR120S receptor. Using the same set of actives and decoys, further enrichment
studies were performed using SMINA docking algorithm and four different scoring
algorithms to re-score the top docked pose of SMINA to benchmark different scoring
functions – SMINA, VINA, NNScore, DLScore and CScore (section 2.1.3.2; Appendix Table
IIc). SMINA scoring function was found to be the best scoring function. The validated
GPR120S model with an EF (1%) of 9.375 was used for further MD studies.
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Figure 3.12: Area under ROC plot of decoys and actives docked to GPR120S shown in linear
scale. The line of identity (black, diagonal) represents the expected line in completely random
selection, which would result in an AUC of 0.5. Performed in R using in-house R-script.
3.7 Comparative analysis of GPR120 model predicted by DeepMind - artificial
intelligence.
DeepMind, a knowledge-based artificial intelligence (AI) operation, developed a 3D model
predictor of protein folding – AlphaFold. It uses a distribution over pairwise distances
between residues corresponding to a statistical potential function to predict the protein
folding (Wei, 2019; Jumper et al., 2021). The prediction algorithm improves the accuracy by
training the AI nodes based on the evolutionary, physical, and geometric constraints of
elucidated protein structures. The 3D model of human GPR120 short isoform (Q5NUL3 361 amino acids) predicted by AlphaFold was published on AlphFold DB in July 2021
(https://alphafold.ebi.ac.uk/entry/Q5NUL3 Jumper et al., 2021). The AI predicted model of
GPR120S (Figure 3.14) was compared to the validated GPR120S model generated for this
study in January 2017. The N-terminal (1-36) and C-terminal (340-361) domains, which were
removed from the GPR120S model to improve the structural quality (section 3.2; Figure 3.5)
due to their low structural similarity to templates were reported as the unstructured regions
with very low prediction scores (per-residue confidence score < 50) in the AI model as well
(Figure 3.13). With the exception of TM5, all the TM domains and Helix 8 of AI model have
the same sequence range (Table 3.3) as used for the GPR120S homology model (Figure
3.13). When the GPR120S homology model was superimposed to the AI predicted model, the
backbone (Cα, C and N atoms) RMSD was found to be 1.351 Å. With such low RMSD
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values, the accuracy of the GPR120S homology model generated by our study is comparable
to the AI predicted model of GPR120 short isoform.

Figure 3.13: 3D structure of human GPR120S predicted by AlphaFold artificial intelligence
(AI) program (Jumper et al., 2021). GPR120S seven TM domains and Helix - H8 of
AlphaFold predicted model (spectrum colour) superimposed on validated GPR120S
homology model (grey). AlphaFold produces a per-residue confidence score (pLDDT)
between 0 and 100.
3.8 Discussion
The initial focus was to build a 3D structural model of GPR120S through in silico
methodologies. Homology models as well as molecular docking are useful predictions and
not the ultimate solutions to determine the structures of macromolecules. Computational
approaches have gone through major developments in recent years and the available software
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packages are powerful and reliable to predict comparative naturally resembling models
(Malathi and Ramaiah, 2018). However, the quality of the predictions completely relies on
the prior knowledgebase available for target proteins. The models produced by combination
of a strong knowledgebase and reliable computational methods are of use in providing
guidance to experimental biologists to minimize unsuccessful experiment setup designs
(Malathi and Ramaiah 2018; Jumper et al., 2021).
Homology modelling of GPCRs has been employed effectively in various structure-based
drug discovery studies of GPCRs (Bissantz, Bernard, Hibert and Rognan, 2002; Jaiteh,
Rodríguez-Espigares, Selent and Carlsson, 2020). Homology modelling based on single
template structure for low sequence identity target proteins often generate less accurate
protein models (Larsson, Wallner, Lindahl and Elofsson, 2008) with GPCRs having sequence
identity in the range of 20-30% are best modelled using multiple template homology
modelling (Baker, 2001; Bender, Marlow and Meiler, 2020).
The homology model of GPR120S was developed, based on the high-resolution crystal
structures of human delta-like opioid and human orexin type-2 receptors, which are closer to
GPR120S in phylogenetic evolution of the available templates (performed in January 2017).
To the best of our knowledge, six different studies of GPR120 generated homology models
have been published which used single template-based modelling such as photoactivated
bovine rhodopsin (Sun et al., 2010; Hara et al., 2011; Takeuchi et al., 2013), active state β2
adrenoreceptor (Hudson, Shimpukade, Milligan and Ulven, 2014), inactive state delta-like
opioid receptor (Chinthakunta et al., 2018) and activated turkey β1 adrenoreceptor (Zhang,
Sun, Wen and Yuan, 2019).
The recently elucidated crystal structure of orexin OX2 receptor (in 2015) was found to be a
suitable template for GPR120S as it covers around 87% of the GPR120S (first 200 residues)
with 26% identity. It was used in combination with the delta-like opioid receptor which
covers around 84% of GPR120S (full sequence) with 26% identity. The MSA of orexin OX2
and delta-like opioid receptor over GPR120S improved the sequence alignment as well as the
quality of the 3D model generated. The current study used an antagonist-bound human deltalike opioid receptor and orexin 2 receptors as templates for GPR120 model prediction
available in January 2017. However, the latest (December 2021) protein BLAST search
(Altschul et al., 1990) conducted for GPR120S templates against the Protein Data Bank
(Deshpande et al., 2005) enlisted the same Orexin 2 receptor and delta-like opioid receptors
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as the best templates for homology model predictions covering 87% and 84% of the full
query sequence, respectively. While the sequence coverage improved to 93% and 96%
respectively for GPR120S sequence N and C terminals removed.
One limitation in the GPR120S model generation that can be argued is the ECL and ICL
domains (loop) modeling, especially ECL2 which plays a significant role in ligand binding in
Class A GPCRs. Side-chain optimization using SCWRL4 was performed to reduce this bias
to some extent and improve ligand binding predictions. Side-chain optimization may also
improve the stereochemistry of the model as during model generation limited rotamers for
each sidechain at fixed C-alpha of the protein backbone are explored. As there can be
exhaustive rotamer conformations for each residue and depending on the protein sequence
length, these enumerations can become astronomical. The side-chain optimization algorithm,
SCWRL4, was used to explore the bigger library of rotamers after homology modelling to
find combination of rotamers representing the lowest-energy conformations. The molecular
docking study against β-catenin by Low et al (Low et al., 2021) reported the application of
SCRWL-based sidechain sampling in iterative fashion to optimise homology models with
improved ligand enrichment performance. Considering the sequence identity of <30% and the
flexibility of loop regions, an initial 50,000 step EM and further molecular dynamics
simulations (Chapter 4) were performed in apo and ligand-bound systems to attain stable
protein ensemble conformations.
The prediction of ligand binding by molecular docking experiments is sensitive to side-chain
conformations of residues forming the binding pocket. The template selection criteria for the
GPR120 homology model were based on the antagonist-bound crystal structures. The
potential of binding pocket sidechain conformations of homology models biased towards the
chemical scaffolds of the templates used particularly for the ligand-bound templates could
result in false positives and pseudo binding predictions.
Over the course of combined energy minimization and semi-flexible molecular docking
studies, the model has been investigated. The reported hydrogen bonding pattern, lipophilic
interactions, and binding energy of the selective ligand – TUG891 has been examined in the
structural refinement. The amino acid residues involved in the putative binding site – Arg99
(TM2), Trp104 (ECL1), Phe115 (TM3), Trp207, Phe211 (TM5), Trp277 (TM6) and Phe304
(TM7) (Hudson et al. 2014) are facing towards the pocket in the validated model and have
shown reliable interactions with the GPR120S selective agonist TUG891. A molecular
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docking study conducted by Hudson (Hudson et al. 2014) used the HM of human GPR120S
(based on β2 adrenoreceptor template; PDB id: 3P0G) to dock TUG891. The predicted
binding poses of TUG891 (Hudson et al. 2014) illustrates the residues in proximity (distance
unknown) of the agonist. There was an extensive overlap between the binding pocket
residues interacting with the agonist in both studies (Table 3.6; Figure3.11).
Enrichment studies are used to measure the selectivity of the receptor towards the active
known binders. The enrichment factor demonstrates the ability of the generated model to
enrich the known / active ligands of the receptor in the top ranks of the screening from among
a wide database of molecules. The screening databases for enrichments are prepared to
contain actives / known ligands and drug-like decoys which resemble the active ligands in
geometry but are chemically distinct from actives. The enrichment factor is evaluated by
plotting the corresponding AUC plots (Lenselink et al. 2014; Mysinger, Carchia, Irwin and
Shoichet, 2012).
A ROC curve is the graphical plot that illustrates the diagnostic ability of the evaluation test.
The true positive rate/known binders (Sensitivity) are plotted in function of the false positive
rate/drug-like decoys (Specificity) for different cut-off points. Each point on the ROC plot
represents a sensitivity/specificity pair corresponding to a particular decision threshold. A test
with perfect discrimination (no overlap in the two distributions) has a ROC plot that passes
through the upper left corner (100% sensitivity, 100% specificity) (Mysinger, Carchia, Irwin
and Shoichet, 2012). Therefore, the closer the ROC plot is to the upper left corner, the higher
the overall accuracy of the test.
AUC is considered as an effective measure of inherent validity of the predicted model to rank
randomly chosen known binders higher than a randomly chosen drug-like decoy. This curve
is useful in (i) evaluating the discriminatory ability of the predicted model to correctly pick
up decoys and known binders; (ii) finding optimal cut-off point to least misclassify decoys
and known binders (Mysinger, Carchia, Irwin and Shoichet, 2012). As mentioned in section
3.6 that benchmarking of different scoring functions – SMINA, VINA, NNScore, DLScore
and CScore (Appendix Table IIc) reported SMINA as the best scoring function. It should be
noted that due to the small number of actives (28) molecules against a large set of decoys
(1400) molecules, the results can be biased. Similarly, the worst performing scoring functions
– NNScore and DLScore, were trained and optimised using a small training set (14 active
molecules; remaining active molecules used as test set) which could have skewed the data
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projections. A consensus score, Cscore, was calculated as an average score from the four
scoring functions which resulted in AUC of 0.77 (Appendix IIc) and it can be proposed as an
unbiased score which overcomes the overcorrected SMINA and VINA functions and
undertrained neural networks of NNScore and DLScore. CScore function was used only for
VS of large databases (Chapter 5) where pose selection by protein-ligand interactions was
difficult otherwise SMINA docking and scoring function was used.
The generated model GPR120S attained EF score of 9.3 and was used for structure-based
pharmacophore design (chapter 4; Appendix I Paper 2; Pal, Curtin and Kinsella, 2021a) as
well as for structure-based virtual screening (see chapter 5; Appendix I Paper 1; Pal, Curtin
and Kinsella, 2021). The limiting factor for the enrichment study was the number and
chemotype of active ligands used for decoy database generation, as all the ligands were either
agonists or partial agonists except AH-7614 (NAMD). Unfortunately, the six different studies
where GPR120 homology models were generated to perform docking and VS experiments
did not published data related to enrichment studies for comparison (Sun et al., 2010; Hara et
al., 2011; Takeuchi et al., 2013; Chinthakunta et al., 2018; Zhang, Sun, Wen and Yuan,
2019).
Nevertheless, the results from the present methodologies provided valuable information
concerning the optimal GPR120S model requirements for agonist selectivity recognition. In
order to design new GPR120S selective ligands, both agonist and antagonist – the nonconserved residues (with respect to FFAR family) involved in the binding pocket need to be
targeted. These residues are identical for GPR120S and GPR120L and share proximity to the
ligands. The binding pattern of the designed ligands through CADD methodologies and MD
simulations of protein-ligand complexes will help to confirm and optimize the validated
GPR120S model.
To address the inherent limitations such as low-sequence identity of templates, disordered
loop regions, binding site plasticity, lower enrichment factors, etc., which can lead to errors /
inaccuracies in the structure-based virtual screening experiments; molecular dynamics
simulations of 300 ns were next conducted (Chapter 4). The resultant refined models would
minimise these limitations for latter SBDD studies.
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Chapter 4
Structure based prediction of a novel GPR120 antagonist
based on pharmacophore screening and molecular
dynamics simulations.
Active state (agonist bound) GPCR structures are known to represent a specific
conformation, which is recognized by the heterotrimeric G proteins at intracellular domains
of GPCR (Kling, Clark and Gmeiner, 2016; Weis and Kobilka, 2018; Zhou et al., 2019). The
conformational changes are transferred from the ligand binding pocket at the extracellular
domain to the intracellular domain. There is a common mechanism of activation of GPCRs
(especially in Class A – explained in section 1.4.3) which starts with agonist binding (step1),
inducing inward motions of the extracellular domains of TM3, TM5, TM6, and TM7 (step 2).
This inward movement is accompanied by an outward movement of the intracellular domain
of TM5, TM6 and TM7 and inward movement of the intracellular domain of TM3 (step 3),
allowing the G protein to bind (step 4) and become activated to relay downstream signalling
(Weis and Kobilka, 2018; Zhou et al., 2019).
During this activation process, some prominent conformational changes have been observed
in Class A GPCRs (Figure 4.1) such as breakage of the “ionic lock” between TM3 (E/DRY
motif: Arg136 and Asp259) and TM6 at the cytoplasmic end; reorganization / rotation of the
“activation switch” residue in TM6 (WxP motif: Trp277) and breakage of an electrostatic
interaction in TM7 (NPxxY motif: Asn317, Pro318 and Tyr321) (Weis and Kobilka, 2018;
Zhou et al., 2019). The conserved P(TM5) I(TM3) F(TM6) motif (Pro219, Ile126 and Phe274)
residues in the TM regions and Proline residues closer to the WxP motif (TM6) serve as
hinges to transfer the conformational motion from extracellular to intracellular domains
(Figure 4.1) (Weis and Kobilka, 2018; Zhou et al., 2019).
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Figure 4.1: General schematic of Class A GPCRs activation with GPR120S specific residues,
Inactive state (Grey) versus Active state (Orange); - illustrate the bound agonist in the
orthosteric pocket activates the microswitches on TM3, TM6 and TM7. The inward motions
of the extracellular domains of TM3, TM5, TM6, and TM7 is followed by the outward
movement of the intracellular domains. The G protein binds at the intracellular domain and
relays the downstream signalling. (Zhou et al., 2019)
As stated, (section 3.1; Figure 3.4), Class A GPCRs share several conserved motifs. The
template structures, delta-like opioid and orexin O2, show the characteristic packing of TM
domains and interactions corresponding to the inactive state of Class A GPCRs, so the
generated model GPR120S should also exhibit specific characteristics such as:
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•

Ionic lock formed between TM3 (D/ERY – Arg136) and TM6 (Asp259) (Figure
4.1, 4.2a)

•

Disulfide bridge between TM3 (Cys111) and ECL2 (Cys194) (Figure 4.2b)

•

H-bond network mediating interactions between TM7 (NPxxY – Asn317, Ser314),
TM1 (Ser54, Asn58), TM2 (Asp85) at cytoplasmic end (Figure 4.1, 4.2c)

•

Conserved interface between TM5, TM3 and TM6 by triad PIF motif - TM5
(Pro219), TM3 (Ile126) and TM6 (Phe274) near the base of the ligand binding
pocket (Figure 4.1, 4.2d).

As the templates for homology modelling were antagonist bound / in the inactive state, these
structural features and interactions were found to be present and stabilize the inactive
conformation of the GPR120S model as reported in other inactive Class A GPCR studies
(Wacker et al., 2013; Kato et al., 2019; Zhou et al., 2019).
Here, with an objective of investigating the structural and conformational changes of
GPR120S from a computational perspective - MD simulations were performed, with a
particular emphasis on the early events of its possible activation mechanism (Zhou et al.,
2019; Perkins et al., 2014). MD simulations for an apo receptor; and two agonist-bound
receptor complexes were performed to study the ligand-induced process of conformational
change that leads to a possibly active receptor conformation (Wang and Chan, 2017; Weis
and Kobilka, 2018; Zhou et al., 2019).
For a comparative study along with TUG891 (Figure 3.11) another agonist bound system was
prepared with Compound39 – a benzofuran propanoic acid analogue (Table 1.8) (Lombardo
et al., 2016) employing the set docking protocols (Figure 4.3). MD simulations were
performed on three systems in a lipid bilayer: (1) Apo-GPR120S, (2) GPR120S-TUG891
(agonist bound; EC50 = 43.65 nM) (Figure 3.11) and (3) GPR120S-Compound39 (agonist
bound; EC50 = 97 nM) (Figure 4.3) (Shimpukade et al., 2012; Lombardo et al., 2016). The
apo protein system (model generated using antagonist-bound templates) was assumed to bias
towards the features characteristics of inactive state whereas simulations of the agonist-bound
systems should bias to express the ligand-induced conformational changes leading to an
active state receptor conformation (Zhou et al., 2019).
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Figure 4.2: Characteristic features of Class A GPCRs observed in the GPR120S receptor
model; a) Ionic lock formed between TM3 and TM6 with a H-bond distance of ~2 Å; b)
Disulfide link between TM3 (Cys111) and ECL2 (Cys194); c) H-bonding (2-3 Å) network at
cytoplasmic end by N317P318xxY321 motif; and d) conserved P219 I126 F274 triad forming an
interface between TM 5, 3 and 6. The images were visualized and rendered in PyMol
(DeLano 2018).
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4.1 Molecular docking analysis of Compound39-bound GPR120S
The docked pose of Compound39 showed favourable hydrophobic interactions and formed
hydrogen bonds with

(Arg99, Trp277) two out of the seven experimentally validated

residues (Figure 1.11) as well as two hydrogen bonds (Thr125, Asn313) with other residues
in the orthosteric binding pocket. Compared to the docked pose of TUG891 (Figure 3.11,
3.13), instead of the carboxylate (-COOH) tail, the carboxyl (C=O) group of Compound39
formed a hydrogen bond with Arg99 (Table 4.1; Figure 4.3). It might be attributed to the
reverse docking – where the ligand gets flipped in the pocket during docking process due to
the presence of carbonyl and carboxylic groups at opposite ends. To confirm if the docking
pose was not just an artifact / anomaly, the ligand was docked using different seeds / input
conformations of the ligand. The consensus from ten different docking runs showed the
obtained docking pose of Compound39, was the most preferred docking pose.

Figure 4.3: Selected docked pose of Compound39 (binding score -9.828 kcal/mol) illustrating
hydrogen bond interactions with Arg99 of GPR120S and a 2D interaction map of
Compound39 in the orthosteric pocket binding pocket. The 3D images were visualized and
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rendered in PyMol v2.1.0. The 2D interaction maps were generated in BIOVIA DS Client
visualizer v19.1 2019.
Table 4.1: List of residues forming contacts with Compound39 docked to the orthosteric
binding pocket of GPR120S.

Residue
Arg99
Arg99
Gly122
Thr125
Trp277
Asn313

Hydrophobic interactions
Residue
Distance (Å)
Trp104
3.88
Met118
3.52
Ile280
3.98
Phe303
3.95
Phe303
3.77
Val307
3.47
Thr310
3.76
H-bonding interactions
Distance (Å) H-A Distance (Å) D-A Donor Angle (degree)
1.90
2.83
151.40
3.39
3.97
118.58
2.81
3.65
149.66
1.80
2.75
157.09
1.80
2.79
171.41
1.77
2.75
165.25

4.2 Conformational analysis of equilibrated GPR120S models in ligand-bound and apo
form.
To generate the conformational ensemble, the equilibrated systems were given random
velocities and subjected to further MD production runs of 300 ns where a stable protein
backbone RMSD was achieved (Figure 4.4). MD trajectory of the systems at checkpoints
every 25 ns was analysed to record the plateauing of protein backbone RMSD as well as
potential energy of the systems, signifying the convergence achieved by the MD simulations
of protein systems. The protein backbone of starting structures in all the three systems (apo;
TUG891 bound; Compound39 bound) reached stability and after 200 ns no significant
changes in the RMSD values were observed. The difference in the RMSD values suggested
that binding of the ligands resulted in different but relatively stable conformations of the
GPR120S model systems during the 300 ns MD production run.
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Figure 4.4: RMSD (Å) of the backbone atoms recorded during the 300 ns MD production run
of GPR12S models without bound ligands – Apo (Grey) and with bound agonists –
Compound39 (Blue) and TUG891 (Orange) plotted versus time (ns).
The RMSF (Root Mean Square Fluctuation) analysis of the protein backbones over the period
of 300 ns MD production runs illustrate the highest range of fluctuation in the loop regions
especially the ECL2 (177-203) and ICL3 (236-252) domains of the ligand bound protein
models compared to the apo protein model (Figure 4.5a). The agonist-bound systems showed
fluctuations in all the loop regions in comparison to apo-protein systems. The Compound39bound system recorded a marked difference in the ICL1 (65-71) domain as well compared to
the TUG891-bound system suggesting that both the agonists might be inducing
conformational changes by two different mechanisms. The fluctuations in the ECL domains
might be due to the presence of ligands, which due to interactions with the essential binding
pocket residues (Arg99 and Trp277 specifically) pull or push the residues and transmit
conformational changes to the ICL domains as well via TM regions to bring the protein to
active conformation. The low range of fluctuations in the apo protein system suggest that the
generated protein model was in stable inactive state and remained in the inactive state as it
might be in a global minimum due to the absence of ligand induced conformational changes
during MD simulation run.
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The continuous disulfide linkage between two cysteine residues (Cys111 and Cys194) was
observed throughout the 300 ns MD production runs (Figure 4.5b). During MD production
runs, no special bond constraints were applied to keep the disulphide bond intact. The
Cysteine bridge between TM3 and ECL2 is highly conserved in most of rhodopsin-like
receptors and used as anchor points in modelling the individual backbone course of
hydrophilic loops (Fredriksson et al., 2003; Kinoshita and Okada, 2015; Zhou et al., 2019).
The analysis confirms that the disulfide bridge is conserved in GPR120S models and
essential for the packing and stabilization of a restricted number of conformations of the
seven TM domains.

Distance (Å)
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2.04
2.02

Compound39-protein
2
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50

TUG-891-protein

100
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Apo-protein
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Figure 4.5: a) RMSF (Å) of the backbone atoms recorded during the 300 ns MD production
run of GPR120S models; b) Distance (Å) between the centre of mass of the “cysteine bridge”
residues (C111-C194) recorded during the 300 ns MD production run of GPR12S models
without bound ligands – Apo (Grey) and with bound agonists – Compound39 (Blue) and
TUG891 (Orange) plotted versus time (ns).
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4.3 Conformational changes in the “ionic lock” [D/E]RY motif
The comparative analysis of the putatively active state models (both agonist-bound) with the
inactive (apo-model) state model was performed and conformational changes in the residues
involved in the ionic lock – Arg136 of TM3 and Asp259 of TM6 were analysed over the
period of the MD runs (Figure 4.6a). The inactive state model (Apo) kept the conformation
with the ionic lock formed between the intracellular ends of TM3 and TM6. The centre of
mass of both the residues stayed within the range of 2-4 Å – appropriate to form and sustain
the salt-bridge, making the inactive state of the model stable (Figure 4.6b). As expected, the
active state model of TUG891-bound GPR120S showed the two residues drifting apart from
each other over the period of the 300 ns MD production runs. The analysis demonstrates that
the two residues were at the distance of 10 Å at the end of production run disrupting the salt
bridge at the very start of the simulation.
However, the Compound39-bound protein model demonstrated unexpected behaviour of
staying close to the inactive conformation. The average distance between the two residues
remained ~ 5 Å throughout the MD production run. Although the residues were not close
enough for salt bridge formation but with these residues being this close suggested that the
intracellular cavity of the receptor would not be able to accommodate the heteromeric G
protein subunits. Two possible inferences can be proposed from the Compound39-bound
protein simulation: 1) The protein model might be in a local minimum of the energy
landscape at that specific conformation (Goedecker, 2004); 2) The interaction network
pattern of Compound39 carboxylate tail with Thr125, Trp277 and Asn313 (Figure 4.3), not
observed in TUG891 docking interactions, led the MD trajectory to different conformational
changes at the intracellular domain especially at TM3 – ER136M motif ([D/E]RY) involved in
the “ionic lock” formation.
The MD production simulation was rerun for 300 ns on the same starting conformation of
Compound39-bound protein system with random initial velocities verified that the variance
was reproducible. The comparative analysis of the distance between the residues (Arg136 and
Asp259 – involved in formation of “ionic lock”) from the 300 ns MD rerun reported an
increase with a higher range of fluctuations compared to the first 300 ns MD run but were
significantly less than those of the TUG891-bound system. The average distance (~8 Å) was
greater than 4 Å limiting the hydrogen bond interactions for the salt bridge formation (Figure
4.6c).
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Figure 4.6: a) Graphical picture of ionic lock closed at simulation time T0 and open
conformation at Tavg; representing the average conformation from the 300 ns MD run of the
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TUG-891 bound protein model; b) Distance between centre of mass of Arg136(TM3) and
Asp259(TM6) recorded during 300 ns MD production run predicting the effect of bound
ligands at the structural conformation of ionic lock residues; c) Distance between centre of
mass of Arg136(TM3) and Asp259(TM6) recorded during 300 ns MD production re-run.
Running average of distance every 1 ns is shown for clarity.
To the best of our knowledge, these are the first simulations of GPR120S complexed with
ligands (TUG891 and Compound39) at a 300 ns timescale. A recently published study
investigated protein-ligand stability from a 200 ns MD simulation of SR13 - a chromane
propionic acid analogue, derived from the same Merck & Co. patented series as
Compound39, (Table 1.8) docked to homology model of GPR120 (Uniprot ID: Q5NUL3-2)
(Zhang, Sun, Wen and Yuan, 2019; Adams et al., 2016). This study highlighted the
conformational changes adopted by SR13 to enter the binding pocket (Zhang, Sun, Wen and
Yuan, 2019). However, to the best of our knowledge, these are the first simulations of
GPR120S complexed with ligands (TUG-891 and Compound39) at a 300 ns timescale.
As the human GPR120S receptor can bind to the flexible FFAs (PUFAs) as well as a diverse
set of rigid compounds such as TUG891 suggested the existence of different binding
conformations in the orthosteric binding pocket of the receptor leading to a cascade effect
inducing protein activation. The difference in binding pattern of TUG891 and Compound39
highlighted residues (Thr125, Trp277 and Asn313) in the orthosteric binding pocket for
further examination. Residues Thr125 and Asn313 were not analyzed in the previous sitespecific mutagenic study while the Trp277Ala mutation resulted in a loss of receptor activity
(Hudson et al., 2014). The hydrogen bonding analysis of Compound39-bound protein
simulations showed an average of ~60% H-bond occupancy between Compound39 and the
Trp277 sidechain during the 300 ns production run accompanied with ~35% and ~10%
occupancy for Asn313 and Thr125 sidechains, respectively. The interaction network of
Trp277 and / or Asn313 with Compound39 might be affecting the conformational changes as
observed in TUG891-bound protein simulations.
4.3.2 Conformational changes in the PIF and NPxxY motif
As shown in Figure 4.2d, the P(TM5) I(TM3) F(TM6) triad of residues form an interface between
TM 5, 3 and 6 near the activation switch - ‘WxP’ (TM6) and inner core of the orthosteric
binding pocket in the GPR120S model which is consistent with the Class A GPCRs (Wacker
et al., 2013; Rasmussen et al., 2007; Ballesteros and Weinstein, 1995). From the
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conformational analysis of TUG891 (Figure 4.7a, c) and Compound39 (Figure 4.7c, c) bound
MD trajectories with respect to the apo-GPR120S MD conformations, a large shift
(movement) in the position of the Phe274 side chain was observed coupled with a rotameric
switch in Ile126. Both these changes corresponded to the down-outward movement of the
intracellular domain of TM6 (Figure 4.7 d, e) with sideways movement in TM5.

Figure 4.7 Conserved P-I-F triad motif in Apo (Grey); a) TUG891-bound (Orange) and b)
Compound39-bound (Green) GPR120S models. A rotameric shift of Ile126 (c) resulted in
rotation of Phe274 in TUG891 bound (orange) and movement of Phe274 in Compound39
bound (Green) GPR120S. The Phe274 (TM6) rotation and / or shift resulted in displacement
of TM3 (d) and TM5 (e).
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Although TUG891 and Compound39 bound systems showed Phe274 sidechain movement in
opposite directions, in both systems the shift resulted in the spatial rearrangement of
intracellular domains of TM helices of different magnitudes of 2-4 Å. Again, the slight
differences in spatial rearrangement in the Compound39 bound system might be attributed to
Thr125 and Asn313 interactions with the ligand. These rearrangements of TM regions were
inferred to open the helical bundle at the intracellular domain and facilitate the G-protein
binding, thus mimicking the translation of receptor confirmation from inactive state (apo) to
active state (agonist-bound) (Rasmussen et al., 2007).
The conserved NPxxY motif at the cytoplasmic end of TM7 is another activation switch of
class A GPCRs and the interplay between residues of D/ERY and NPxxY motifs has been
defined as a crucial determinant during transition of Class A GPCRs from the inactive to
active state (Fritze et al., 2003). In the classical example of β2 adrenergic receptors the
intracellular end of TM7 moves towards the TM bundle core accompanied by the Tyr (of
NPxxY motif) side chain rotation, which moves the side chain further into the TM bundle
(Katritch, Cherezov and Stevens, 2013; Rasmussen et al., 2007). MD trajectory analysis of
TUG891-bound and Compound39-bound GPR120S systems reported sharp rotation of
Tyr321 sidechain during the 300 ns simulation compared to the apo-protein system (Figure
4.8) with a difference of small outward displacement of TM7 in both agonist-bound systems.
Asn317 – the first residue of NPxxY motif, reported a highly conserved H-bond interaction
with Asp85 of TM2, which is a characteristic feature known in the inactive state of Class A
GPCRs (Rasmussen et al., 2007). The interaction was not reported in either agonist bound
GPR120S MD systems (Figure 4.8 c) due to displacement of intracellular domain of TM7 by
2-3 Å (Figure 4.8 a, b).
As the human GPR120S receptor can bind to the flexible FFAs (PUFAs) as well as a diverse
set of rigid compounds such as TUG891 suggested the existence of different binding
conformations in the orthosteric binding pocket of the receptor leading to a cascade effect
inducing protein activation. The difference in binding pattern of TUG891 and Compound39
highlighted residues (Thr125, Trp277 and Asn313) in the orthosteric binding pocket for
further examination. Residues Thr125 and Asn313 were not analyzed in the previous sitespecific mutagenic study while the Trp277Ala mutation resulted in a loss of receptor activity
(Hudson et al., 2014). The hydrogen bonding analysis of Compound39-bound protein
simulations showed an average of ~60% H-bond occupancy between Compound39 and the
Trp277 sidechain during the 300 ns production run accompanied with ~35% and ~10%
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occupancy for Asn313 and Thr125 sidechains, respectively. The interaction network of
Trp277 and / or Asn313 with Compound39 might be affecting the conformational changes as
observed in TUG891-bound protein simulations.

Figure 4.8: Conserved NPxxY motif in Apo (Grey); a) TUG891-bound (Orange) and b)
Compound39-bound (Green) GPR120S models. H-bond interaction between TM7 and TM2
were not observed in agonist bound protein models (c). A sharp rotation of Tyr321 (d) side
chain was observed in agonist bound protein models with respect to apo model.
The above stated results from the conformational analysis of the MD trajectories of apo and
agonist bound GPR120S receptor models suggested that the binding of agonists – especially
TUG891, enabled the transition of GPR120S receptor modelled using inactive templates
towards the active state conformation. The specific reasons for larger shifts observed in
Compound39-bound model such as Cα of Phe274 and rotation of Tyr321 sidechain compared
to TUG891-bound model from the present MD simulation production runs remain to be fully
determined. The conformational changes and coupling interactions between conserved motifs
were consistent with the Class A GPCRs and validated the docking predictions of TUG891 as
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its binding decreases the probability of inactive-like states for PIF, D/ERY, WxP, NPxxY and
ionic lock motifs. By definition an antagonist is a drug molecule which upon binding to the
receptor prevents the conformational transition of the receptor from inactive state to active
state and inhibits the physiological action (Figure 1.7). These results also further established
the hypothesis that the Compound39 interactions with Trp277 and / or Asn313 due to reverse
docking prediction might be affecting the conformational transition of protein from inactive
to active state compared to TUG891-bound protein simulations. A small molecule with stable
binding interactions with Trp277 and / or Asn313 might act as a GPR120 antagonist and
stabilizes GPR120 receptor in the basal activity state.
4.4 Trp277 and Asn313-based pharmacophore screening
Based on the inferred significance of the Trp277 and Asn313 interaction network with the
carboxylate chain of Compound39, a single structure-based pharmacophore model was
generated by enumerating the 3D conformation of functional features present in the receptor
binding pocket. The docked conformations of TUG-891 and Compound39 were
superimposed to generate the pharmacophore model using the ZINCPharmer package (Koes
and Camacho, 2012), which resulted in a six-featured hypothesis consisting of two HBA
(Hydrogen bond acceptor), two Ar (Aromatic ring systems) and two Hb (hydrophobic) with
preferred chemical features (Figure 4.9, Appendix Table IIe). The selected hypothesis was
generated to focus screening on ligands interacting with the Trp277 and Asn313 (Figure 4.9b)
residues with scaffold features of TUG-891 and Compound39 being added to attain rigidity
and better anchorage in the binding pocket by interacting with essential binding residues
(Hudson et al., 2014; Hudson et al., 2013) such as Arg99, Trp104, Phe115, Trp207, Phe211
and Phe304.
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Figure 4.9: a) Superimposed docked poses of TUG-891 (Cyan stick model) and Compound39
(Green stick model) with GPR120S. TM5 is hidden in the image for a clearer view; b)
Developed pharmacophore model with its corresponding chemical features used for screening
the ZINC database (Sterling and Irwin, 2015; Koes and Camacho, 2012); c) Protein-ligand
interaction fingerprint map of the 9 docked compounds with GPR120S; Green – (HB)
Hydrogen bond; Yellow – (HP) Hydrophobic interactions; Grey – No interactions.
The pharmacophore-based virtual screening (VS) resulted in 63 unique chemical hits
identified from the ZINC15 commercial database of ~230 million compounds. Further,
selection of these 63 compounds for structure-based VS was performed by physicochemical
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profiling using SwissADME (Daina, Michielin and Zoete, 2017) to predict the druglike and /
or lead-like nature of the compounds. In combination with analysis of predicted
physicochemical descriptors, an in cerebro assessment was applied to select compounds with
diverse and synthesizable scaffolds. The final screening resulted in 9 best-hits (shown in
Table 4.2, 4.3 and 4.4) based on the SwissADME predictions over compounds’
physicochemical and pharmacokinetic properties.
Table 4.2: Assigned nomenclature and 2D structures of selected 9 best hit compounds from
SBPM.

Cpd1

Cpd4

Cpd7

Cpd2

Cpd5

Cpd8

Cpd3

Cpd6

Cpd9

110 | P a g e

The physicochemical and pharmacokinetic parameters of the selected candidates were
following the drug-like molecule rules such as - Lipinski violations, Ghose violations, Veber
violations, Egan violations and Muegge violations (section 1.7.5; Table 4.3, 4.4). Molecular
weights (MW) of all the 9 best hits were in the range of 300-400 Daltons and the impact of
the MW being in the ideal range can be observed on the GI absorption predictions (Table 4.4)
of these compounds. Similarly, lipophilicity (iLOG Po/w) of 9 hit compounds was predicted
to be lower than 3.5 by SwissADME which can be a determinant factor in several ADMETox
parameters as well as potency. Solubility and metabolism of the drug candidates are known to
be reduced at high lipophilicity (~5) as well as blood brain barrier permeability of the test
candidates is high which can result in the adverse effects. SwissADME predictions reported
that the hit compounds (except Cpd 2) are not BBB permeant and are soluble in aqueous
phase (Table 4.4). The number of hydrogen bonding donors (<5) and acceptors (<10) present
in the drug-like candidate are related to the molecule’s polarity and permeability of oral
drugs. As TPSA is related to hydrogen bonding donors and acceptors, these parameters
dictate the predictions of drug permeability and oral bioavailability (Daina, Michielin and
Zoete, 2017). As lower TPSA values (~80 Å) are known to favor permeability and oral
bioavailability, Cpd 6 was reported to have highest (137 Å) TPSA which can be attributed to
8 H-bond acceptors in the molecular structure.
Cytochrome P450 monooxygenase (CYP) enzymes play a pivotal role in drug metabolism
and elimination (Daina, Michielin and Zoete, 2017) and 50-90% of the drug candidates have
been estimated to act as CYP enzyme substrates and result in adverse effects. Cpd 4 was
predicted to be a substrate of the five major CYP enzymes (Table 4.4) and should be reported
clearly if Cpd 4 proceeds to later stages of drug discovery. Identification of unfavorable
fragments which can lead to toxicity was reported as PAINS – pan-assay interference
compounds and Brenk alerts. Cpd 6 and Cpd 7 raised the alert that they contain fragments
which could either interfere with the assay readouts or cause covalent protein/DNA
modifications and subsequently relay adverse effects (Daina, Michielin and Zoete, 2017).
Such an informed manual selection of ligands after virtual screenings have previously been
reported to refine the screening performance (Voet, Kumar, Berenger and Zhang, 2014; Voet
et al., 2011). These hit compounds were then prepared and docked into the receptor binding
pocket following the set protocol (section 2.1.3). The protein-ligand interactions of these 9
compounds were analyzed (Figure 4.9c, Appendix Figure IIf) to confirm Trp277 / Asn313 H111 | P a g e

bond interaction(s) before preparing the protein-ligand complexes for 100 ns MD production
runs following the set protocol (section 2.1.4).
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Table 4.3: Physicochemical parameters and docked binding scores (kcal/mol) from SMINA of the selected pharmacophore-based VS hits
obtained SwissADME drug-likeness profiling enlisting molecular weight (MW), hydrogen bond acceptors (HBA), hydrogen bond donors
(HBD), total polar surface area (TPSA) and predicted oil/water partition co-efficient (iLOG Po/w) (Daina, Michielin and Zoete, 2017).
Molecule
Cpd 1
Cpd 2
Cpd 3
Cpd 4
Cpd 5
Cpd 6
Cpd 7
Cpd 8
Cpd 9

MW
357.38
358.43
354.36
344.37
377.39
380.35
364.35
373.4
336.34

H-bond acceptors
6
5
7
4
6
8
7
7
5

H-bond donors
1
1
2
2
3
4
3
2
4

TPSA (Å)
106.7
75.8
112.58
80.04
104.57
137.16
116.93
105.01
107.37

iLOG Po/w
2.54
3.06
2.75
2.63
2.86
1.7
2.36
3.24
1.87

SMINA Score (kcal/mol)
-10.9
-10.8
-9.8
-9.5
-9.3
-9.0
-9.0
-8.7
-8.7
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Table 4.4: Pharmacokinetics parameters of the selected pharmacophore-based VS hits obtained from SwissADME drug-likeness profiling
(Daina, Michielin and Zoete, 2017). Color code – Green : Highly favourable; White : Favourable; Red : Unfavourable.
Cpd 1

Cpd 2

Cpd 3

Cpd 4

Cpd 5

Cpd 6

Cpd 7

Cpd 8

Cpd 9

GI absorption
High
High
High
High
High
High
High
High
High
BBB permeant
No
Yes
No
No
No
No
No
No
No
P-glycoprotein interaction
No
No
Yes
Yes
No
No
No
Yes
No
CYP1A2 inhibitor
No
No
No
Yes
No
Yes
Yes
No
Yes
CYP2C19 inhibitor
Yes
No
No
Yes
No
No
No
No
No
CYP2C9 inhibitor
No
No
No
Yes
Yes
No
Yes
No
No
CYP2D6 inhibitor
No
Yes
No
Yes
Yes
No
No
No
Yes
CYP3A4 inhibitor
No
Yes
No
Yes
No
No
No
No
Yes
Skin permeant log Kp (cm/s)
-6.85
-6.57
-7.41
-6.43
-6.18
-7.03
-6.68
-7.18
-5.26
Lipinski violations
0
0
0
0
0
0
0
0
0
Ghose violations
0
0
0
0
0
0
0
0
0
Veber violations
0
0
0
0
0
0
0
0
0
Egan violations
0
0
0
0
0
1
0
0
0
Muegge violations
0
0
0
0
0
0
0
0
0
PAINS alerts
0
0
0
0
0
1
0
0
0
Brenk alerts
0
0
0
0
0
2
1
0
0
Lead likeness violations
1
1
1
0
1
1
1
1
1
Synthetic Accessibility
3.47
3.99
4.06
2.25
3.37
3.09
3.03
3.58
2.55
Estimated Aqueous Solubility Soluble Soluble Soluble Soluble Moderately soluble Soluble Soluble Soluble Moderately soluble
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4.4.1 MD simulations of Trp277 and Asn313 interacting compounds.
Comparative MD simulations of 100 ns duration for each of the 9 complexes were carried out
to evaluate the significance of the Asn313 interaction in terms of conformational changes to
the protein. A MD time scale of 100 ns was chosen based on observations from previous MD
simulation of TUG891 and Compound39 (Figure 4.6) as well as other studies where 100 ns
MD simulations were shown to be sufficient to illustrate the dynamics of protein-ligand
fingerprinting and induced conformational changes in GPCR molecular studies (Chan,
Filipek and Yuan, 2016; Rahman et al., 2020; Zhang, Sun, Wen and Yuan, 2019).
The protein-ligand binding affinity of the selected 9 compounds over the duration of 100 ns
MD simulations predicts the strength of the binding interaction between the receptor and the
compounds (Figure 4.10a). Cpd 2 and Cpd 8 were predicted to show a continuous decreasing
gradient in the binding affinity while Cpd 9 was predicted to show a continuous increase in
the binding affinity over time during the MD simulation. Other compounds did not show a
consistent pattern of decreasing or increasing binding affinity predictions (Figure 4.10a).
The binding affinity predictions from the 100 ns MD studies gave insights to the binding
stability of docked hits and non-covalent interactions with residues in the binding pocket.
Amongst all the compounds, Cpd 1, 7 and 9 were predicted to conserve Trp277 and Asn313
H-bond interactions during the 100 ns MD simulations (Figure 4.10b). As the binding
affinities predicted for this study used only the protein-ligand complex (without solvent)
snapshots extracted from the MD simulations, it should be cautioned that solvent (water)
molecules also play an important role in non-covalent interactions – forming bridge
interactions between ligand and protein (Venkatakrishnan et al., 2019).
Most of the interactions with Cpd9 (electrostatic or hydrophobic) were observed to be
continuous during the simulation. Similarly, the protein-ligand binding affinity prediction
over the 100 ns MD simulation suggested a stable binding of Cpd9 in the orthosteric binding
pocket of GPR120 (Figure 4.10a). In contrast, Cpd 2 showed the lowest binding affinity in
the binding pocket compared to the other ligands and Cpd 2 was the only ligand which did
not form hydrophobic and /or H-bond interactions with Arg99 as well as Asn313 (Figure 4.9c
and 4.10a) at the starting conformation. Cpd 7, which had a Asn313 H-bond interaction
(Figure 4.9c) at the initial (0 ns) conformation was predicted to have a high binding affinity
of -10.8 kcal/mol. However, the binding affinity of Cpd 7 reduced to -10.25 kcal/mol over the
MD simulation as the number of Asn313 H-bond interactions of Cpd 7 reduced (Figure
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4.10b). The correlative binding affinity predictions and Asn313 interactions could infer the
important role of Asn313 residue in the ligand binding stability.

Figure 4.10: a) Heatmap of protein-ligand binding affinities (kcal/mol) of snapshots extracted
from the 100 ns MD simulation trajectory and scored by webserver WADDAICA (Bai et al.,
2021) (continued)
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Figure 4.10: b) Protein-ligand interaction fingerprint map (Available at GitHub link:
https://github.com/tavolivos/Molecular-dynamics-Interaction-plot) plotting the normalized
frequency of interactions of the residue with the ligands, shows compounds 1, 7 and 9 with
conserved Trp277 and Asn313 H-bond interactions over the period of 100 ns MD production
runs.
As GPR120S was modelled from templates in the inactive form, the binding of ligands with
antagonistic activity should keep the receptor in the inactive state without causing major
conformational changes at the intracellular domain of the receptor. The protein’s structural
stability evaluation by RMSF analysis of 100 ns trajectory showed (Figure 4.11a; Additional
Figures in Appendix VII a-e) that Cpd 9 and Cpd 1 stabilized the protein backbone as well as
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reducing the fluctuations of ECL2 (177-203) and ICL3 (236-252) regions observed in Apo,
TUG-891 and Compound39 bound protein systems while Cpd 7 bound protein system has
recorded the highest range of fluctuations (~12 Å) in the ICL3 region. Binding of other ligand
molecules have an overall similar effect on the protein backbone fluctuations, but higher than
that of Cpd 9.
Focusing on the ligands themselves Cpd 9 and Cpd 7, they were also found to be the most
stable in the GPR120S orthosteric binding pocket with RMSD values below ~1.5 Å and 2 Å
respectively throughout the 100 ns MD trajectory (Figure 4.11b). Such low ligand RMSD
values suggest that these two ligands are tightly bound to the orthosteric binding pocket
without major changes in their initial docked orientations. It is important to mention that both
ligands lead to contrasting effects on the protein-backbone RMSD values – Cpd 9 stabilized
the protein-backbone in its initial inactive form whereas Cpd 7 deviated the protein-backbone
away from its initial conformation. Cpd 9 stabilized the protein within the timespan of the
first 20 ns, keeping the average RMSD of protein model below 4 Å. While the binding of
Cpd 7 to GPR120S leads to the highest RMSD values (~ 8 Å). Ligand RMSD analysis of Cpd
1 also presented a range of fluctuations with protein backbone RMSD reaching above ~5 Å
(Figure 4.11b; Additional Figures in Appendix VII a-e).
During the 100 ns production run the “ionic lock” remained closed, inhibiting the coupling
between receptor and G-protein, and hence keeping the receptor in the inactive state.
Compared with other

ligands, the Cpd 9 bound

protein

model

predicted

the

least

movement of the distance between Arg136 and Asp259 (involved in the “Ionic lock”) at
the intracellular domain of GPR120S (Figure 4.11c) that is the site specific for G-protein
coupling. The study published by Provasi et al. (Provasi et al., 2011) used inactive and active
crystal structures of GPCRs with ligands eliciting different pharmacological actions
performing 20 ns MD simulations. The study reported that depending on their
pharmacological activity, the ligand bound to the receptor can shift the conformational
equilibrium towards active or inactive state of the receptor. A similar conformational shift
(Cpd7 – from inactive to active state) as well as stability (Cpd9 – stabilized inactive state) in
receptor state was observed in our study. Here, during the 100 ns MD production run of Cpd9
the “ionic lock” remained closed (Figure 4.11c, Figure in Appendix VII d), inhibiting the
coupling between receptor and G-protein, and hence keeping the receptor in the inactive
state.
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Figure 4.11: Comparative MD simulation analysis of best hits, compound 1, 7 and 9 with
respect to Apo, TUG-891 and Compound39 bound proteins over 100 ns timescale;
a) RMSF plot of the protein backbone. The intracellular loop (ICL) and extracellular loop
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(ECL) regions are highlighted as shaded regions. The transmembrane regions in the 3D
structure are - TM1: 36-65; TM2: 73-101; TM3: 107-141; TM4: 152-175; TM5: 204-233;
TM6: 252-289; TM7: 296-324; b) RMSD plot of the ligand atoms; c) Distance plot
between the center of mass of residues Arg136(TM3) and Asp259(TM6) involved in “ioniclock” conformation.
4.4.2 Multiple linear regression model and structural diversity analysis of the selected
compounds
For further analysis, MLR was applied to predict the contribution of physicochemical
descriptors (independent variable) such as molecular weight, H-bond donors, H-bond
acceptors, logP and topological polar surface area (TPSA) on binding affinity (dependent
variable) (Funar-Timofei, Borota and Crisan, 2017; da Silva Costa et al., 2018) (Figure 4.12).
The average binding affinity (obtained from WADDAICA webserver) of the last 20 ns of
MD snapshots (from 80 to 100 ns) was used for the MLR model. The performance of the
MLR model is expressed in terms of R2, which was found to be 0.799 signifying that ~ 80%
of the data fit the regression model. Cpd 9 with the highest binding affinity value
from the WADDAICA server (Bai et al., 2021), was also predicted to have the highest
binding affinity by the MLR model. Indeed, the MLR model agreed with the binding affinity
predictions of the WADDAICA webserver, but it should be noted that the majority of the
variables used in the MLR model were obtained from other prediction algorithms – such as
binding affinity, logP and TPSA.

Figure 4.12: Scatter plot of a multiple linear regression model of the contribution of
physicochemical descriptors –molecular weight, number of H-bond acceptors and H-bond
donors,

TPSA and logP from SwissADME (Daina,

Michielin

and

Zoete,

2017) over the WADDAICA (Bai et al., 2021) binding affinity for the 9 compounds.
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The selected compounds Cpd 1-9 were also clustered with the co-crystalized ligands of
templates (4N6H-EJ4 and 4S0V-SUV) used for homology model generation and reference
ligands used for generation of pharmacophore (TUG-891 and Compound39) to verify the
unbiased nature of the screened compounds. The two-dimensional scaling cluster (Figure
4.13; Table 4.5) confirms that screening of Cpd9 and Cpd7 was not biased towards the
templates or reference ligands used in the study.
Table 4.5: Clustering of structures based on distance matrix analysis of 2D structural
similarity. (Backman, Cao and Girke, 2011) V1 and V2 denotes distance values derived from
all-against-all comparisons of compounds using atom pair similarity scores.
Molecules
Cpd_1
Cpd_2
Cpd_3
Cpd_4
Cpd_5
Cpd_6
Cpd_7
Cpd_8
Cpd_9
4S0V-SUV
4N6H-EJ4
Compound39
TUG-891

cluster
1
1
3
4
5
5
5
8
5
10
11
10
13

V1
-0.085
-0.057
-0.122
-0.225
-0.222
-0.264
-0.265
-0.093
-0.218
0.6775
-0.024
0.6775
0.2192

V2
0.3574
0.3855
0.243
-0.188
-0.205
-0.327
-0.34
0.2649
-0.272
-0.191
0.2465
-0.191
0.215

Figure 4.13: Clustering of template ligands (PDBs: 4S0V-SUV and 4N6H-EJ4); agonists
(TUG-891 and Compound 39) and selected compounds 1-9 by Two Dimensional similarities
with a default similarity cut-off of 0.4 (Backman, Cao and Girke, 2011).
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Finally, with the design and discovery of novel scaffolds by in silico methods, the
pharmacokinetic profile and synthesizability of these compounds can be a limiting factor.
The proposed antagonist Cpd9 has a promising predicted ADME profile indicating
leadlikeness but with a moderate predicted solubility (see supplementary material).
Furthermore,

a

feasible

retrosynthesis

scheme

obtained from CAS SciFinder (https://scifinder.cas.org) confirms the ease to synthesis of this
compound (Figure 4.14).

Figure 4.14: Retrosynthesis
(https://scifinder.cas.org)

plan

for

Cpd9

predicted

using

CAS

SciFinder.

To summarize the results (Figure 4.15), virtual screening of ZINC database against SBPM
targeting Trp277 and Asn313 enlisted 63 hits. Furthering screening analysis by SwissADME
and protein-ligand interaction fingerprinting, nine compounds were selected for 100 ns MD
simulations. MD analysis predicted compounds 1, 7 and 9 as candidates of interest to be
acting as GPR120 agonists (Cpd1) and GPR120 antagonists (Cpd7 and Cpd9).
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Figure 4.15: Summary of the methodology and results from pharmacophore-based screening
of ZINC database.
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4.5 Discussion
The conformational sampling by MD simulations enhanced the study of receptor activation
using mathematical algorithms and high-performance computers. MD simulations can be set
biased to favor the exploration of conformational energy landscape of protein systems and the
selection of parameters can be challenging as well as crucial for achieving sufficient
sampling at the most efficient computational cost.
The embedding of the protein model in a phospholipid lipid bilayer to mimic the in-situ
environment of the protein during MD production run is of functional importance (Lee,
2011). The lipid molecules modify the ways that TM helices pack into bundles. The
hydrophobic residues orientate towards the lipids of the bilayer and the hydrophilic residues
move towards the core of the TM bundle. The lipid molecules penetrate between the helices
and bind into clefts between the helices to modulate the activity of a membrane protein
(Liang, Adamian and Jackups, 2005; Lee, 2011; Stansfeld and Sansom, 2011; Marrink et al.,
2019). The GPR120S model was embedded in a POPC bilayer to relax the TM bundle in the
lipid environment to mimic the lipid raft paradigm (Marrink et al., 2019; Lingwood and
Simons, 2009). The lipid raft paradigm states that the membrane protein and the bilayer lipids
form nanoscale functional units and when the protein (G protein subunits) match with lipid
molecules at specific locations they both can contribute to protein activation (Lingwood and
Simons, 2009). For future work, GPR120S and G-protein complex can be analyzed for the
lipid raft paradigm at microscale MD simulations.
For the best conformational sampling of inactive and active states of GPCRs by MD
simulations, comparative studies between agonist bound and antagonist bound protein
systems is one of the accepted criteria. As there were no orthosteric antagonists of GPR120
known at the time of this research, the apo protein system was set as the reference point for
inactive protein conformation state. Although all the conserved motifs such as [E/D]RY,
WxP, NPxxY and PIF, cys-cys disulfide bond between TM3 and ECL2 as well as “ionic
lock” interaction of TM3-TM6 observed in the GPR120S apo protein model were consistent
with Class A GPCRs inactive state (Figure 4.1, 4.2), it could be a limiting factor in sampling
the conformational space of the inactive state. On the other hand, focusing on the primary
objective of our research to perform in silico screening of chemical databases to discover a
series of small molecules which can bind into the orthosteric binding pocket and show
pharmacological activity in in vitro screening assays (Chapter 5). As mentioned in Chapter 3,
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the orthosteric binding pocket of GPR120S model in an inactive or basal activity state (apo
model) will be able to facilitate the ligand binding which can either transit the receptor from
an inactive to active state or stabilize the receptor in the inactive state.
A recent steered and supervised MD study of lipid receptors (cannabinoid receptor 1,
sphingosine-1-phosphate receptor and lysophosphatidic receptor) which employed tabu-like /
“forbidden” search algorithm (Jakowiecki et al., 2020) suggested that the large N-terminal
domain plugs the ligand binding channel located between extracellular domain of TM1 and
TM7 and plays a significant role in the ligand entry and exit into the orthosteric binding site
from the extracellular domain. Similarly, the protein-water H-bond networks of GPCRs has
been suggested to form an extensive flexible H-bond network that spans the inner core of
GPCR bundle and bridge all conserved motifs leading to activation mechanism of GPCRs
(Bertalan, Lešnik, Bren and Bondar, 2020).
In the present study, the GPR120S protein was modelled and simulated without N and C
termini and the MD simulations performed for the screening of potential of GPR120 ligands
were to only validate the docked agonist models and predict conformational changes in
conserved motifs induced by screened ligands. They were not steered or supervised to study
either entry or exit of the ligands into the orthosteric binding pocket. Further studies can be
proposed with models of both short and long isoforms of GPR120 containing N and C
termini along with sodium ion bound in the allosteric pocket (Zhou et al., 2019) to improve
the pharmacodynamics of the proposed ligands and refine the prediction of activation
mechanism. To consider protein-water H-bond for prediction of receptor activation
mechanism and virtual screening of potential ligands high resolution crystal structures of
GPR120 are preferred to verify the number of internal water molecules. As the templates
used for GPR120S homology modelling has <25% sequence identity, it is not recommended
as a reliable methodology to superimpose the templates to the energy minimised water
solvated GPR120S model to locate the conserved water clusters for MD simulations and
predictions.
The study of binding mechanisms of drugs and induced activation pathway of GPCRs require
long-time scale all-atom MD simulations to perform conformational state sampling. The
enormous system size and energy barriers between various ligand-bound and ligand-free
states are difficult to cross and limit the conformation sampling by conventional MD
simulations. Enhanced sampling techniques such as accelerated MD (aMD) and Gaussian
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accelerated MD (GaMD) (Miao, Nichols and McCammon, 2014), can be applied to
overcome this limitation. The aMD sampling technique, as the name suggests, accelerate the
conformational sampling by providing a boost potential to the system and decrease the
energy barriers allowing easy transition of system from one energy well to another. The aMD
simulations can be used to verify the discrepancies observed in Compound39-bound systems
behavior from TUG891-bound as if the system was stuck in local minima or the effects were
ligand specific. As the aMD simulations generate large energetic noise which can
overshadow the results. GaMD follows a near-Gaussian distribution to improve the aMD
method (Miao, Nichols and McCammon, 2014) and can be used for further sampling of
Compound39 and TUG891 bound systems.
The MD analysis of 300 ns production runs of agonist bound GPR120S models led to the
generation of a pharmacophore hypothesis targeting Trp277 and Asn313 residues of GPR120
receptor to discover potential candidates as GPR120 antagonists. The pharmacophore
generated on the basis of the Trp277 and Asn313 hypothesis was used to screen ZINC
database for potential GPR120 antagonists. The present hypothesis was validated by running
MD simulations of pharmacophore identified 9 hits over a period of 100 ns suggesting that
H-bond

interactions of Cpd 9

(2-hydroxy-N-{4-[(6-hydroxy-2-methylpyrimidin-4-

yl)amino]phenyl}benzamide) with Trp277 and Asn313 stabilized the occupancy of the ligand
in the orthosteric pocket and kept the protein in the inactive form. While the interactions
of a phenylimino-phenol analogue - Cpd 7 phased the protein from inactive to active form
due to breakage of the ionic lock which could lead to G-protein coupling at the intracellular
domain. Cpd 1 warrants further investigation as although it stabilized the “ionic lock” with
slight fluctuations at the end of MD run (Figure 4.11c), a large range of fluctuations in the
ligand RMSD with respect to protein backbone (> 5 Å) were observed (Figure 4.11b)
suggesting weak protein-ligand interactions.
Further in silico site-specific mutation studies or in vitro alanine scanning studies targeting
Asn313 alone as well as in combination with other binding pocket residues could confirm the
importance of Asn313 interactions in GPR120 antagonist design. Therefore, the insights
from the present study can potentially be employed to enhance the selectivity of GPR120S
ligands and target interactions with key residues (Trp277 and Asn313) to develop novel
agonists and antagonists.
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As the conformational analysis of the 300 ns long MD trajectories of apo and TUG891 bound
GPR120S receptor models validated the GPR120S receptor modelled using inactive
templates - the energy minimized apo model was selected to screen chemical libraries
(Chapter 5) to discover and design GPR120 antagonist or inverse agonist for CRC
management.
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Chapter 5
In silico and in vitro screening of chemical databases for
potential anti-cancer candidates targeting GPR120.
Virtual screening (VS) is an in-silico drug discovery tool to predict novel hit compounds by
evaluating their high potency and selectivity towards the target protein in a computational
model. The strategy of applying ‘in silico’ screening is to bring a more focused approach to
the wet-lab experiments using pharmacophore searches of 3D databases, homology searching
and docking (Zhu et al., 2013; Ul-Haq, Uddin and Gul, 2011). Some important points to be
considered for virtual screening are - the availability of the compounds to be screened against
the receptor; the knowledge about the structure of the receptor and the receptor-ligand
interactions; and the knowledge about required drugs and their characteristics (Zhu et al.,
2013).
VS can be performed by two approaches: the first is “structure-based drug discovery
(SBDD)”, which requires knowledge of the 3D structure of the target protein and binding site
to increase the success rate (Figure 5.1); and the second is “ligand-based drug discovery
(LBDD)”, where no information on the protein is necessary. Instead, one or more compounds
that are known to bind to the protein are used as a structural query to predict hit compounds
for subsequent experimental validation (Zhu et al., 2013).
VS of chemical libraries by SBPMs is focused on specific 3D arrangement of chemical
moieties with respect to selective protein-ligand interaction (as applied in Chapter 4). The
SBPM model targeting Trp277 and Asn313 residues previously used for screening ZINC
database was built on a prediction inferred from MD simulations. Similarly, LBDD (includes
ligand-based pharmacophore model) is focussed on physical and chemical similarities to
known drug candidates previously proposed to interact with the protein of interest. Both these
SBPMs and LBDD approaches can limit the chemical scaffold diversity of the libraries and
miss out potential hit compounds (Dhasmana et al., 2019). On the contrary, SBDD is a robust
approach to screen the available chemical libraries to predict the best interaction modes
between the ligand and the residues of the defined binding pocket of the protein target.
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Figure 5.1: General schematic of VS applied for the search of human GPR120S receptor
modulators.
The overall objective of this chapter is to apply SBDD methodology to screen potential
GPR120 binding ligands and validate the in-silico hits. The protocol developed for
identifying GPR120S hit compounds was based on the optimised 3D homology model of
GPR120S (as described in chapter 3) and the docking protocol (section 2.1.3) summarised in
Figure 5.1. Subsequently, identified hits will be evaluated by in vitro functional assays such
as fluorometric cell viability assay using Alamar Blue, cell viability assay in GPR120-siRNA
transfected cells for target identification, wound healing assay and clonogenic assay.
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5.1 Chemical databases and drug-likeness
In VS, large chemical databases / libraries such as DrugBank (Wishart, 2006), ZINC (Irwin et
al., 2012), ASINEX (www.asinex.com), SPECS (www.specs.net), contain small molecules
which are screened for hit compounds by SBDD, LBDD or both. These computational
databases require pre-screening filtration to remove unwanted compounds with undesirable or
toxic physicochemical properties. The filtered databases should have compounds with
favourable characteristics (termed drug-likeness) such as solubility, stability, and the absence
of toxic moieties (reactive functional groups / toxicophores) (detailed in section 1.7.4). The
filtration process also reduces the library size making VS computationally less expensive as
well as increasing the chances of finding new ligands. Some databases (e.g., ZINC) prescreen compounds for drug-likeness using several rules such as “Lipinski’s Rule of Five”
(Lipinski, Lombardo, Dominy and Feeney, 2012), which states that drug-like compounds for
oral bioavailability should have molecular weight (m.wt.) lower than 500 Daltons,
lipophilicity (logP) lower than 5, less than five hydrogen bond donors, and less than 10
hydrogen bond acceptors.
For VS of the GPR120S receptor, the DrugBank and SPECS databases were selected which
are freely available online databases. DrugBank is a knowledgebase for drugs and drug
targets with comprehensive drug action information, first released in 2006. The latest release
of DrugBank (version 5 at the time of study, 2017) (Wishart, 2006; Wishart et al., 2017) was
used which contained 2,627 FDA approved small molecule drugs to potentially repurpose the
approved drugs as GPR120 targeting therapeutics. The SPECS database (www.specs.net) is
another online database of commercially (purchasable) available compounds used, which
contains ~350,000 compounds. All the databases were pre-screened for Lipinski’s Rule of
Five using BIOVIA Pipeline Pilot (Dassault Systèmes 2017) to increase the VS efficiency as
the orthosteric binding pocket of GPR120S (Class A GPCRs) cannot accommodate
molecules bigger than ~600 Dalton (m.wt.) (Jaiteh, Rodríguez-Espigares, Selent and
Carlsson, 2020; Beuming et al., 2015).
5.2 Structure based drug discovery / VS
In this study, the SBDD approach was used to identify the binding pose of each small
molecule in a test library (by docking), and from that identify the predicted binding affinity of
that molecule (scoring).

The set of hit compounds are then predicted by sorting all

compounds in the test library by their binding affinity score and deciding on a threshold
score. Compounds scoring better than the threshold are regarded as hits and evaluated further.
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This approach is analogous to experimental high throughput screening - HTS, where the
percentage inhibition obtained from HTS serve the same role as the score in structure-based
VS (Ruiz-Torres et al., 2017; Chan and Zhang, 2020). The virtual screening method is fast
and economical to predict active compounds.
The validated GPR120S receptor homology model was used as the structural basis for the
following database search. As mentioned earlier (section 1.5.2), the essential binding motifs
for GPR120S known ligands involves hydrogen bonding interactions between Arg99 (TM2)
and Trp277 (TM6), aromatic stacking interactions and hydrophobic interactions with: Trp104
(ECL1), Phe115 (TM3), Trp207, Phe211 (TM5) and Phe304 (TM7). In addition to these core
interactions, ligands might be able to extend their interaction network in binding pocket. The
set of pre-screened databases with all the possible stereoisomers were screened against the
GPR120S target using the docking protocol (section 2.1.3).
For molecular docking, a set of 28 active ligands (Appendix IIb) of human GPR120S was
prepared for which the experimental data (EC50) was available to validate the VS protocol
(section 3.6; Figure 3.12). The experimental data obtained from previous published studies
was not uniform as the type of bioassays varied in all the studies (Lombardo et al., 2016;
Sparks et al., 2014; Azevedo et al., 2016; Hudson, Shimpukade, Milligan and Ulven, 2014). It
should be noted that the ability of this docking model to successfully predict correlation
between binding affinities and experimental activity is a complex function governed by
several factors, such as the bioavailability of drug in the experimental models,
physicochemical parameters of these compounds and the experimental values (Ki / EC50)
used. In this regard, the set docking protocol with a validated consensus scoring (CScore)
function (section 2.1.3; section 3.6, 3.8 and Appendix IIc) was used as the pose selection by
protein-ligand interactions was difficult for the VS of large chemical databases.
5.2.1 SBDD of the DrugBank database
From screening of the prepared DrugBank database (Wishart, 2006), 73 top scoring poses
(cut off of -9.0 with respect to binding score of TUG891 of -9.8) of small molecule approved
drugs were obtained. These top scoring poses of drugs were then analysed manually for the
interactions with essential binding residues - Arg99, Trp104, Phe115, Trp207, Phe211,
Trp277, and Phe304 (section 3.6) as well as based on the known targets of the candidates.
The selected 24 compounds (enlisted in Table 5.1) were further characterised based on their
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mechanism of actions – if they are known binders of transmembrane receptors and main
chemical entity (scaffold) for selection of compounds for further in vitro screening assays.
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Table 5.1: Selected hits from the top scoring molecules from VS of DrugBank database with GPR120S receptor model and their indication.
Drug – DrugBank ID

SMINA

Treatment indications

Mechanism of Action

Reference

5-alpha reductase inhibitor

Keam and Scott,

Score
Dutasteride (DB01126) Steroidal

-13.085 Benign prostatic hyperplasia

compound
Lapatinib (DB-1259) Anilinoqiunozoline compound

2008
-12.249 Solid tumours in breast cancer
and lung cancer

Tyrosine kinase inhibitor for

Nelson and Dolder,

epidermal growth factor receptor

2006

type 2 (HER2/ ERBB2) and
epidermal growth factor receptor
(HER1/EGFR/EGBB1)
Eluxadoline (DB09272) Benzoic
acid derivative

-12.180 Diarrhea and abdominal pain;
inflammatory bowel disesease

Mu- and kappa-opioid receptor

Garnock-Jones, 2015

agonist; delta-opioid receptor
antagonist

Lumacaftor (DB09280) Benzoic

-11.728 Cystic fibrosis

acid derivative

Acts as a protein-folding chaperone

Boyle et al., 2014

preventing misfolding of CFTR ion
channels destruction

Sonidegib / LDE225 (DB09143)
Biphenyl carboxamide

-11.613 Anticancer agent; Hedgehog
signalling pathway inhibitor

Smoothened receptor inhibtor –

Zollinger et al., 2014

GPCR (Class F)

compound
Adapalene (DB00210)
Naphthoic acid derivative

-11.182 Topical retinoid; acne vulgaris;
anti-inflammatory

Binds to retinoid X receptors;

Kolli et al., 2019

normalize differentiation of
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follicular epithelial cells
Amrubicin (DB06263) synthetic
anthracycline derivative
Nandrolone (DB13169)
Androgenic steroid

-11.094 Bladder and gastric carcinoma;
lung cancer
-10.916 Anabolcic steroids for catabolic
states such as burn injuries.

Inhibit topoisomerase II; acts as

Katou et al., 2008;

cytotoxic and antimitotic agent

Maesaka et al., 2019

binds to the androgen receptor

Ghizoni, Bertelli,

(agonist)

Grala and da Silva,
2012

Tasosartan (DB01349)

-10.908 essential hypertension;

Pyrimidinone compound
Dasabuvir (DB09183)

(DB08822) Benzodiazole

-10.871 Antiviral; chronic Hepatitis C
-10.844 mild to moderate essential

NS5B inhibitor- terminating RNA

Gentile, Buonomo

polymerization

and Borgia, 2014

Angiotensin II receptor antagonist

Sica et al., 2011;

hypertension

Sood, Bajaj and

compound
Posaconazole (DB01263)
Triazole compound
Gliquidone (DB01252)
Sulfonylurea compounds
Abiraterone (DB05812)
Steroidal progesterone

Elokdah et al., 2002

receptor blocker

Pyrimidinyl-naphthalenyl
Azilsartan medoxomil

long-acting angiotensin II (AngII)

Bajaj, 2018
-10.761 Antifungal drug used in

Impaire the functions of

invasive Candida and

membrane-bound CYP-450 enzyme

Aspergillus infections.

systems.

-10.684 Anti-diabetic drug – Type 2
diabetes mellitus
-10.602 Hormone refractory prostate
cancer

ATP-dependent potassium (KATP)

Greer, 2007

Furman, 2016

channel blocker
Selective and irreversible inhibitor

O'Donnell et al.,

of 17 alpha-hydroxylase

2004
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(CYP17A1)
Bazedoxifene (DB06401) indole
derivatives
Darifenacin (DB00496)
Pyrrolidineacetamide
Apixaban (DB07828) Pyridinecarboxamide

-10.570

Post-menopausal osteoporosis;

oestrogen-receptor modulator

Komm and Chines,

decreases bone resorption;

(agonist and/or antagonist)

2011

M3 muscarinic acetylcholine

Steers, 2006

-10.499 Treatment of urinary
incontinence
-10.439 Thromboembolic diseases reduce the risk of stroke and

receptor blocker
Factor Xa (FXa) inhibitor (clotting

Deshpande, 2012

factor)

systemic embolism
Ezetimibe (DB00973)
Hydroxyphenyl-azetidinone
Canagliflozin (DB08907)

-10.145 Anti-hyperlipidemic;

Piperidine carboxylic acid

Hammersley and

decreasing cholesterol

(NPC1L1) protein on GIT epithelial Signy, 2016

absorption in the small intestine

cells and hepatocytes

-10.083 Anti-diabetic

Oxane-triol moiety
Levocabastine (DB01106)

Blocks Niemann-Pick C1-Like 1

-10.129 Selective second-generation

Inhibit the sodium-glucose

Jakher, Chang, Tan

transport protein 2 (SGLT2)

and Mahaffey, 2019

allergic conjunctivitis

Dechant and Goa,

Histamine H1-receptor

1991

antagonist
Deferasirox (DB01609)
Triazolyl benzoic acid

-9.899 Iron chelator; treatment of
chronic iron overload due to

Binds to trivalent ferric ion and

Yang, Keam and

forms a stable complex

Keating, 2007

long-term blood transfusion
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Estradiol (DB00783) Steroid

-9.639 Urogenital symptoms

Estrogen receptor agonist

Rossouw, 2002

Antagonist of dopaminergic-

Mustafa, 2016

associated with postmenopausal atrophy
Pipotiazine (DB01621)
Phenothiazine

-9.548 CNS depressants and
anaesthetics

receptors, serotonergic-receptors,
histaminergic-receptors, M1/M2receptors

Enzalutamide (DB08899)
Benzamide

-9.533 Treatment of castration-

Androgen receptor inhibitor

Beer et al., 2014

resistant prostate cancer
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In addition, Table 5.2 shows the predicted GPR120S binding poses of candidate compounds
representing different chemical scaffolds – adapalene, azilsartan, gliquidone, lapatinib and
LDE225, which were selected for an initial in vitro screening assay based on structural
diversity, cost, and availability at the time of procurement. Adapalene is a retinoid X receptor
used for topical skin applications (Kolli et al., 2019). The retinoid X receptors are nuclear
receptors which interact with PPARγ receptors. As mentioned in chapter 1, there is a
proposed theory of interaction between PPARγ and GPR120 through EPA (Figure 1.12),
screening this compound for GPR120 specific might lead to positive results. Azilsartan is a
mild hypertension drug which targets Angiotensin II receptor acting as its antagonist (Sica et
al., 2011; Sood, Bajaj and Bajaj, 2018). As Angiotensin II and GPR120 both are rhodopsinlike receptors, which share common features both in TM and orthosteric binding domains,
Azilsartan was selected for in vitro screening assays. The docked pose of Azilsartan (Table
5.2) was found to have H-bond interactions with Arg99 and Trp277 as well as Asn313 as
hypothesized for SBPM for GPR120 antagonist. As the functional assays performed in the
present study cannot verify if the ligand is acting as an agonist or an antagonist, Azilsartan
can be a proposed as a potential candidate for future studies.
Past studies available throughout the literature suggest the significant involvement of
GPR120 isoforms in anti-diabetic therapies (Azevedo et al., 2016). Gliquidone, an antidiabetic drug (Furman, 2016) was selected for in vitro screening from top scoring poses as
anti-diabetic compounds are probable binders of GPR120S and are of significant interest as
dual therapeutics. Lapatinib is a tyrosine kinase inhibitor for epidermal growth factor receptor
type 2 (HER2/ ERBB2) and epidermal growth factor receptor (HER1/EGFR/EGBB1) and
plays a significant role in breast cancer tumour therapy (Nelson and Dolder, 2006). Another
anticancer agent- LDE225 - Hedgehog signalling pathway inhibitor which acts by inhibiting
the smoothened GPCR receptor (Class F) was top scoring ligand in VS (Zollinger et al.,
2014). Both the anticancer ligands were also selected for initial in vitro screenings.
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Table 5.2: Predicted binding modes of the 5 hit compounds selected for in vitro screening
assays from DrugBank. The 2D interaction maps were generated in BIOVIA DS Client
visualizer v19.1.
Test Compound

2D interaction map

Adapalene
Docking SMINA Score: -11.182
kcal/mol

Azilsartan
Docking SMINA Score: -10.844
kcal/mol

Gliquidone
Docking SMINA Score: -10.684
kcal/mol
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Lapatinib
Docking SMINA Score: -12.249
kcal/mol

Sonidegib / LDE225
Docking SMINA Score: -11.613
kcal/mol

5.2.2 In vitro screening of VS hits from the DrugBank database
The stock solutions of procured (section 2.2.1) test drugs were prepared at 10 µM
concentrations in 0.05% DMSO / RPMI-1640 culture media. Serial dilutions from 10 to
0.039 µM were tested in SW480 cells according to the set protocol for 24-hour alamar blue
cytotoxicity assay (section 2.2.2; Figure 5.2). With the exception of lapatinib (IC50 1.16 to
1.77 µM), all test compounds failed to show strong cytotoxic activity against the SW480
cells. As mentioned earlier, lapatinib is actively used for breast cancer and tumour therapy,
such results were expected for lapatinib as well as LDE225. But LDE225 showed negligible
cytotoxic effects with IC50 values of 21.6 to 68.2 µM, which might be related to the
expression of smoothened GPCR receptor in SW480 cells. The expression levels of
smoothened GPCR receptor in SW480 are currently unknown.
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Figure 5.2: Cytotoxicity profile of DrugBank compounds using SW480 cells for 24-hour
treatment. Results show mean and standard error of 5 replica samples. Where no error bars
are visible, they are obscured by the symbol.
Validated 27mer GPR120 siRNA duplex (from Origene) was used to silence the GPR120
expression in SW480 cell-line. Successful downregulation of the GPR120 was validated by
the data obtained from RT-qPCR analysis of GPR120 mRNA levels from siRNA transfected
SW480 cells (Figure 5.3a). GPR120 siRNA duplex kit was provided with two different
samples of GPR120-siRNA. GPR120 expression was found to be ~36% in siRNNA-2 treated
SW480 cells and ~59% in siRNA-1 treated SW480 cells in comparison to untreated (control)
SW480 cell line (Figure 5.3a). As the siRNA-2 transfected SW480 cell lines reported the
lowest expression (~36%) of GPR120, inferring that siRNA-2 is a more potent GPR120 gene
silencer than siRNA-1. siRNA-2 was used to silence GPR120 expression in SW480 cell
cultures for further experiments, if not mentioned otherwise. Detailed data and relative fold
gene expression calculations delta-delta Ct method for RT-qPCR are provided in appendix
VIII.
As the cytotoxic effect of lapatinib observed in the above experiment might be solely due to
tyrosine kinase inhibition in HER/EGFR receptors, lapatinib was tested in GPR120-siRNA
transfected SW480 cells (Figure 5.3b). The comparative results between GPR120-silenced
(IC50 0.61 to 1.21 µM) and control (IC50 1.16 to 1.77 µM) experiments presented no
significant change in the cytotoxic activity of lapatinib confirming that the lapatinib is not a
GPR120 binder and the observed cytotoxic activity could be due to other protein targets.

141 | P a g e

b

% Relative Fold

100
80
60
40

****
****

20
0

siRNA-1 siRNA-2 Control

% cell viability(100% of control)

a

120

GPR120_siRNA

100

Control

80
60
40
20
0

-2

-1

0

1

2

Laptatinib treatment - Log[Drug(µM)]

Figure 5.3: a) Percentage relative fold gene expression (by ∆∆Cт method) of GPR120 in
GPR120-siRNA transfected SW480 cells within 72-hours of transfection. Results show mean
and standard error of 3 replica samples from 2 independent experiments. Where error bars are
not visible, they are negligible; b) siRNA-mediated silencing of GPR120 in SW480 cells –
Lapatinib was screened against GPR120-siRNA transfected and non-transfected (control)
SW480 cells for 24-hour treatment. Results from five replicates are expressed as the mean ±
standard error, Percent relative cell viability for all treatments were quantified and normalised
to the maximal response induced by vehicle control. Data was analysed by two-way ANOVA
followed by Tukey’s multiple comparison and asterisk values denote significance (****P <
0.0001).
5.2.3 Design and In vitro screening of Deferasirox and derivatives
Deferasirox, an iron chelator (Yang, Keam and Keating, 2007), was also predicted as one of
the VS hits from the DrugBank database. It is a tridentate binder of iron (III), the phenols
from two molecules of deferasirox trap one iron atom. Replacing either of the two phenols by
a phenyl (removal of a hydroxy group) might result in reduced or negligible iron chelation
properties of deferasirox (Figure 5.4). The 3D conformation of deferasirox was found to be
similar to AH7614 – a negative allosteric modulator of GPR120 (Watterson et al., 2017;
Lombardo et al., 2016). It was hypothesized that removal of a single hydroxyl from one of
the phenols of deferasirox might strip the molecule’s iron chelation property and act as a
novel GPR120 allosteric modulator or binding competitor of AH7614. It was proposed that
the flexible di-phenyl triazol moiety of the analogue compared to the xanthene moiety of
AH7614 would enable the molecule to adapt to the 3D space in the allosteric binding pocket
(location not currently elucidated) and act as a strong binder.
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Figure 5.4: Structures of AH7614, deferasirox and deferasirox_analogue, a proposed model
of a novel GPR120 allosteric modulator. 3D molecular overlay of AH7614 (Green) against
Deferasirox (Grey) and Deferasirox_analogue (Pink) was generated using consensus method
with flexible alignment of rotatable bonds in BIOVIA DS Client visualizer v19.1 2019.

The proposed deferasirox_analogue was synthesized by Dr Gráinne Hargaden (Hargaden
Chemistry Lab, TU Dublin). TUG891, AH7614, deferasirox and deferasirox_analogue were
tested in vitro in GPR120-siRNA transfected and non-transfected SW480 cells by alamar
blue cytotoxicity assay (Figure 5.5). The cytotoxic effects of deferasirox (50 µM) were
reduced from 80% to ~30% (deferasirox_analogue) by replacing the phenol with a phenyl
group. It was notable that deferasirox (50 µM) exhibited ~40-50% cytotoxicity even in the
GPR120_siRNA transfected cells, while the deferasirox_analogue did not show any cytotoxic
activity in GPR120_siRNA transfected cells showing that the deferasirox_analogue might be
active through the GPR120 receptor. Additional experiments are required to confirm whether
the effects are due to orthosteric or allosteric binding at GPR120 receptor.
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AH7614 and TUG891 did not show significant changes in the cytotoxicity or cell
proliferation rates. TUG891 treated non-transfected SW480 cells registered a slight (~30%)
increase in the proliferation rate, while no such increase in proliferation rate was observed in
GPR120_siRNA transfected cells suggesting that TUG891 induced GPR120 activation can
result in increased rate of CRC cell proliferation. A similar study in bovine granulosa cells
(Maillard et al., 2018) reported 2-fold increase in cell proliferation when treated with
TUG891 (50 µM). On the contrary, another study in prostate cancer cells (Liu et al., 2014)
showed that TUG891 as the most potent inhibitor of proliferation induced by endogenous
GPR120 ligands. The ambiguous role of TUG891 induced stimulation of GPR120 in cell
proliferation with respect to various cell types is still not clearly defined.
The above experiments and observations show that none of the selected compounds from the
DrugBank database were able to induce cytotoxic effects through GPR120 in SW480 cells.
While deferasirox (iron chelator) and the analogue of deferasirox modified to mimic and
compete against the GPR120 NAMD AH7614 was found to be a significant cytotoxic agent
acting through GPR120 receptor.
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Figure 5.5: Cytotoxicity profile of AH7614, Deferasirox, TUG891 and Deferasirox_analogue
using GPR120-siRNA transfected and non-transfected (control) SW480 cells for 24-hour
treatment. Results show mean and standard error of 5 replica samples from two independent
experiments. Where no error bars are visible, they are obscured by the symbol; Results from
replicates are expressed as the mean ± standard error, Percent relative cell viability for all
treatments were quantified and normalised to the maximal response induced by vehicle
control. Data was analysed by two-way ANOVA followed by Tukey’s multiple comparison
and asterisk values denote significance (*P < 0.05; **P < 0.01; ***P < 0.001; ****P <
0.0001).
5.3 SBDD of the SPECS database
For virtual screening, the SPECS database (www.specs.net) containing ~350,000
commercially available, well-characterised and drug-like molecules was screened against the
GPR120S homology model. AutoDock SMINA was used as the molecular docking algorithm
and the docked poses were rescored using an in-house consensus scoring function from
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Equation I (see methods). The best scoring poses docked into the receptor were manually
evaluated by comparison with the docked pose of TUG891.
The docking-based virtual screening with a Cscore cut off was set lower than -9 (comparable
to the reference ligand TUG891 of -9.8) resulted in ~66,000 compounds. These were further
analysed manually using PyMol Open-source version 2.1.0 (DeLano, 2018) to enlist
molecules for phase I of the in vitro screening through Alamar Blue cytotoxicity assay
(section 2.2.2). The manual docking-pose analysis resulted in 13 compounds (Table 5.3)
based on their diverse scaffold chemistry. As per the docking evaluation, these compounds
are predicted to bind to the orthosteric binding pocket of GPR120S (Figure 5.6) as well as
having similar hydrophobic and / or electrostatic interactions with one or more of the residues
reported essential for the pharmacological activity of the receptor.
Table 5.3: Virtual-HTS hit compounds for GPR120S identified from the SPECS database
with scores from each scoring function and the consensus score (Cscore).
SPECS_ID

VINA

NNScore

DLScore

SMINA

Cscore

AN-970/40920574

-14.079

10.616

7.580

-14.082

-11.589

AK-968/41925665

-14.150

8.477

8.173

-14.154

-11.238

AO-299/41877474

-13.332

9.334

8.266

-13.334

-11.066

AE-848/32608035

-13.030

9.560

8.375

-13.030

-10.999

AN-970/40920575

-12.821

9.985

7.643

-12.825

-10.818

AG-690/40104520

-13.103

8.887

8.141

-13.103

-10.809

AJ-292/40857565

-13.176

8.324

8.034

-13.178

-10.678

AN-758/14707017

-12.559

9.557

7.362

-12.558

-10.509

AK-968/15252756

-12.586

8.380

8.211

-12.583

-10.441

AO-081/14456496

-11.786

9.224

7.783

-12.258

-10.263

AK-968/12713190

-12.337

8.540

7.689

-12.337

-10.226

AB-131/42301549

-12.271

8.472

6.879

-12.852

-10.119

AG-690/12137150

-12.267

6.848

7.074

-12.268

-9.614

146 | P a g e

a

b

-5.000

+5.000

Figure 5.6: Docking simulation of 13 test molecules with surface topology of the GPR120S
orthosteric binding pocket (a). Zoomed in view of the electrostatic potential molecular
surface of the orthosteric binding pocket as viewed from above (b) was calculated with APBS
(Adaptive Poisson-Boltzmann Solver) plugin in PyMOL. Blue denotes a positively charged
surface; red denotes a negatively charged surface. The bound test molecules are shown as
green stick models. The 3D images were visualized and rendered in PyMol v2.1.0.
5.3.1 in vitro screening of VS hits from the SPECS database
The selected 13 compounds from the in silico VS were evaluated for their potential
anticancer activity by an alamar blue cytotoxicity assay (section 2.2.2) using SW480 cells
expressing GPR120 (Wu et al., 2013). For initial screening, the SW480 cell-line was treated
with three concentrations (100, 10 and 1 µM) of each test compound for 72 hours to confirm
if extended treatment at lower concentrations (1 µM) result in significant cytostatic effects
(Kummar, Gutierrez, Doroshow and Murgo, 2006). As illustrated in Figure 5.7a, most of the
compounds (11 out of 13) displayed null to negligible (~30%) cytotoxic or cytostatic effects
against SW480 cells at the highest tested concentration of 100 µM. However, two of the test
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compounds showed significant (> 90%) inhibitory effects on cell growth with micromolar
affinities (at 100 µM), reported in Figure 5.7a.

Figure 5.7: a) Cytotoxicity assay of test compounds in SW480 cells which express GPR120
at three concentrations 100, 10 and 1 µM. Results from six replicates are expressed as the
mean ± Standard error. The cytotoxicity of b) AK-968/12713190 (experimental 24-hour IC50
23.21 to 26.69 µM) and c) AG-690/40104520 (experimental 24-hour IC50 26.55 to 33.2 µM)
was assayed by using SW480 cells using 9 serial dilutions from 100 µM to 0.39 µM at three
different treatment time periods. Results show mean and standard error of 5 replica samples.
Results are representative of three individual experiments. Where no error bars are visible,
they are obscured by the symbol. Percent relative cell viability for all treatments were
quantified and normalised to the maximal response induced by vehicle control. Data for (a)
was analysed by two-way ANOVA followed by Tukey’s multiple comparison and asterisk
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values denote significant differences between 100, 10 and 1 µM treatment for each
compound (*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001).
The two active compounds - AK-968/12713190 and AG-690/40104520, were further tested
at a wider concentration range to construct a dose-response curve and determine their IC50
values (see Figure 5.7 b, c). Both the test compounds were active in cell line measurements
with modest inhibitory activity at different treatment times. The 24-hour drug treatments
indicated IC50 values of 23.21- 26.69 µM for AK-968/12713190 and 26.55 - 33.2 µM for
AG-690/40104520.
As the Dose-response-time (DRT) can highlight the dose-response patterns over time in
pharmacological studies (Gabrielsson, Andersson, Jirstrand and Hjorth, 2018), these two test
compounds were tested over a longer treatment time of 48 hours and 72 hours for their
cytotoxicity activity (see Figure 5.6b, c). After 48 hours, the IC50 of both compounds drops to
~50-60 µM. Similar effects over time have been reported in another oncogenic study
(Zakharia et al., 2017) suggesting that the cells might have developed acquired resistance to
test compounds at lower concentration after 48 hours of exposure. This acquired resistance
might enable them to escape the cytostatic state and start cell proliferation which can be
traced back to the augmented chemoresistance in breast cancer treatment through GPR120
overexpression (Wang et al., 2019). Also, the increased metabolic activity of cancer cells can
be related to anticancer drug metabolism responsible for the resistance to cytotoxic agents
(Cree, 2011; Iyanagi, 2007), hence reducing the cytotoxicity of these two compounds over
time. While the 72-hour experiments showed a slight decrease of 10 µM in IC50 values of
both compounds, it should be noted that the drug concentrations were not replaced over the
treatment time intervals. The decreased cell growth or increased cytotoxic effects of these
two compounds at 72 hours might be the result of a lack of nutrients and increased metabolic
waste in the culture solution (Ackermann and Tardito, 2019).
5.3.2 SAR / similarity search and in vitro screening of SAR compounds
The top-scoring docked poses of AK-968/12713190 and AG-690/40104520 (Figure 5.8)
predicted that the two molecules interact with several residues reported significant for
protein-ligand binding by Hudson et al. 2014 and which also interacted with the selected
docked pose of TUG891 (Figure 3.11) such as Ile280, Ile284, Val307. AK-968/12713190
consists of a benzo-quinazoline ring structure as the chemical scaffold with smaller benzylmethyl and benzyl substituents. The phenylalanine residue at TM3 (Phe115) shows strong π149 | P a g e

π interactions with the main scaffold as well as π-sulfur interactions with the sulfanyl linker.
While AG-690/40104520 consists of a 9-fluorenone as the chemical scaffold with symmetric
dimeric naphthalene groups at both ends linked by an aminosulfonyl. The presence of dimeric
naphthyl substituents showing strong hydrophobic π-π stacked interactions at one end and
simple π-Sigma interactions at the other suggesting strong binding interactions in the binding
pocket. The chemical scaffold of AG-690/40104520 - (PubChem CID: 10241) is actively
used in preparation of antimalarial drugs, functional polymers, and dyes (9-Fluorenone,
2021).

Figure 5.8: 2D interaction maps of docked poses of compounds AK-968/12713190 and AG690/40104520 with hGPR120S. The 2D interaction maps were generated in BIOVIA DS
Client visualizer v19.1 2019.
These two compounds were selected for SAR studies based on the strong docking predictions
with the GPR120S model, their novelty with respect to the literature and the micromolar
cytotoxic activity in CRC cell line. For phase II of in vitro screening, the chemical scaffold of
the two most cytotoxic test compounds (from phase I) was used for a substructure search
from the SPECS database docked pool using Discovery Studio’s Pipeline Pilot
from Dassault Systèmes 2017.
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5.3.2.1 SAR profiling of AK-968/12713190
To

expand

the

SAR

profile,

the

generic

chemical

structure

of

968/12713190, dihydrospiro(benzo[h]quinazoline-5,1′-cyclopentane)-4(3H)-one,

AKin

combination with sulfanyl acetone tail was used as a query for a substructure search against
the pre-processed SPECS database using Biovia pipeline pilot (Table 5.4).
The substructure search of AK-968/12713190 resulted in 16 compounds from the prescreened SPECS database. This set of compounds explored R-groups in position R1 and R2 of
the scaffold (Table 5.2) in combination with in silico ADME profiling using SwissADME
(http://www.swissadme.ch/) (Daina, Michielin and Zoete, 2017) to procure the selective
compounds for in vitro screening. The analogues were selected exploring the alkyl to aryl
substitutions at the R2 position and simple halobenzene substitutions at the R1 position
connected by a sulfanyl acetone linker keeping dihydrospiro(benzo[h]quinazoline-5,1′cyclopentane)-4(3H)-one scaffold structure intact. Based on the docking analysis, manual
screening, and the availability of compounds at SPECS, seven compounds were tested for in
vitro cytotoxicity assay in SW480 cell line following the set protocol (Figure 5.9).
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Table 5.4: SAR profile of AK-968/12713190 with modified groups to determine functional
potency. Cytotoxic activity (experimental 24-hour IC50) of SAR compounds in SW480 cell
line measured by Alamar Blue assay. Lipinski filters provided by SPECS database.
O

O

R1
S

N

N
N

N

O

dihydrospiro(benzo[h]quinazoline-5,1′cyclopentane)-4(3H)-one

R2

O

Generic SAR structure
Experimental
Lipinski’s
IC50 (µM)
Violations

SPECS
Compound ID

-R1

-R2

Docking
Cscore

AL-281/36997030

1,4C6H4Cl

-CH3

-9.339

22.92 to 27.58

0

AJ-292/12930007

1,4C6H4Cl

-C5H9

-9.741

24.26 to 26.95

2 (MW 505;
logP 4.57)

AL-281/36997031

1,4C6H4Cl

-C6H5

-10.706

5.890 to 6.715

2 (MW 513;
logP 4.03)
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1,4C6H4Cl

-C2H4-C6H5
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2 (MW 571;
logP 4.77)

AN-512/12674229

1,4C6H4Br

2,2-( CH3)2C5H7O

-9.988

N/A

2 (MW 593;
logP 4.5)
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Figure 5.9: Cytotoxicity profile of compound AK-968/12713190 SAR analogues using
SW480 cells for 24-hour treatment. Results show mean and standard error of 4 replica
samples. Where no error bars are visible, they are obscured by the symbol; Percent relative
cell viability for all treatments were quantified and normalised to the maximal response
induced by vehicle control.
Based on the SAR study, the IC50 values of the new hits enable an initial identification of the
essential pharmacophore features required in the dihydrospiro(benzo[h]quinazoline-5,1′cyclopentane)-4(3H)-one scaffold. The presence of an aromatic halogen at the sulfanyl
acetone tail exhibited an increase in potency (AL-281/36997030, AL-281/36997031 and AL281/36997034). However, the substitution of chloride in comparison to bromide seems to be
more effective for pharmacological activity. The drop in potency of AN-512/12673388 with
respect to the parent compound (AK-968/12713190) and AL-281/36997031 can be related to

the larger atomic size of bromine atom compared to chlorine which can result in decreased
solubility and hence lowering the bioavailability of the compounds. Although not predicted in
molecular docking which showed similar binding scores −10.22, −10.706 and −10.704
(compounds AK-968/12713190, AL-281/36997031 and AN-512/12673388 respectively), the
greater size of bromine might be responsible for steric clashes with neighbouring residues in
the binding pocket which can be further analysed by future MD studies. Fluorine atom is
smaller in size and exhibit slight electronegativity which has been reported to increase the
electrostatic bonding affinity of the compounds (Khosravan, Marani and Sadeghi Googheri,
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2017). Incorporation of fluoroaromatics at the sulfanyl acetone tail may increase the
solubility and hence bioavailability of these SAR analogues.
Substitution of the benzo-methyl at the R2 position in the parent structure and AN512/12673388 by a smaller methyl group (AL-281/36997030) or an aromatic six-membered
group (AL-281/36997031) resulted in a significant increase in potency of the analogues. The
substitution of a non-aromatic cyclic group (AJ-292/12930007) resulted in reduced activity of
the parent compound (AK-968/12713190). The addition of a methoxy group to this aromatic
ring at R2 position in AL-281/36997034 resulted in the second most active compound of the
SAR profiling. The quinazoline ring linked to five or six membered aromatic ring structures
at R2 position by a single C-C bond length seems to be the optimum as when the linker length
in AL-281/36997031 is

increased

(-C-C2H4-C-),

the

cytotoxic

activity

of AG-

690/12134207 registered a drastic decrease from ~ 6 µM to ~ 80 µM. The total inactivity
of AN-512/12674229 may confirm the above inferences as it contains bromo-aromatic group
at R1 position and non-aromatic cyclic ring with a longer linker at the R2 position.
5.3.2.2 SAR profiling of AG-690/40104520
Similarly, the generic chemical structure of AG-690/40104520, fluoren-9-one, was used as a
query for a substructure search. The substructure search of fluoren-9-one from the prescreened SPECS database resulted in 28 hits, out of which 8 compounds (Table 5.5) were
procured for in vitro cytotoxicity screenings based on the docking analysis and in silico
ADME profiling using SwissADME (Daina, Michielin and Zoete, 2017). Substitutions at the
R1 and R2 positions of the fluoren-9-one substructure were explored to build a SAR profile
(Figure 5.10). The IC50 (µM) values obtained from the cytotoxicity assay (Table 5.5)
suggested that the presence of the sulfonamide linker and/or identical substitutions at the R1
and R2 positions did not exhibit significant changes in potency of SAR compounds. Since the
only two active compounds in the SAR study were AG-205/11944202 (non-identical
substitutions without the sulfonamide linker) and AP-845/40876799 (identical substitutions
with sulfonamide linkers).
The substitution of methoxy-phenyl by phenol group in the imidazole R2 groups of
compounds AG-205/11945004 and AG-205/11944202 increased the cytotoxicity from
negligible (>1446 µM) to ~40 µM. The drastic increase in cytotoxicity by replacing the OCH3 (methoxy phenyl) with -OH (phenol) suggested that the bigger hydrophobic -OCH3
group might be having strong steric clashes which impacted the binding or entry of AG154 | P a g e

205/11945004 while the hydrophilic -OH group eased the binding of AG-205/11944202 in
the orthosteric pocket of GPR120 receptor. Further removal of the second phenyl group from
the imidazole ring of AG-205/11944202 could be proposed to reduce the hydrophobicity as
well as size at the R2 substitution which might increase the cytotoxicity profile of R2
imidazole substitution analogues.
Amongst symmetrical compounds with identical R1 and R2 substitutions in the presence of the
sulfonamide linker, except AP-845/40876799 no other compounds (AP-845/40876779, AG690/11665662 and AG-690/11665659) exhibit cytotoxicity activity. AP-845/40876799 was
found to be the best hit compound compared to the parent compound (AG-690/40104520)
with improved IC50 values from ~32 µM to 18 µM. The inactivity of compound AG690/11665659 can be attributed to the bulky phenyl-piperazine groups preventing the ligandreceptor binding or the strong lipophilic character (logP 6.58) might have resulted in the
ligand getting trapped (dissolving) in the plasma membrane.
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Table 5.5: SAR of AG-690/40104520 with modified groups to determine functional potency.
Cytotoxic activity (experimental 24-hour IC50) of SAR compounds in SW480 cell line
measured by Alamar Blue assay. Lipinski filters provided by SPECS database.
O

O
1

R

R2

fluoren-9-one
SPECS
Compound
ID

-R1

AG205/11945004

-H

Generic SAR structure
Docking Experimental Lipinski’s
Cscore
IC50 (µM)
Violations

-R2

N

NH

-11.533
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1 (logP
6.99)

-11.467

38.73-44.8

1 (logP
6.43)

-11.218
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Figure 5.10: Cytotoxicity profile of compound AG-690/40104520 SAR analogues using
SW480 cells for 24-hour treatment. Results show mean and standard error of 4 replica
samples. Where no error bars are visible, they are obscured by the symbol; Percent relative
cell viability for all treatments were quantified and normalised to the maximal response
induced by vehicle control.
157 | P a g e

Compounds AP-845/40876779 and AG-690/11665662 are approximately of the same size as
compound AP-845/40876799 (Figure 5.11), with a difference of aromatic ring structure and a
rotatable -N-C- bond between fluorophenyl and sulfonamide. Absence of both the aromatic
ring structure linked by a rotatable linker might be the contributing factors for the inactivity
of AP-845/40876779 and AG-690/11665662, where the strong π–π (or weaker Sigma-π)
interactions between the aromatic phenyl ring and the aromatic residues in the receptor
binding pocket might be stabilising the protein-ligand binding. While compound AO080/43378433 with aromatic benzo-dioxole at R2 position linked by an amide bond showed
negligible cytotoxicity (> 480 µM). It is a well-studied fact that rotation is not permitted
about amide bonds but with allowed torsion about –(C=O) – (benzo-dioxole) as well as
(fluoren-9-one)–NH- bonds (Fischer, 2000). The rigidity of the amide bond in AO080/43378433 might be the limiting factor, therefore, suggesting that the presence of an
aromatic ring attached to the main scaffold by a rotatable linker might be essential for
substitution groups. While the smallest and the most flexible compound AG-219/37040030
also showed negligible (>571.6 µM) cytotoxic activity as it lacks the aromatic groups at R2
position in comparison to AO-080/43378433.
The present SAR study explored some of the chemical space around the two parent
compounds AK-968/12713190 and AG-690/40104520 and resulted in identification of two
analogues of AK-968/12713190 (AL-281/36997031 and AL-281/36997034) and one
analogue of AG-690/40104520 (AP-845/40876799) with improved cytotoxicity activities
(Figure 5.11). The pharmacokinetics profiling of these five test compounds (Table 5.6)
showed that they are poorly soluble in the aqueous phase which could result in low
gastrointestinal absorption. The lower gastrointestinal absorption of these compounds is
predicted to reduce the oral bioavailability of these compounds.
The profiling also enlisted violations of different rules set for the compounds to have druglikeness. Recent drug discovery has shown marketed drugs breaking some of these rules
which has resulted in many extensions to the Lipinski’s Rule of Five (Congreve, Carr,
Murray and Jhoti, 2003; Jhoti, Williams, Rees and Murray, 2013). The newer drug-likeness
rules such as Ghose’s, Veber’s, Muegge’s filters, etc., (Table 5.6; enlisted in section 1.7.4)
choose lower parameter values for drug-like and fragment-like compounds because during
ligand / lead optimisation the values of the parameters such as molecular weight,
hydrophobicity, rotatable bonds, etc. increase inevitably (Brogi, 2019). As the SAR analysis
of the above compounds also laid the blueprint for scaffold design as well as selection of new
158 | P a g e

compounds for in vitro screenings, further optimisation by SAR profiling of these compounds
is required to improve their pharmacokinetics. The improved pharmacokinetics might result
in more potent and selective cytotoxic agents targeting GPR120 receptor.

Figure 5.11: 2D interaction maps of docked poses of compounds AL-281/36997031 and AL281/36997034 and AP-845/40876799 with hGPR120S. The 2D interaction maps were
generated in BIOVIA DS Client visualizer v19.1 2019.
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Table 5.6: Physicochemical and pharmacokinetics parameters of the potential anticancer two
parent compounds and their SAR hits obtained from SwissADME drug-likeness profiling
(Daina, Michielin and Zoete, 2017). Color code – Green : Highly favourable; White :
Favourable; Red : Unfavourable;
Physicochemical
properties
Molecular Weight
Rotatable bonds
H-bond acceptors
H-bond donors
TPSA
iLOG Po/w
GI absorption
BBB permeant
P-glycoprotein
interaction
CYP1A2 inhibitor
CYP2C19 inhibitor
CYP2C9 inhibitor
CYP2D6 inhibitor
CYP3A4 inhibitor
Skin permeant log
Kp (cm/s)
Lipinski violations
Ghose violations
Veber violations
Egan violations
Muegge violations
PAINS alerts
Brenk alerts
Lead likeness
violations
Synthetic
Accessibility
Estimated Aqueous
Solubility

AK-968AL-281AL-28112713190
36997031
36997034
(Parent1)
(SAR hit)
(SAR hit)
492.63
513.05
543.08
5
5
6
3
3
4
0
0
0
77.26
77.26
86.49
4.44
4.03
4.38
Pharmacokinetic properties
Low
Low
Low
No
No
No

AG-69040104520
(Parent2)
590.67
6
5
2
126.17
2.92

AP-84540876799
(SAR hit)
526.53
6
7
2
126.17
2.17

Low
No

Low
No

Yes

Yes

Yes

No

No

No
No
Yes
No
No

No
Yes
Yes
No
No

No
Yes
Yes
No
No

Yes
No
No
No
Yes

No
Yes
Yes
No
Yes

-4.04

-3.98

-4.18

-5.21

-6.45

1
3
0
1
1
0
0

2
3
0
1
1
0
0

2
3
0
1
1
0
0

1
3
0
1
1
0
0

1
2
0
1
0
0
0

2

2

2

2

2

4.62

4.5

4.57

3.82

3.31

Poorly
soluble

Poorly
soluble

Poorly
soluble

Poorly
soluble

Moderately
soluble
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5.3.3 Target validation of hit compounds by siRNA cell transfection.
As cancer therapies need to be target specific to limit their general toxicity to healthy cells
and prevent obstruction to normal cellular homeostasis (Padma, 2015). The next step after
identification of three potential hit compounds (AL-281/36997031, AL-281/36997034 and
AP-845/40876799) (Figure 5.11) was to confirm that the cytotoxic compounds were
exhibiting their effects by targeting the intended GPR120 receptor, hence showing target
specificity. Scientific literature and public databases such as DrugBank, ChEMBL, ZINC,
etc., (Wishart, 2006; Papadatos and Overington, 2014; Irwin et al., 2012) can be used to
identify drug targets in cases where the potential test compounds are well researched or
already known. For novel test compounds, the process of regulating the target expression in
vitro and quantifying the drug response in regulated and unregulated environment can be
used for target identification.
The three test compounds - AL-281/36997031 and AL-281/36997034 were tested in GPR120
silenced SW480 cells at approximate experimental IC50 (5 µM) and AP-845/40876799 was
tested at approximate experimental IC50 (15 µM) (Figure 5.12). The cytotoxicity of AL281/36997031 and AP-845/40876799 was observed to be significantly suppressed in
GPR120-siRNA transfected SW480 cells compared to non-transfected SW480 cell line. AL281/36997034 presented a slight change in its cytotoxicity properties in GPR120-siRNA
transfected SW480 cells. The comparative results between GPR120-silenced and control
experiments suggested that AL-281/36997031 and AP-845/40876799 were GPR120 specific
as they exhibit their cytotoxic effects via GPR120 while AL-281/36997034 might be
exhibiting cytotoxic activity through multiple targets including GPR120. TUG891 (10 µM)
presented neither cytotoxic nor proliferative activity and was equivalent to the vehicle. Also,
no significant change was observed with TUG891 in control GPR120_siRNA transfected cell
lines.
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Figure 5.12: siRNA-mediated silencing of GPR120 in SW480 cells – Compounds AL281/36997031, AL-281/36997034 and AP-845/40876799 were screened against GPR120siRNA and scrambled-siRNA (control) transfected SW480 cells. Results from five replicates
are expressed as the mean ± standard error, ****p<0.0001, ***p=0.0003, *p=0.0420, ns =>
not significant as indicated (from two-way ANOVA, Sidak's multiple comparisons test).
Percent relative cell viability for all treatments were quantified and normalised to the
maximal response induced by vehicle control.
5.3.4 Wound healing assay of test compounds
Cell migration is a hallmark of wound repair, cancer invasion, metastasis, angiogenesis, etc
(Arnold, Opdenaker, Flynn and Sims-Mourtada, 2015). Wound healing is a complex cellular
process involving dynamic interactions and crosstalk between intra- and extra-cellular matrix
molecules (Arwert, Hoste and Watt, 2012). Analysis of cell migration in vitro is useful to
quantify alterations in cell migration in response to various factors or treatments. Cancer celllines (SW480) can migrate at a higher rate compared to normal cell-lines and promote tumour
invasion, tumour angiogenesis and metastasis (He et al., 2018). Wound healing or in vitro
scratch assay is a well-developed inexpensive, simple, and versatile methodology to quantify
the migration capacity of the cells. It can be real-time image monitoring or time-interval
image monitoring of cell migration to heal the wound i.e., scratched cellular monolayer (He
et al., 2018; Somchai et al., 2020). The percentage scratch area recovered overtime in the
presence of cytotoxic drug treatments per experiment measures the migration rate. The image
analysis of scratch area by image capturing and analysis via software tools like Fiji with

162 | P a g e

Wound healing tool automate the process (Schindelin et al., 2012) and reduce the human
error.
In this study, the three cytotoxic hits (AL-281/36997031, AL-281/36997034 and AP845/40876799) identified from previous results were tested for their ability to inhibit cell
migration in SW480 cell-line at subtoxic concentrations (from approximated IC50 values –
Table 5.4 and 5.5) obtained from their dose-response curves. Representative images of
mechanical scratch wound in the absence or presence from timepoints 0 and 16 hours are
illustrated in Figure 5.13a. The experimental data (Figure 5.13b) illustrated that treatment
with AL-281/36997031 and AL-281/36997034 (scaffold: dihydrospiro(benzo[h]quinazoline5,1′-cyclopentane)-4(3H)-one) caused significant inhibition of cell migration in comparison
to the compound AP-845/40876799 and control. The time interval of 16 hours was selected
based on the trial experiments of control to find the optimum range where mechanical wound
scratch would not be completely recovered. The inhibitory effects of test compounds agreed
with their cytotoxicity profiling results where AL-281/36997031 was found to be the most
active of the three test compounds.
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AL-281/36997031
Subtoxic Conc.
(IC25) 3 µM (IC50
5.890 - 6.715 µM)

AL-281/36997034
Subtoxic Conc.
(IC25) 3.5 µM (IC50
6.789 - 7.502 µM)

AP-845/40876799
Subtoxic Conc.
(IC25) 7.5 µM (IC50
14.24 to 18.02 µM)
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Figure 5.13: a) Representative images of scratched SW480 monolayer captured at time 0
(Top) and 16 (bottom) hours against Control (0.5% DMSO / RPMI+10%FBS) and treatment
of three test compounds AL-281/36997031, AL-281/36997034 and AP-845/40876799; b) Bar
plot illustrating scratch assay results from 3 independent experiments performed in triplicates
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with standard error of mean. Rate of migration of SW480 cells in presence of drug treatments
calculated as percentage recovered surface area (%RSA). Data was analysed by two-way
ANOVA followed by Sidak's multiple comparisons test and asterisk values denote
significance (****P < 0.0001).
5.3.5 Colony formation or clonogenic assay
Colony formation / clonogenic assays were developed to determine the ability of a single cell
to form a colony of cells (He et al., 2018; Franken et al., 2006), especially stem cells can
form colonies. In tumours, only a few cells retain this property and after migration and
metastasis initiate tumorigenesis (He et al., 2018). A clonogenic assay was used to screen the
three test compounds AL-281/36997031, AL-281/36997034 and AP-845/40876799 in a dosedependent manner. The survival fraction (Figure 5.14) calculated from the clonogenic assay
revealed that treatment with test compounds decreased the colony forming ability of SW480
cells in comparison to the control (0.5% DMSO/RPMI1640). Due to the lower number of
cells per well (5 cells/well) the survival rate at concentrations higher than IC50 was negligible
and colony formation was observed only below IC50 values in each drug treatment (Figure
5.14a). AL-281/36997031 was found to be the most potent of all three test compounds
keeping the survival rate ~ 30% at 3 µM. The results indicated that` the selected test
compounds possess cytotoxic function and can be developed as potential anticancer
therapeutic.
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Figure 5.14: a) Representative images of SW480 colonies captured after two weeks of
incubation against treatment of three test compounds AL-281/36997031, AL-281/36997034
and AP-845/40876799; b) Bar plot illustrating dose-dependent survival rate of SW480 cells
with results from 3 independent experiments performed in triplicates with standard error of
mean; ****p<0.0001 as indicated (from two-way ANOVA, Sidak's multiple comparisons
test). Percent relative cell viability for all treatments were quantified and normalised to the
maximal response induced by vehicle control.
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To summarise the findings from in silico and in vitro screenings (Table 5.7), the lead
optimization of AK-968/12713190 and AG-690/40104520 with structural modifications
using SAR analysis resulted in better hit compounds. Based on the identification and
validation using in vitro assays, the cytotoxic properties of the three test compounds AL281/36997031, AL-281/36997034 and AP-845/40876799 in a CRC cell line was confirmed.
Table 5.7: Summary of results obtained from VS of screening of Chemical libraries –
DrugBank (left) and SPECS (right) databases against GPR120S model and in vitro screening
assays in SW480 cells.
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5.4 Discussion
The research aim was to identify novel lead molecules for selective binding to the human
GPR120S receptor. The predicted and validated model of GPR120S was used for virtual
screening of commercially available databases to find hit compounds having better binding
scores using the molecular docking program SMINA (Koes, Baumgartner and Camacho
2013). Docking-based VS are growing in the number of success cases reported (Villoutreix et
al., 2009; Rognan, 2017). The development of an accurate empirical scoring functions to
predict protein–ligand binding affinities is a key aspect in SBDD.
Random forest-based scoring functions has been reported as best performing scoring
functions (Wójcikowski, Ballester and Siedlecki 2017). The random forest is an ensemble
approach that acts as a nearest neighbour predictor. The working principle of this method is
that a group of “weak learners” (training set with limited parameters) can come together to
form a “strong learner”. For developing a random forest-based scoring function large number
(minimum 300) of known ligands of GPR120S were required (Wójcikowski, Ballester and
Siedlecki 2017). As the number of active ligands with uniform experimental data on
GPR120S is low, preparing the random-forest based scoring function would not be useful in
scoring and ranking the protein-ligand interactions. In this regard, consensus-based scoring
function using rescoring programs which employ diverse types of algorithms was used to
predict the best docking poses.
The iterative combination of in silico and in vitro methods employed resulting in discovery of
three potential cytotoxic compounds (Table 5.6). From 73 top scoring virtual hits of
DrugBank only 24 were selected for in vitro screening but only 5 compounds were procured
and tested in vitro. The VS of DrugBank database might be useful in drug repurposing once
the remaining virtual hits from DrugBank are screening in vitro (Sahragardjoonegani, Beall,
Kesselheim and Hollis, 2021). While the initial in vitro screening of SPECS virtual hits
reported AK-968/12713190 and AG-690/40104520 as lead cytotoxic compounds. SAR
profiling of these two cytotoxic compounds resulted in three potential hits - AL281/36997031, AL-281/36997034 and AP-845/40876799. When these compounds were
tested at concentrations below experimental IC50 values in GPR120-silenced SW480 cells,
this cytotoxic effect of AL-281/36997031 and AP-845/40876799 was significantly
suppressed in GPR120-siRNA transfected SW480 cells while AL-281/36997034 showed ~
10% higher cytotoxicity levels in siRNA transfected cells. The comparative study between
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GPR120-silenced and control experiments suggested that AL-281/36997031 exhibited
cytotoxic effects through GPR120 binding while cytotoxic activity of AL-281/36997034
might be either through multiple targets including GPR120 or through another target.
However, further in silico and in vitro validation is required to confirm their anti-cancer
potential targeting GPR120. As literature suggests that high levels of GPR120 expression in
CRC cell lines increases the cell proliferation rate and reduces apoptosis, it can be
hypothesized that compounds AL-281/36997031, AL-281/36997034 and AP-845/40876799
inhibit GPR120 and hence increase the apoptosis rate.
A comparative study of these test compounds against a competitive antagonist would be
useful, but as mentioned earlier no GPR120 antagonists are available to date. AH7614 (4Methyl-N-9H-xanthen-9-yl-benzenesulfonamide) was first reported as a GPR120 selective
antagonist by GlaxoSmithKline in 2014 but its mechanism of antagonism was not known.
Later collaborative research by the Ulven and Milligan labs in 2017 reported that AH7614
was a negative allosteric modulator of GPR120 (Watterson et al., 2017). As it does not bind
at the orthosteric binding pocket of the receptor, hence AH7614 is not a competitive
antagonist of GPR120. The deferasirox_analogue designed as a novel GPR120 ligand showed
significant activity and further functional assays are required to validate it as an allosteric or
orthosteric ligand of GPR120.
As mentioned previously cell migration and colony formation are the characteristic hallmarks
of cancer cells – a cytotoxic compound capable of preventing cell migration and colony
formation can be characterised as an anti-cancer drug molecule (Arnold, Opdenaker, Flynn
and Sims-Mourtada, 2015; Arwert, Hoste and Watt, 2012; He et al., 2018). Treatment with
compound AP-845/40876799 (7.5 µM) showed lower inhibitory effects on the cell migration
compared to AL-281/36997031 (3 µM) and AL-281/36997034 (3.5 µM), even though it was
used at double concentration (Figure 5.13). While AP-845/40876799 reported higher
significance in target identification when tested with SW480 cells with downregulated
GPR120 expression (Figure 5.12). Similar results were observed in the clonogenic assay
(Figure 5.14). The lower inhibitory effects of AP-845/40876799 can be related to its lower
binding affinity towards the GPR120 orthosteric binding pocket. Further design optimisation
of AP-845/40876799 by SAR analysis might improve the potency of new compounds from
micro-molar to nano molars.
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Chapter 6
Overall Discussion and Conclusion with Future Prospects
Being key sensors of extracellular signalling and regulation of various physiological
processes, GPCR structural biology has been flooded with atomic-level information to design
GPCR-targeted drugs (Zhu, Wu, Huang and An, 2021). Insights into GPCR-ligand binding
and resulting conformational changes in GPCR structure upon activation are being studied.
During this period, CADD – specifically SBDD has increasingly become popular for
identifying novel therapeutics against GPCR families (Kosciolek, Mordalski and Bojarski,
2011; Yuan and Xu, 2018; Ferruz et al., 2018; Ibrahim and Clark, 2019).

Recent studies

have profiled GPR120 as a target of interest for developing anticancer therapeutics as it was
found to play a significant role in chemoresistance in breast cancer tumour cells (Houthuijzen
et al., 2017; Wang et al., 2019; Senatorov and Moniri, 2018). GPR120 is a Class A GPCR
which has been reported to play a pro-oncogenic role in CRC by enhancing tumour
angiogenesis and cell migration (Wu et al., 2013), and multifaceted roles in other cancer
management (Senatorov and Moniri, 2018).
The present work has focused on studying the SBDD against GPR120 for development of
anticancer drugs in CRC (Wu et al., 2013; Kumari, Reabroi and North, 2021). To attain the
research goal, a spectrum of computational and biological methods to discover potential
anticancer ligands from large chemical libraries, VS hits to potent lead optimisation, and
molecular dynamics of ligand binding and activation were explored.
In the absence of experimentally elucidated 3D structure of GPR120, knowledge-based
predictive computational methodologies such as homology modelling, molecular docking and
MD simulations were applied to guide the in vitro studies towards the design and discovery
of novel GPR120 ligands. Our first step was to build a 3D structural model of GPR120S
through in silico methodologies. It is worthwhile reporting the inherent limitations in
homology modelling of GPCRs with templates with low sequence identity (below 40%) (Tiss
et al., 2021).
The previous GPR120 homology models reported in literature were generated using only a
single template (Sun et al., 2010; Hara et al., 2011; Takeuchi et al., 2013; Chinthakunta et al.,
2018; Zhang, Sun, Wen and Yuan, 2019). While the data regarding template selection for the
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human GPR120 short isoform (Q5NUL3 - 361 amino acids) model prediction by AlphaFold2
is not available.
In this work, the highest sequence identity of templates available for GPR120 homology
modelling was ~25% - Delta opioid and orexin 2 receptor, with 80 % query sequence
coverage. Only recently, (January 2021), new crystal structures with higher sequence identity
have been deposited in PDB database such as Neuropeptide Y2 receptor (~30%) with only
50% sequence coverage (Tang et al., 2021). An improved GPR120 homology model can be
built using these higher sequence identity templates for future work as the recently developed
software packages are powerful and reliable to predict comparative naturally resembling
models such as AlhpaFold2 – AI predictive algorithm for protein folding (Malathi and
Ramaiah 2018; Jumper et al., 2021).
To date and to the best of our knowledge, our GPR120S model was the first to be generated
using pairwise template alignment using antagonist-bound human delta-like opioid receptor
and orexin 2 receptors as templates covering 87% and 84% of the full query sequence,
respectively. The homology model of GPR120S (short isoform) generated by combination of
the two templates for the present study (generated in January 2017) provided apt guidance to
focus our in vitro evaluation assays on the potential GPR120 ligands and enhanced the
success rate of experimental design setup for lead screenings. Furthermore, none of the listed
studies published data related to enrichment studies as well which prevented us from
performing comparative analysis between these models and the generated model.
Another major knowledge gap missing is the link between active and inactive conformations
of GPCRs obtained from X-ray crystallography or cryo-electron microscopic models. As
mentioned earlier, ligand binding results in conformational changes leading to receptor
activation. These conformational insights can lead to designing ligands with specific efficacy
and activity profiles. In order to predict conformational changes upon activation, the
GPR120S homology model in this study was built using templates in an inactive state (bound
to an antagonist). The inactive state of generated GPR120S model was confirmed by
structural analysis of characteristic Class A GPCR motifs such as [D/E]RY motif – “ionic
lock” between TM3 and TM6 (Figure 4.3) (Katritch, Cherezov and Stevens, 2013;
Rasmussen et al., 2007).
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Using in silico methodology of molecular docking, GPR120 agonists (TUG891 and
Compound39) were docked into the orthosteric binding pocket of the generated GPR120S
model. The protein-ligand interaction profiling of the selected docked poses showed that the
ligands are interacting with Arg99 of TM3 and all the residues essential for biological activity
(Sun et al., 2010; Hudson, Shimpukade, Milligan and Ulven, 2014) are in the proximity of the
ligands (~ 4 Å). The ligand bound GPR120S receptor models obtained by molecular docking
were energy minimized to bring models to local minima (stable energy state) in the protein
conformational energy landscape using steepest descent before MD assisted structural
investigation of the ligand bound models. The site-specific mutation studies by Hudson et al
reported – Arg99 (TM2), Trp104 (ECL1), Phe115 (TM3), Trp207, Phe211 (TM5), Trp277
(TM6) and Phe304 (TM7) (Hudson et al 2014) as essential amino acid residues required for
significant binding interactions with the GPR120 agonists.
Our study performed 300 ns long all atomic MD simulations using the agonist-bound
GPR120S models (TUG891 and Compound39) to mimic / predict and understand the liganddriven modulation of equilibrium between different states of receptor. The topology
(secondary structure) of the transmembrane receptors, which dictates the functionality of the
receptor, is established by their physiological environment. As the effects and importance of
immediate environment of transmembrane proteins on stabilising their folded protein
conformations is well understood (Liang, Adamian and Jackups, 2005; Lee, 2011; Stansfeld
and Sansom, 2011; Sandoval-Perez, Pluhackova and Böckmann, 2017; Marrink et al., 2019),
we embedded the GPR120S models in the lipid bilayer followed by solvation with SPC water
molecules and neutralisation by sodium and chloride ions to run MD simulations.
In the absence of a known GPR120 antagonist, one apo-GPR120S protein system and two
agonist-bound GPR120S protein systems were built to run MD simulations (sections 4.1, 4.2)
to get comparative results for structural analysis. MD analysis of the apo-GPR120S system
(GPR120S model without a docked ligand) confirmed our two hypothesizes that - (i) the
inactive state GPR120S homology model was generated by using templates of inactive
receptors and (ii) an inactive GPR120S model will remain in an inactive state if not
stimulated by agonist binding. The lowest energy conformation of apo-GPR120S model was
extracted from the 300 ns MD trajectory and used for structure-based pharmacophore
screening and VS of SPECS chemical database detailed in chapters 4 and 5 respectively.
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While the MD analysis of the agonist-bound GPR120S model (TUG891) confirmed that
agonist binding stimulated the GPR120S receptor and steered the protein conformation from
an inactive state to an active state (Figure 4.6). The molecular docking analysis from
consensus docking runs of Compound39 (Figure 4.3 and Table 4.1) illustrated that in addition
to H-bond interactions shown by TUG891 (Arg99 and Trp277), Compound39 formed Hbonding interactions with Thr125 and Asn313 as well. As the comparative analysis of various
GPCR Class A conserved motifs such as PIF, D/ERY and NPxxY motifs in the apo and the
agonist-bound models characterised residues Asn313 as a molecular switch for antagonist
binding. Further site-specific mutation studies targeting Asn313 alone as well as in
combination with other binding pocket residues could be employed to confirm the importance
of Asn313 interactions in GPR120 antagonist design.
Based on the inferred results, a structure-based pharmacophore hypothesis focused on Trp277
and Asn313 was generated (Figure 4.9b) to screen ZINC chemical library for small molecules
which can conserve the Class A GPCR “ionic lock” and stabilise the protein in inactive state,
preventing receptor activation. Structure-based pharmacophore screening resulted in
screening of 63 compounds which were further analysed for interacting with residues
essential for biological activity (Hudson, Shimpukade, Milligan and Ulven, 2014) as well as
Asn313 (section 4.3, Table 4.2). MD analysis from the 100 ns all-atomic simulations of the
final nine compounds reported significant differences in the conformational changes
stimulated by docked ligands – Cpd1, Cpd7 and Cpd9 (Figure 4.11). The protein-ligand
interaction fingerprint mapping of these three compounds over the 100 ns simulation period
showed conserved interactions with Trp277 and Asn313. PLIF results were seconded by
ligand RMSD studies which showed that Cpd1, Cpd7 and Cpd9 were the most stable in the
orthosteric binding pocket of the GPR120S model (Appendix VII). Further analysis of the
MD trajectory focusing on the “ionic lock” (Arg136-Asp259) conservation predicted that
docking of Cpd7 could induce a conformational shift in receptor from inactive state towards
active state, thus acting as a potential agonist of GPR120 receptor. While Cpd9

was

predicted to stabilise the inactive state conformation of the GPR120S model thus acting as a
potential GPR120 antagonist. The MD results obtained from our study illustrate the
importance of understanding the conformational changes to design ligands with specific
activities.
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As mentioned in section 4.5, in silico investigations can be performed using extended
ensemble MD sampling in presence of allosteric ions, protein-water H-bond networks, as
well as water bridges between ligand and protein (Bertalan, Lešnik, Bren and Bondar, 2020).
In silico site-specific mutations studies, especially for Asn313 as well as in combination with
Trp277 of GPR120 (for short and long isoforms) can be further explored to confirm their
predicted effects on ligand binding and receptor activation. Further the predictions from the
MD derived structure-based pharmacophore screenings require validation by in vitro GPCR
binding assays such as surface plasmon resonance (SPR) GPCR-ligand binding assay,
radioligand or fluorescent ligand binding assays to study ligand bias, agonism and
antagonistic profiling and G-protein dependent assays (cAMP assay, calcium influx assay,
etc.) as well as G-protein independent assays (GPCR internalisation assay, label-free whole
cell assay, β-Arrestin recruitment assay, etc.) (Zhang and Xie, 2012).
Recent review studies (Congreve, de Graaf, Swain and Tate, 2020; Zhu, Wu, Huang and An,
2021; Sanjeevi et al., 2022) elaborate on the impact of structural elucidation of GPCRs on
development and increasing number of SBDD studies. GPCR-targeted SBDD methodology
has been emplyed by successfully by well known CADD industrial players like DESRES (D.
E.

Shaw

Research

https://www.deshawresearch.com/),

Sosei

Heptares

(https://soseiheptares.com/ - previously known as HEPTARES Therapeutics) as well as by
newly emerging biotech companies like leadXpro (https://leadxpro.ch/), Confo Therpaeutics
(http://www.confotherapeutics.com/), are some of the several which are working on SBDD.
With a primary objective of GPCR-targeted SBDD, the energy refined model of GPR120S
was used for VS experiments in chapter 5.
As specified in section 3.6 (Figure 3.11), the binding pocket defined for the docking
algorithm (SMINA) was based on the site-specific mutation studies (Hudson et al. 2014). For
future prospects, improvements in the homology model based on the available templates with
higher sequence identity and homology together with increasing computational power will
enable the evaluation of large set of analogs to improve hits from VS. As mentioned in
section 3.8 and 5.4, due to low number of known ligands of GPR120 the AUC scores for
Cscore from enrichment studies of the homology model of GPR120S was found to be lower
than accepted (>0.9). The haystack used for enrichment studies can be refined using the
actives and in-actives obtained from the present study to future work. An alternative approach
could be employed to reduce the chemotype bias of the binding pocket is to generate an
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ensemble of models and perform ensemble enrichment studies by evaluating the docked
poses and protein-ligand interactions of the known ligands among the multiple homology
models. Scoring or ranking of docked poses by scoring functions remains the principal
bottleneck in SBDD. Different studies have published contrasting results related to consensus
scoring for molecular docking experiments. Teramoto and Fukunishi proposed that
supervised consensus scoring can improve the predictive power of VS by compensating for
the deficiencies of each scoring function and taking into account protein-ligand interactions
(Teramoto and Fukunishi, 2007). While one of the latest studies on evaluation of consensus
scoring functions for AutoDock Vina and SMINA reported no performance gain in ranking
docking poses and proposed that default scoring function of SMINA is the best approach for
researchers (Masters, Eagon and Heying, 2020).
DrugBank and SPECS are the two chemical libraries screened against GPR120S model to
discover lead candidates binding to GPR120 receptor (Table 5.7). For future studies, the
present methods can be combined with improved computational approaches and specifc
biological assays to further explore chemical databases like ZINC, ASINEX, etc,. As
observed in various studies, the screening of large chemical databases can be improved by
applying pan-assay interference (PAINs) analysis as well as selectivity screenings predocking which can filter out the chemical conpounds containing chemical moeties known to
impart non-specificity, toxicity and potency related adverse effects (Baell and Holloway,
2010). In the present study, PAINs were performed through SwissADME only for hit
candidates obtained after screening experiments (Table 4.4 and Table 5.6). For future
propspects, these filters can be applied pre-docking a large chemical database like ZINC.
VS of DrugBank against GPR120S model was performed aiming to repurpose the
commercially available FDA approved drugs which have been reported in various studies
(Crisan, Avram and Pacureanu, 2017; Sahragardjoonegani, Beall, Kesselheim and Hollis,
2021). Only five hit candidates from VS of DrugBank were screened in vitro, out of which
only Lapatinib - a known tyrosine kinase inhibitor of HER/EGFR receptors, showed strong
cytotoxicity (IC50 1.16 to 1.77 µM) against SW480 cells. Lapatinib failed to show selectivity
when tested against GPR120_siRNA treated cells confirming that the observed cytotoxic
activity was not through GPR120 binding.
Visual analysis of Deferasirox – FDA approved iron chelating drug, and further 3D molecular
overlay of Deferasirox against AH7614 (Figure 5.4) showed significant structural similarity.
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AH7614 is a negative allosteric modulator of GPR120 (Watterson et al. 2017). Since the
residues composing the allosteric site of GPR120 where AH7614 binds have not been
confirmed by previous studies, design of Deferasirox_analogue (Figure 5.4) can be
interpreted as ligand-based drug design. It can be argued that the DrugBank database was
screened against GPR120S model focusing on the orthosteric binding pocket of GPR120
receptor (Hudson, Shimpukade, Milligan and Ulven, 2014). Elucidation of AH7614 bound
GPR120 receptor by NMR, X-ray, or cryo-EM methods or site-specific mutation studies are
required to debate this argument in detail. Both Deferasirox and the analogue when tested for
GPR120 selectivity in GPR120-siRNA (Figure 5.5) treated were found to be inactive
confirming their selectivity towards GPR120 providing a novel purpose for the Deferasirox
scaffold (1,3,5-triphenyl-1H-[1,2,4] triazole). The present 2D cell experimental setup for this
study did not provide significant results for proliferative or anti-proliferative effects of
TUG891 (GPR120 agonist), due to which co-treatment of TUG891 and AH7614 versus
TUG891 and Deferasirox_analogue was not performed for comparative analysis of allosteric
activity of Deferasirox and the analogue. To the best of our knowledge, most of the published
TUG891 studies assayed Ca2+ mobilization, β-arrestin recruitment, ERK phosphorylation,
etc., (Son, Kim and Im, 2021), no studies have been published regarding proliferative or antiproliferative effects of TUG891.
As academic research projects have limited funds, procurement of hit candidates obtained
from VS of chemical databases often becomes a bottleneck due to high costs of custom
synthesis or overseas shipments. To prevent such procurement limitations, our study focused
VS of chemical libraries available in SPECS database (https://www.specs.net/), as the library
inlcues only test compounds which are available for procurement. The hits from VS of
SPECS were screened in vitro to test cytotoxic effects of the hit compounds (Pal, 2021). The
combination of iterative optimization and testing of hit compounds from the initial in silico
and in vitro screenings through physicochemical profiling and SAR analysis resulted in the
discovery of three potential anticancer drugs. The three compounds - AL-281/36997031, AL281/36997034 and AP-845/40876799 were confirmed as cytotoxic agents by wound healing
and clonogenicity assays.
The SAR analysis of two test compounds AK-968/12713190 and AG-690/40104520, from
initial screenings lead to the discovery of three compounds AL-281/36997031, AL281/36997034 and AP-845/40876799 with improved IC50 values (section 5.3.2). SAR
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performed in the present study was limited to the peripheral substitutions and replacements to
the identified substructure and within the scope of SAR compounds available for
procurement from the SPECS database. SAR profiling can be expanded beyond the SPECS
database to screen a larger set of compounds to discover potential anti-cancer agents targeting
GPR120. SAR profiling of substructures of AK-968/12713190 and AG-690/40104520 (Table
5.2; 5.3) may also lead to discovery of novel scaffolds exhibiting anticancer properties.
While GPR120-siRNA transfected cell lines showed that only compounds AL-281/36997031
and AP-845/40876799 are exhibiting their cytotoxic activity through GPR120. As mentioned,
to confirm these compounds as GPR120-targeted therapeutics further binding assays such as
calcium influx assay, BRET assay, etc., are required to be performed (Zhang and Xie, 2012;
Shimpukade et al., 2012; Lombardo et al., 2016; Watterson et al., 2017). As the project was
inspired by Wu et al., 2013 study, which identified GPR120 as angiogenesis inducing and
tumour-promoting receptor, we aimed to discover and design GPR120-targeted novel
anticancer therapeutics for CRC – the proposed future studies could focus on measurement of
angiogenic phenotype in 2D or 3D cell models, if possible, animal models such as zebrafish
models could be of great interest. Quantification of alterations in the angiogenic phenotype
by delivery of screened candidates could confirm if the results are in agreement with Wu’s
lab (Wu et al., 2013).
Finally, since GPR120 is a hot target for therapeutics in metabolic disorders, escpecialy type
2 diabetes mellitus and obesity (Azevedo et al., 2016; Houthuijzen, 2016; Houthuijzen et al.,
2017) – repurposing of the designed ligands such as Cpd1, Cpd7, Cpd9, and
Deferasirox_analogue as well as compounds AL-281/36997031, AL-281/36997034 and AP845/40876799 can be studied for various metabolic disorders.
To conclude, the present research has shown SBDD approaches and rigorous MD studies can
focus the in vitro studies towards identification and optimisation of GPCR ligands. GPCRbased therapeutics continue to be developed as anticancer agents as they have the potential
for use as a component of novel target selective agents to regulate tumour growth and
metastasis. This work presents an example of the necessity and novelty of the convergence
between computational and biological approaches to reap new grounds in molecular biology.
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Appendix I: Publications and disseminations
Paper 1:
In silico and in vitro screening for potential anticancer candidates targeting GPR120.
Ajay Pal; James F. Curtin; Gemma K. Kinsella
Bioorganic & Medicinal Chemistry Letters, Volume 31, 2021, 127672.
DOI: https://doi.org/10.1016/j.bmcl.2020.127672

The G-protein coupled receptor - GPR120 has recently been implicated as a novel target for
colorectal cancer (CRC) and other cancer managements. In this study, a homology model of
GPR120S (short isoform) was generated to identify potential anti-cancer compounds
targeting the GPR120 receptor using a combined in silico docking-based virtual screening
(DBVS), structure–activity relationships (SAR) and in vitro screening approach. SPECS
database of synthetic chemical compounds (~350,000) was screened using the developed
GPR120S model to identify molecules binding to the orthosteric binding pocket followed by
an AutoDock SMINA rigid-flexible docking protocol.
The best 13 hit molecules were then tested in vitro to evaluate their cytotoxic activity against
SW480 – human CRC cell line expressing GPR120. The test compound 1 (3-(4methylphenyl)-2-[(2-oxo-2-phenylethyl)sulfanyl]-5,6-dihydrospiro(benzo[h]quinazoline-5,1′cyclopentane)-4(3H)-one) showed ~ 90% inhibitory effects on cell growth with micromolar
affinities (IC50 = 23.21–26.69 µM). Finally, SAR analysis of compound 1 led to the
identification of a more active compound from the SPECS database showing better efficacy
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during cell-based cytotoxicity assay –5 (IC50 = 5.89–6.715 µM), while a significant reduction
in cytotoxic effects of 5 was observed in GPR120-siRNA pre-treated SW480 cells.
The GPR120S homology model generated, and SAR analysis conducted by this work
discovered

a

potential

chemical

scaffold, dihydrospiro(benzo[h]quinazoline-5,1′-

cyclopentane)-4(3H)-one, which will aid future research on anti-cancer drug development for
CRC management.

Paper 2:
Structure based prediction of a novel GPR120 antagonist based on pharmacophore screening
and molecular dynamics simulations.
Ajay Pal; James F. Curtin; Gemma K. Kinsella
Computational and Structural Biotechnology Journal, Volume 19, 2021, Pages 6050-6063.
DOI: https://doi.org/10.1016/j.csbj.2021.11.005

The G-protein coupled receptor, GPR120, has ubiquitous expression and multifaceted roles in
modulating metabolic and anti-inflammatory processes. Recent implications of its role in
cancer progression have presented GPR120 as an attractive oncogenic drug target. GPR120
gene knockdown in breast cancer studies revealed a role of GPR120-induced
chemoresistance in epirubicin and cisplatin-induced DNA damage in tumour cells. Higher
expression and activation levels of GPR120 is also reported to promote tumour angiogenesis
and cell migration in colorectal cancer. Some agonists targeting GPR120 have been reported,
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such as TUG891 and Compound39, but to date development of small-molecule inhibitors of
GPR120 is limited.
Herein, following homology modelling of the receptor a pharmacophore hypothesis was
derived from 300 ns all-atomic molecular dynamics (MD) simulations on apo, TUG891bound and Compound39-bound GPR120S (short isoform) receptor models embedded in a
water solvated lipid bilayer system. We performed comparative MD analysis on proteinligand interactions between the two agonist and apo simulations on the stability of the “ionic
lock” – a Class A GPCRs characteristic of receptor activation and inactivation. The detailed
analysis predicted that ligand interactions with W277 and N313 are critical to conserve the
“ionic-lock” conformation (R136 of Helix 3) and prevent GPR120S receptor activation. The
results led to generation of a W277 and N313 focused pharmacophore hypothesis and the
screening of the ZINC15 database using ZINCPharmer through the structure-based
pharmacophore. 100 ns all-atomic molecular dynamics (MD) simulations were performed on
9 small molecules identified and Cpd 9, (2-hydroxy-N-{4-[(6-hydroxy-2-methylpyrimidin-4yl) amino] phenyl} benzamide) was predicted to be a small-molecule GPR120S antagonist.
The conformational results from the collective all-atomic MD analysis provided structural
information for further identification and optimisation of novel druggable inhibitors of
GPR120S using this rational design approach, which could have future potential for anticancer drug development studies.
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Paper 3:
G-protein-coupled receptors as therapeutic targets for glioblastoma.
Kate F. Byrne; Ajay Pal; James F. Curtin; John C. Stephens; Gemma K. Kinsella
Drug Discovery Today, Volume 26, Issue 12, 2021, Pages 2858-2870.
DOI: https://doi.org/10.1016/j.drudis.2021.07.008

Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumour
in adults. Treatments include surgical resection, radiotherapy, and chemotherapy. Despite
this, the prognosis remains poor, with an impacted quality of life during treatment coupled
with brain tumour recurrence; thus, new treatments are desperately needed. In this review, we
focus on recent advances in G-protein-coupled receptor (GPCR) targets. To date, the most
promising targets are the chemokine, cannabinoid, and dopamine receptors, but future work
should further examine the melanocortin receptor-4 (MC4R), adhesion, lysophosphatidic acid
(LPA) and smoothened (Smo) receptors to initiate new drug-screening strategies and targeted
delivery of safe and effective GBM therapies.
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Appendix II: Supplementary tables and figures
Appendix Table IIa: Combinations of multiple templates (PDB codes) used to build
GPR120 homology models. 4S0V (OX2 orexin receptor); 4N6H (Delta-like opioid receptor);
4DJH

(kappa-opioid

receptor);

5GLI

(Endothelin

type-B

receptor);

4EA3

(Nociceptin/Orphanin FQ opioid receptor).
4S0V

4S0V-4N6H

4DJH-5GLI

4S0V-4N6H-4DJH

4DJH-4EA3-5GLI

4N6H 4S0V-4DJH

4DJH-4EA3

4S0V-4N6H-5GLI

4S0V-4N6H-4DJH-5GLI

4DJH

4S0V-5GLI

4N6H-4DJH

4S0V-4N6H-4EA3

4S0V-4N6H-4DJH-4EA3

5GLI

4S0V-4EA3

4N6H-5GLI

4N6H-4DJH-5GLI

4N6H-4DJH-5GLI-4EA3

4EA3

5GLI-4EA3

4N6H-4EA3

4N6H-4DJH-4EA3

4S0V-4N6H-4DJH-5GLI4EA3
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Appendix IIb: GPR120 actives used for Decoy generation (Lombardo et al., 2016; Sparks et al., 2014; Azevedo et al., 2016; Hudson,
Shimpukade, Milligan and Ulven, 2014)
Compound name
Compound48
TUG891
Compound40
PartialA1
Compound39
Compound18
Compound10
Compound41
Compound5
TUG1197
TUG1506
Compound37
Compound27
Compound6
CpdA
Compound19
AH7614
Compound20
Compound28
PartialA2_full
Compound23
Compound8
Compound24
Compound1
GSK39

Binding Score
(kcal/mol)
-9.9143
-9.87591
-9.87491
-9.82831
-9.82688
-9.7935
-9.7395
-9.5415
-9.4734
-9.44996
-9.2101
-9.1646
-9.11864
-9.0261
-9.02491
-8.92716
-8.90068
-8.73304
-8.59616
-8.56813
-8.30635
-8.24819
-7.91255
-7.87396
-7.60468

EC50 (nM)

SMILES representation

83
43
102
NA
97
88
100
68
170
128
NA
63
149
57
66
60
79.43
182
20
NA
94
290
185
474
79

c1cc2c(cc1c3cc(ccc3F)OC(F)(F)F)cc(o2)CCC(=O)[O-]
Cc1ccc(cc1)c2ccc(cc2COc3ccc(cc3)CCC(=O)[O-])F
c1cc2c(cc1c3cc(ccc3Cl)OC(F)(F)F)cc(o2)CCC(=O)[O-]
CC#C[C@@H](CC(=O)[O-])c1ccc(s1)OCc2cccc(c2)c3c(cc(cc3C)OCCCS(=O)(=O)C)C
c1cc2c(cc1c3cc(ccc3F)C(=O)C4CC4)cc(o2)CCC(=O)[O-]
c1cc(cnc1)Oc2ccc(c(c2)c3ccc(cc3)OCCCC(=O)[O-])Cl
c1ccc(cc1)Oc2ccc(c(c2)c3ccc(cc3)OCCCC(=O)[O-])F
Cc1cc(cc(c1)OC2CCC2)c3ccc4c(c3)cc(o4)CCC(=O)[O-]
c1ccc(cc1)Oc2cccc(c2)c3ccc(cc3)OCCCC(=O)[O-]
c1ccnc(c1)Oc2cc(cc(c2)F)N3C[C@@H]4C=CC=C[C@@H]4S3(=O)=O
Cc1ccc(cc1)S(=O)(=O)C[C@H]2c3ccccc3S[C@@H]4[C@H]2C=CC=C4
c1cc2c(cc1c3cc(ccc3F)OC(F)(F)F)cc(o2)CCC(=O)[O-]
Cc1cc(cc(c1OCCCC(=O)[O-])C)c2cc(ccc2F)OC(F)(F)F
c1cc(ccc1c2cc(ccc2Cl)OC(F)(F)F)OCCCC(=O)[O-]
c1cc(c(cc1OC(F)(F)F)N2CCC3(CCC(CC3)CC(=O)[O-])CC2)Cl
c1cc(cc(c1)F)Oc2ccc(c(c2)c3ccc(cc3)OCCCC(=O)[O-])F
Cc1ccc(cc1)S(=O)(=O)N[C@H]2c3c(cccc3)Oc4c2cccc4
Cc1ccc(cc1)Oc2cccc(c2)c3ccc(cc3)OCCCC(=O)[O-]
c1cc(c(cc1OC(F)(F)F)c2cc(c(c(c2)F)OCCCC(=O)[O-])F)F
Cc1cc(cc(c1c2cccc(c2)COc3ccc4c(c3)OC[C@H]4CC(=O)[O-])C)OCCCS(=O)(=O)C
Cc1cc(cc(c1OCCCC(=O)[O-])C)c2cc(ccc2Cl)OC(F)(F)F
CCOc1ccc(c(c1)c2ccc(cc2)OCCCC(=O)[O-])F
Cc1cc(ccc1OCCCC(=O)[O-])c2cc(ccc2Cl)OC(F)(F)F
c1ccc2c(c1)c(no2)c3ccc(c(c3Cl)Cl)OCCCC(=O)[O-]
Cc1ccc(cc1)S(=O)(=O)[N-]c2cccc(c2C)C(=O)OC
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Compound17
GSK137647A
Compound7

-7.57706
-7.46444
-7.40539

198
398.11
121

Cc1ccc(cc1c2ccc(cc2)OCCCC(=O)[O-])Oc3cccc(c3)F
Cc1cc(c(c(c1)C)NS(=O)(=O)c2ccc(cc2)OC)C
CCOc1ccc(c(c1)c2ccc(cc2)OCCCC(=O)[O-])Cl
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Appendix IIc: ROC and enrichment studies to benchmark different scoring functions.
Docking Algorithm: SMINA
Scoring Algorithm: SMINA
AUC obtained: 0.892295
Top 1% EF score: 9.735

Docking Algorithm: SMINA
Scoring Algorithm: VINA
AUC obtained: 0.8633163
Top 1% EF score: 3.33
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Docking Algorithm: SMINA
Scoring Algorithm: NNScore
AUC obtained: 0.546352
Top 1% EF score: 0

Docking Algorithm: SMINA
Scoring Algorithm: DLScore
AUC obtained: 0.6107143
Top 1% EF score: 0
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Scoring

Algorithm:

CScore

(obtained by Equation I)
AUC obtained: 0.7114976
Top 1% EF score: 3.33

########### ROC Script written in R to find ROC – AUC and Enrichment factors####################
library("ROCR")
lig <- unique(Actives$Ligands)
dec <- unique(Decoy$Compounds)
#merging active and decoy and #chnaging colnames to identicals
colnames(Decoy) =c("Ligands","SMINA","VINA","Nnscore","Dlscore")
ROC$IsActive=as.numeric(ROC$Ligands %in% lig)
predSminaScore = prediction((ROC$SMINA*-1), ROC$IsActive)
perfSmina = performance(predSminaScore, 'tpr','fpr')
jpeg("test_ROC.jpg")
plot(perfSmina,main="SMINA ROC Curves",col="blue")
abline(0,1,col="grey")
dev.off()
#AUC
auc_SMINA=ROCR::performance(predSminaScore,"auc")
auc.area_SMINA= slot(auc_SMINA,"y.values")[[1]]
cat(auc.area_SMINA)
#Enrichment
EF_Smina=perfSmina@y.values[[1]]/perfSmina@x.values[[1]]
EF_Smina1=EF_Smina[which(perfSmina@x.values[[1]]>0.01)[1]]
EF_Smina20=EF_Smina[which(perfSmina@x.values[[1]]>0.2)[1]]
cat(EF_Smina1)
cat(EF_Smina20)
#ROC for VINA, NNScore, DLScore, Cscore can be calulcauted using the scripted blocks
###########################################################################
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Appendix IId: RNA yield of the collected sample calculated using the µDrop.
230nm 260nm 280nm
Blank

260/280

0.0615 0.0791 0.0724 1.091851

RNA Yield (ng/µL)
= (260)nm*50*20
-

GPR120_siRNA-1 0.7213 1.4750 0.7415 1.989122

1475.0

GPR120_siRNA-2 0.8813 1.7918 0.8895

2.01439

1791.8

0.9113 1.9577 0.9733 2.011508

1957.7

Control

Appendix IIe: List of pharmacophore features used to screen ZINC database
using ZincPharmer
Pharmacophore feature

X-coordinate

Y-coordinate

Z-coordinate

Radii

Aromatic

61.42

60.36

40.99

1.1

Aromatic

62.41

60.4

52.66

1.1

Hydrogen Acceptor

62.66

61.45

53.17

0.5

Hydrogen Acceptor

64.23

60.23

54.29

0.5

Hydrophobic

61.42

60.36

40.99

1

Hydrophobic

62.41

60.4

52.66

1

Hydrophobic

61.02

57.04

44.38

1

Hydrophobic

59.04

60.5

42.67

1
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Appendix IIf: Docked pose analysis of Cpd1-9 by 2D interaction map generated in BIOVIA
DS Client visualizer v19.1 2019.

Some of the protein-ligands interactions are
missing with respect to Figure 4.9c due to
different calculation algorithm used by PLIP
and DS client visualizer.
Cpd1

Cpd2

Cpd3

Cpd4

Cpd5
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Cpd6

Cpd8

Cpd7

Cpd9
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Appendix III: Benchmarking of docking algorithms
Four docking algorithms (AutoDock SMINA (Trott and Olson 2009), Dock6 (Allen et al.
2015), AutoDock4 (Morris et al. 2009) and ROSIE (Moretti et al. 2017)) were validated
using high-resolution X-ray co-crystal structures of five Class A GPCRs (PDB IDs: 3EML
[AdenosineA2A]; 2VT4 [β1-Adr]; 3NY8 [β2-Adr]; 3PBL [Dopa D3]; 3ODU [CXCR4]) to
select a docking algorithm to be used. The structures of protein and ligand were prepared
according to the input requirements for each docking algorithm. Then the docking algorithms
were applied to reproduce the bound conformation of a ligand in crystal structure. The
docking protocols were compared in reproducing the crystallographic pose of ligand inside
the receptor binding pocket and the one with the lowest RMSD value, the lowest mean
RMSD value and the highest number of poses with RMSD value < 2 Å was selected.
AutoDock SMINA demonstrated the best performance in comparison to the other liganddocking algorithms considered for G-protein coupled receptors. SMINA is a fork of the
AutoDock VINA software – which uses the same docking and scoring algorithms with
additional flexibility to use user-defined custom scoring function, was used for molecular
docking experiments in the project instead of VINA (Koes, Baumgartner and Camacho
2013). Also, SMINA overcomes the limitation of VINA to enlist only one ligand in the
ligand file set for docking. SMINA allows the user to set a ligand file comprising different
conformations of different molecules for the docking experiment.
Table IIIa: Evaluation of docking algorithms by RMSD (Å) between co-crystalised and the
re-docked co-crystalised ligand into the GPCR orthosteric binding pocket.
GPCR X-ray Crystals

SMINA

Dock6

Autodock4

ROSIE

3EML[AdenosineA2A]

0.82

0.55

0.93

0.96

2VT4[β1-Adr]

0.49

0.89

2.93

0.51

3NY8[β2-Adr]

1.02

0.71

1.22

1.00

3PBL[Dopa D3]

0.99

0.41

0.48

0.98

3ODU[CXCR4]

0.79

3.98

2.63

0.79

RMSD Avg. (Å)

0.82

1.31

1.64

0.85

RMSD Std. Deviation

0.21

1.51

1.08

0.21
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Appendix IV: Automated KNIME pipeline for GPCR
homology modelling and molecular docking.

Figure IV.1: Schematic of KNIME workflow for GPCR homology modelling and molecular
docking for virtual screening.
The KNIME workflow was designed to incorporate the open-source tools to serve as a
backbone of the desktop CADD infrastructure targeting GPCRs on the linux platforms
(specifically Ubuntu distributions). The secondary structure topology provided by the user
from the TMHMM server along with GPCR protein sequence files was used to predict the 3D
model of desired proteins. The user can choose between HM tool - MODELLER (opensource academic license) to predict the 3D models or define the database of GPCR 3D
models. The advanced user has the option to develop a pipeline to include different HM
algorithms of their choice and incorporate it into the workflow.
The predicted models were combined in a temporary virtual database which can be used in
virtual screening if the user decides to proceed with workflow. The user can skip the HM
pipeline if they already have a pre-processed database of 3D protein models / structures for
VS through molecular docking using SMINA. The next pre-requisite for VS is the defined
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binding pocket of each protein target to be used for screening in the docking experiments. At
this point, the user has an option to define the configuration file with binding pockets for each
protein or GHECOM site finder tool embedded in the pipeline can automatically detect the
protein cavities. The python script embedded in pipeline chooses the largest pocket (from the
GHECOM predictions) at the extracellular end of the GPCRs as the orthosteric binding
pocket for the docking experiment.
The ligand databases to be screened against the protein structures were prepared and
processed by the OpenBabel tool available as an open-source software package. The pipeline
creates sub-directories for all the docking results with respect to the protein target in the
working directory. The KNIME pipeline is designed to provide preconfigured starting points
for the new users introduced to the field of CADD-SBDD. The advanced users can adapt the
flexible workflow according to their needs using the various chemoinformatics research
nodes available in the KNIME repository. The workflow developed will be available as open
source via GitHub web portal (https://github.com/jay4pal/KNIME_GPCRs).
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Appendix V: Topology prediction of human GPR120 and
homology modelling
Appendix Va: Topology Prediction of GPR120L by TMHMM:
#TMHMM ------ WEBSEQUENCE Length: 377
# WEBSEQUENCE Number of predicted TMHs: 7
# WEBSEQUENCE POSSIBLE N-term signal sequence
WEBSEQUENCE TMHMM2.0

outside

1

43

WEBSEQUENCE TMHMM2.0

TMhelix

44

66

WEBSEQUENCE TMHMM2.0

inside

67

74

WEBSEQUENCE TMHMM2.0

TMhelix

75

97

WEBSEQUENCE TMHMM2.0

outside

98

111

WEBSEQUENCE TMHMM2.0

TMhelix

112

134

WEBSEQUENCE TMHMM2.0

inside

135

154

WEBSEQUENCE TMHMM2.0

TMhelix

155

177

WEBSEQUENCE TMHMM2.0

outside

178

208

WEBSEQUENCE TMHMM2.0

TMhelix

209

231

WEBSEQUENCE TMHMM2.0

inside

232

282

WEBSEQUENCE TMHMM2.0

TMhelix

283

305

WEBSEQUENCE TMHMM2.0

outside

306

314

WEBSEQUENCE TMHMM2.0

TMhelix

315

337

WEBSEQUENCE TMHMM2.0

inside

338

377
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Appendix Vb: GPR120 Topology Prediction of GPR120S by UCD-Porter: C- coil; H-helix (Green); E-beta sheet (Yellow).

M S P E C A R A A G D A P L R S L E Q A N R T R F P F F S D V K G D H R L V L A A V E T T V L V L I F A V S L L G N V C
C C C C C C C C C C C C C C C C C C C C C C C C C C H H H C C C C C C C H H H H H H H H H H H H H H H H H H H H H H H H
TM1 (37-66)
A L V L V A R R R R R G A T A C L V L N L F C A D L L F I S A I P L V L A V R WT E A WL L G P V A C H L L F Y V M T L
H H H H H H C C C C C C H H H H H H H H H H H H H H H H H H C C H H H H H H H H H C C C C C C H H H H H H H H H H H H H
TM1

TM2 (73-101)

TM3 (108-141)

S G S V T I L T L A A V S L E R M V C I V H L Q R G V R G P G R R A R A V L L A L I WG Y S A V A A L P L C V F F R V V
H H H H H H H H H H H H H H H H H H H H H C C C C C C C C C C H H H H H H H H H H H H H H H H H H C C H H H H C E E E E
TM3

TM4 (152-174)

P Q R L P G A D Q E I S I C T L I WP T I P G E I S WD V S F V T L N F L V P G L V I V I S Y S K I L Q T S E H L L D A
E E C C C C E E E E E C C C C C C H H H H H H H H H H H H H H H H H H H H H H H H H H H H H H H H H H H C C C C C C C C
TM5 (198-232)
R A V V T H S E I T K A S R K R L T V S L A Y S E S H Q I R V S Q Q D F R L F R T L F L L M V S F F I M WS P I I I T I
C C C C C C C C C C H H H H C C C C C C C C C C C C C C H H H H H H H H H H H H H H H H H H H H H H H H H H H H H H H H
TM6 (253-289)
L L I L I Q N F K Q D L V I WP S L F F WV V A F T F A N S A L N P I L Y N M T L C R N E WK K I F C C F WF P E K G A
H H H H H C C C C C C C C H H H H H H H H H H H H H H H H H H H H H H H H H H H H H H H H H H H H H C C C C C C C C C C
TM6

TM7 (298-334)

I L T D T S V K R N D L S I I S G
C C C C C C C C C C C C C C C C C
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Appendix Vc: Topology Prediction of GPR120L by JPred Secondary Structure Prediction; (Red: Helix; Green-Beta sheet; Black- coil/loop)
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Appendix Vd: Homology models of GPR120L

Figure Vd: Validated model of GPR120S (A) used as template for predicting GPR120L (B)
structure. (C) Superimposed structures of GPR120S (Grey) and GPR120L (Spectrum colour)
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Appendix VI: Equilibration of GPR120S receptor
Equilibration of Apo GPR120S receptor
The 500 ps NVT equilibration run of the Apo GPR120S system showed that both the total
energy and potential energy of the system plateaued after ~400 ps characterised by the
decrease in total energy from -1,432,239 (2 ps) to -1,513,052 kJ/mol (372 ps) (Figure VIa).
The visual inspection of the system ensemble after NVT run showed that the phospholipid
bilayer leaflets started separating after 20 ps of NVT run (Figure VIb). The leaflets stayed
separated throughout the 500 ps NVT run. This leaflet separation phenomenon has been
observed frequently in MD with large heterogeneous systems as the POPC molecules were
trying to orient themselves with respect to both water and protein.

Figure VIa: Total energy (left) and Potential energy (right) of Apo GPR120S during NVT
equilibration run of 500ps.
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NVT – 0 ps

NVT – 20 ps

NVT – 500 ps

Figure VIb: Snapshots of the phospholipid bilayer leaflets in the Apo GPR120S system. The
leaflets separated during 500 ps NVT equilibration step; Phosphate heads are shown as
orange spheres and lipid tails as green sticks with the GPR120S protein (cyan) embedded.
The water box is not shown in the image for clarity. The image was visualized and rendered
in PyMol (DeLano 2018).

The extended NPT run with consecutively decreasing position restraints on POPC phosphate
heads was simulated to bring the leaflets closer without stretching the lipid bonds. The
position restraints of 1000, 500, 100, 50 and 10 kJ/mol/nm2 were applied for five consecutive
NPT runs of 1000 ps (1 ns) each to harmonically reduce stress and relax the system. The total
energy as well as the potential energy of the system were observed to stabilise around 4000
ps with lowest potential energy of -1,823,318.5 kJ/mol at 4118 ps. The biggest decline in
total energy as well as potential energy of the system occurred during the first 3 ns (Figure
VIc) which can be attributed to the relaxation in position restraints. Afterwards, with a
gradual decrease the total energy of the system plateaued during the last 500 ps of the
equilibration simulations. The temperature of the system portrayed a uniform trend (300 K
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+/- 2) throughout the 5 ns equilibration simulation (Figure VId-Left). As pressure is a
macroscopic property, the system showed large fluctuations from one simulation step to
another. But the average pressure overtime stabilized at ~1 bar after equilibration (Figure
VId-Right). The visual analysis of NPT ensemble also showed that the leaflet has returned to
their normal locations and relaxed with the system (Figure VIe). The system conformation at
4,118 ps (with lowest potential energy of -1,823,318.5 kJ/mol) was used for running MD
production runs.

Figure VIc: Total energy (left) and Potential energy (right) of Apo GPR120S during NPT
equilibration run of 5 ns with position constraint on phosphate heads of POPC.

Figure VId: Temperature (left) and pressure (right) of Apo GPR120S during NPT
equilibration run of 5 ns with position constraint on phosphate heads of POPC.
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Figure VIe: Snapshots of the phospholipid bilayer leaflets in the Apo GPR120S system. The
leaflets retained “sandwich” conformation after 5 ns NPT equilibration step; Phosphate heads
are shown as orange spheres and lipid tails as green sticks with the GPR120S protein
(cartoon) embedded. The water box is not shown in the image. The image was visualized and
rendered in PyMol (DeLano 2018).
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EQUILIBRATION OF THE ANTAGONIST AND AGONIST-BOUND
SYSTEM
The equilibration of the prepared systems with position constraints on ligands (TUG891 and
Compound39) successfully kept the ligands inside the binding pocket throughout the
simulations. But a similar problem of leaflet separation was observed in agonist-bound
systems during NVT equilibration. As the project was aimed to look for differences in the
conformational behaviour of the GPR120S model in the presence of an agonist from the apo
system, first equilibration of the receptor model in the bilayer had to be ensured. The same
protocol of Apo system - NVT (500 ps) and five consecutive NPT (1 ns each) with
decreasing position constraints for phosphate heads of phospholipid bilayer to prevent leaflet
separation was followed. The total energies of both the agonist-bound systems were stable by
the end of the equilibration process (Figure VIf).
At this point, the AH7614-bound system was dropped from further MD simulation studies as
it was declared NAMD of GPR120 receptor isoforms (Watterson et al. 2017).

Figure VIf: Total energy of TUG891-bound GPR120S model (Left) and Compound39-bound
GPR120S model (right) during NPT equilibration run of 5 ns with position constraint on
phosphate heads of POPC
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Appendix VII: Analysis of 100 ns MD simulations of
Compounds Cpd1-9

Figure VIIa: Root Mean Square Deviation (RMSD) plot of Cα of the protein backbone (Å)
recorded during 100 ns MD simulation run of GPR120S in unbound (Apo) and bound form
with TUG891, Compound39 and compounds 1-9.
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Figure VIIb: Root Mean Square Fluctuation (RMSF) plot of the protein backbone (Å)
recorded during 100 ns MD simulation run of GPR120S in unbound (Apo) and bound form
with TUG891, Compound39 and compounds 1-9.

Figure VIIc: Root Mean Square Deviation (RMSD) plot of ligands bound to protein (Å)
recorded during 100 ns MD simulation run of GPR120S in bound forms with TUG891,
Compound39 and compounds 1-9.
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Figure VIId: Distance (Å) plot between the center of mass of residues Arg136(TM3) and
Asp259(TM6) involved in “ionic-lock” conformation recorded during 100 ns MD simulation
run of GPR120S in bound forms with TUG891, Compound39 and compounds 1-9

Figure VIIe: Interaction energy of (Coulombic interactions) of ligand bound protein systems
recorded during 100 ns MD simulation run of GPR120S in bound forms with TUG891,
Compound39 and compounds 1-9
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Appendix VIII: RT-qPCR readings of GPR120 siRNA expression
1

2

Sample
siRNA-1
siRNA-2
Control

Cт
8.192475
7.732936
8.513725

Cт
8.708578
7.338948
8.449002

Sample
siRNA-1
siRNA-2
Control

Cт1
Cт2
30.20934 31.91719
31.09578 31.43562
30.42481 31.7924

Housekeeping GAPDH
Cт
Cт4
Cт5
9.434944
8.442725
8.778606
7.806002
7.550343
8.087684
9.202267
8.873232
9.143499
Target gene GPR120
Cт3
Cт4
Cт5
Cт6
Cтmean
32.2821 31.89163 32.14431 31.98971 31.73905
31.66361 31.85941 31.09859 31.53338 31.44773
30.86534 31.71351 30.54261 31.52996 31.14477
3

Cт6
8.722689
7.664701
9.024377

Cтmean
8.713336
7.696769
8.867684

∆Cт
∆∆Cт
2^-∆∆Ct %Relative Fold
23.02571 0.748621 0.595172
59.517
23.75096 1.473875 0.360014
36.001
22.27709
0
1
100

Where:
Cтmean = Average of Cт values
∆Cт = Cтmean (Target gene GPR120) - Cтmean (Housekeeping gene GAPDH)
Calibrator / reference sample ∆Cт = ∆Cт (Control of target gene) => 22.27709
∆∆Cт = ∆Cт (treated sample) - ∆Cт (Calibrator)
Relative fold gene expression = 2-∆∆Cт
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Appendix IX: List of Employability Skill and Discipline
Specific Skills Training
Module Title

Institution

Discipline Specific Skills
BIOL 9222 Biological Basis of Disease
TU Dublin
GRSO 1001 Research Methods
TU Dublin
GRSO 1005 Introduction to Statistics
TU Dublin
Employability Skills
GRSO 1010 Introduction to Pedagogy
TU Dublin
Scientific Programming Concepts
ICHEC

ECTs
awarded

Date

10
5
5

January 2017
October 2017
March 2018

5
5

January 2017
February 2018
November
2018
December
2018

RESM 1953 Research Integrity

TU Dublin

5

Techniques and Strategies in Molecular
Medicine

CRDI TCD

5
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